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Osteopontin (OPN), a glycosylated phosphoprotein, is down regulated in 
remaining dopaminergic neurones in Parkinson’s disease.  It has protective properties 
including anti-inflammatory and anti-apoptotic effects.  Therefore, it was 
hypothesised that OPN treatment protects dopaminergic neurons from toxin induced 
cell death, and its endogenous expression in cells confers intrinsic protection.  
Consequently, OPN was investigated for neuroprotective effects in toxin models of 
dopaminergic cell death using SH-SY5Y and N1E-115 cell lines with different OPN 
expression phenotypes, primary E14 ventral mesencephalic (VM) culture and rats. 
Cell lines expressed receptors linked to the pro-survival effects of OPN (Igαv, 
Igβ3, Igβ1 and CD44).  However, endogenous OPN expression did not affect 
vulnerability of cell lines to the toxins MPP
+
 or H2O2 and exogenous pre-treatment 
with OPN did not protect them from toxin-induced cell death.  By contrast, pre-
treatment of VM cultures with OPN protected them against MPP
+
-induced 
dopaminergic cell loss.  Importantly, a 15-mer peptide fragment of OPN containing 
the RGD integrin binding site retained protective properties of OPN.  Further, 
treatment with the integrin receptor antagonists, RGDS and GRGDSPK, prevented 
OPN’s protective effect, suggesting a role for integrins in the protective effect.  OPN 
induced an increase in the number of microglia in VM cultures but the role of glial 
cells in OPN’s protective effect is not fully clear.  In the LPS lesioned rats, there was 
an up-regulation of the expression of Igαv, Igβ3, Igβ1 and CD44 receptors and prior 
intra-nigral OPN injection protected dopaminergic cells of the substantia nigra 
against LPS toxicity.  Immunohistochemical investigation revealed that OPN 
significantly decreased the inflammatory microgliosis produced by LPS. 
In conclusion, OPN was protective against toxin induced cell death in primary 
VM culture in vitro and inflammation mediated cell death in vivo, but not in 
immortalised cell lines.  The protective effects of OPN were mediated through an 
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1.1 Parkinson’s disease  
Parkinson’s disease (PD) is a progressive neurodegenerative disease 
characterised by the cardinal symptoms of bradykinesia, rigidity, resting tremor, gait 
dysfunction and postural instability (Jankovic, 2008).  Non-motor symptoms can also 
occur including depression, anxiety, autonomic dysfunction, cognitive impairment, 
and sleep disturbance (Jankovic, 2008).  PD is the second most common 
neurodegenerative disorder after Alzheimer’s disease.  It affects 1% of the 
population over 60 years of age and the incidence increases with age (Alves et al., 
2008).   
Current treatments available for PD focus on alleviating motor symptoms by 
replacing striatal dopamine and are, therefore, only symptomatic in nature.  Levo-
DOPA (L-DOPA), the amino acid precursor of dopamine, is the most effective 
treatment available (Halkias et al., 2007; Rezak, 2007; Singh et al., 2007).  It is used 
in combination with the peripheral dopa-decarboxylase inhibitor, carbidopa to reduce 
peripheral metabolism allowing a reduction in L-DOPA dose and limiting side 
effects such as nausea, vomiting and hypotension.  Dopamine agonists are used as 
adjunct to L-DOPA therapy to reduce motor fluctuations but are also widely used as 
first line therapy in early disease and can delay the need for L-DOPA for up to 5 
years (Lees, 2005).  Monoamine oxidase-B (MAO-B) inhibitors, selegiline and 
rasagiline are used early in the treatment to reduce endogenous dopamine 
metabolism and in later disease to potentiate the effects of L-DOPA (Schapira, 
2009b).  Inhibitors of catechol-O-methyl transferase (COMT) such as entacapone 
and tolcapone are also used to prevent peripheral L-DOPA metabolism so 
maximising delivery to the brain.  However, motor complications or fluctuations 
(dyskinesia, “ON” and “OFF” periods and wearing off effect) develop in 40% of 
patients after 4-6 years of L-DOPA therapy and 70% of patients after 9 years 
(Ahlskog et al., 2001) and can cause significant social and functional disability 
(Pahwa et al., 2006; Rezak, 2007; Singh et al., 2007).   
Therefore there is a clear need for a neuroprotective agent that can prevent 
further loss of dopaminergic neurones from the substantia nigra (SN) and ultimately 
stop progression of the disease.  There are currently no proven treatments for PD that 
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act to stop or slow progression of the illness although development of 
neuroprotective strategies is on-going. 
1.1.1 Neuroprotective therapies in PD 
Many drugs have been tested for their neuroprotective effects including 
dopamine agonists, MAO-B inhibitors, anti-apoptotic agents and neurotrophic 
factors (Table 1.1) but so far no drug has been proven to slow progression of the 
disease (Lohle et al., 2010; Schapira, 2008b).  Some examples of drug strategies that 
have been investigated for neuroprotection are given below. 
Despite promising pre-clinical data of neuroprotective properties of MAO-B 
inhibitors (Olanow et al., 2006; Schapira, 2009a) , clinical trials have not been 
conclusive as to their benefit.    Selegiline was first chosen for investigation based on 
its capacity to inhibit oxidative stress related to the oxidation of dopamine by MAO-
B (Cohen et al., 1989).  In a randomised double-blind placebo controlled study 
(DATATOP), selegiline appeared to slow the progression of motor symptoms of PD 
(PSG, 1989) but there was insufficient allowance made for its symptomatic effects 
which biased the initial interpretation of a delay in the time to introduction of L-
DOPA (Olanow et al., 1995).  Most subsequent studies have shown that after several 
years of treatments, selegiline treated patients have similar levels of disability to 
those not receiving the drug (Brannan et al., 1995; Lees, 1995; PSG, 1996).  
However, there are long term monitoring trials of the effects of selegiline which still 
appear to show a better outcome than those not receiving the drug (Larsen et al., 
1999).  Despite controversy over effects of selegiline, another MAO-B inhibitor; 
rasagiline has also been tested for its ability to slow progression of PD.  In a short 
term clinical trial, where rasagiline was tested in early onset PD patients (TEMPO), 
motor scores and quality of life measures improved significantly with both dosages 
used (1 or 2mg daily) compared to placebo-treated control (PSG, 2002a).  However, 
in another study designed to minimise symptomatic effects of rasagiline (1 or 2mg 
daily) where early treatment with rasagiline was compared to a 6 month-delayed start 
in a year-long study (ADAGIO) showed different results.  Early start treatment with 
rasagiline 1mg but not 2mg provided a small improvement on the total Unified 
Parkinson's Disease Rating Scale (UPDRS) (Olanow et al., 2009).  The significance 
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of this benefit is questioned, compared to the annual decline in total UPDRS score in 
untreated PD (Lohle et al., 2010).   
In a similar manner, there is a large body of pre-clinical evidence suggesting 
that dopamine agonists may be neuroprotective (Schapira, 2002; Schapira, 2009a).  
Consequently, two main clinical studies have been undertaken in PD patients using 
the dopamine agonists pramipexole, CALM-PD (Ahlskog, 2005; 2002b) or 
ropinirole, REAL-PET (Whone et al., 2003).  In the first trial, pramipexole treatment 
achieved a more significant decrease in dopamine transporter loss compared to L-
DOPA (Ahlskog, 2005; 2002b).  In the second trial, ropinirole treatment resulted in 
significantly lesser reduction in the uptake of 
18
F-L-DOPA by SN and putamen 
compared to L-DOPA (Whone et al., 2003).  These results show that dopamine 
agonists can slow the deterioration of nigro-striatal function as measured by imaging 
markers, suggesting that these drugs may be protecting against the progressive loss 
of nigral neurons.  However both studies have the criticism of lacking a placebo 
control group.  In addition, these changes in striatal function measured by imaging 
markers could be due to pharmacological difference between L-DOPA and dopamine 
agonists in regulating dopamine transporter or 
18
F-L-DOPA metabolism (Schapira, 
2008b).  Therefore, at this stage, it cannot be unequivoqually concluded that the 
observed effects are due to protection against loss of nigral neurons.  Consequently, 
pramipexole entered a new trial (PROUD) using both clinical and imaging end-
points in order to clarify the protective effects of the drug (Schapira et al., 2010). 
Another type of agents investigated for neuroprotection in PD is anti-oxidants, 
based on implication of oxidative stress in PD pathogenesis (Section 1.1.4.b).  
Coenzyme Q10 (CoQ10), a co-factor in the mitochondrial electron transfer chain and 
a potent anti-oxidant (Echtay et al., 2000; Ernster et al., 1995), is an example of anti-
oxidants examined as a potential protective treatment in PD.  CoQ10 was 
investigated for neuroprotection based on its protective effects in MPTP-treated mice 
(Beal et al., 1998) and in transgenic mice models of Huntington’s disease (Ferrante 
et al., 2002).  However, in a randomized, placebo-controlled, double-blind clinical 
trial in early untreated PD patients using different doses of CoQ10, there was an 
inverse correlation between dose and degree of clinical change as measured by 
UPDRS and significant benefit in each treatment group compared to placebo 
suggesting possible neuroprotection.  However, there was no effect on time until L-
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DOPA therapy initiation was required or on timed tapping test of motor function 
(Shults et al., 2002).  This trial received the criticism that CoQ10 may be having a 
symptomatic effect by restoring the impaired energy metabolism of remaining 
dysfunctional neurons (Hauser et al., 2006).  Therefore, a larger multicenter study 
using CoQ10 was undertaken (Schapira, 2008b) but this was recently stopped due to 
lack of evidence of any positive or negative effects of CoQ10 (NINDS clinical trials, 
2011).  Although there is good rationale for using antioxidants as neuroprotective 
agents, clinical trials have not shown unequivocal data to prove this. 
Apoptosis is also implicated in the pathogenesis of PD (Section 1.1.4.a) and 
this has led to investigation of anti-apoptotic agents as possible neuroprotective 
therapies for the disease.  For example, CEP-1347 is an anti-apoptotic compound that 
inhibits mixed lineage kinases which induce apoptosis via activation of the JNK 
pathway (Maroney et al., 1998).  In-vitro and in-vivo pre-clinical data suggested that 
CEP-1347 may have neuroprotective activity (Silva et al., 2005).  Therefore, a 
clinical trial (PRECEPT) was conducted in early diagnosed patients to test the 
clinical potential of this agent (PSG, 2007).  However, the outcome of the trial was 
that patients receiving the drug had higher deterioration and required dopaminergic 
therapy quicker than placebo treated controls (PSG, 2007).  This suggested that use 
of this drug is detrimental rather than protective.  Therefore further investigation is 
required in order to determine the exact role of anti-apoptotic agents as a 
neuroprotective strategy in PD.     
A different approach to altering progression of PD is to not simply stop 
degeneration of neurons but also to induce a neurorestorative effect.  In this respect, 
a range of neurotrophic factors have been investigated.  Glial derived neurotrophic 
factor (GDNF) has been the most studied neurotrophic factor in PD research as a 
potential treatment.  GDNF protected dopaminergic neurons in 6-OHDA or MPTP 
lesioned rodents (Hoffer et al., 1994; Lapchak et al., 1997; Tomac et al., 1995), and 
in MPTP-treated monkeys, resulted in an increase in nigral dopaminergic neurons 
and an overall improvement in disability as measured by modified UPDRS (Grondin 
et al., 2002).  Consequently, a small open label trial where 5 PD patients receiving 
continuous intraputaminal infusion of GDNF showed significant improvement in 
symptoms (48% reduction in UPDRS) after one year, and an increase in dopamine 
storage in the putamen after 18 months (Gill et al., 2003).  After the promising 
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results of the previous trial, a larger, randomised, double blind, placebo-controlled 
study was carried out to assess the clinical effectiveness of GDNF as a 
neuroprotective agent (Lang et al., 2006).  Results showed that despite a 26% 
increase in putamen dopamine storage, continuous intraputaminal infusion of GDNF 
did not result in any significant clinical improvement of motor function.  There is 
considerable evidence for the potential benefits of neurotrophic factors as a treatment 
of PD.  However, the discrepancy in clinical results suggests that more clinical trials 
are required to clarify the role of GDNF as a potential neuroprotective treatment in 
PD. 
In summary, there have been positive results from pre-clinical studies for some 
potential neuroprotective agents but in clinical trials, none have shown solid 
evidence for slowing or stopping progression of the disease by means of protecting 
against neuronal loss (Lohle et al., 2010; Schapira, 2008b).  Thus despite the 
immense efforts made to find a neuroprotective approach to PD, translation from the 
laboratory to man has so far failed and new approaches are required.  A better 
understanding of aetiology and pathogenesis of the disease and the mechanisms 
involved in neurodegeneration may help highlight the properties required for a 





 Primary outcome Duration 
Antiapoptotic agents 
–TCH346 Olanow et al. 301 Time to symptomatic 
treatment 
12–18 months 




–Minocycline NINDS NET-PD FS-1  200 Change in total UPDRS 12 months 
Antioxidants 
–Vitamin E DATATOP  800 Time to symptomatic 
treatment 
Terminated after 
 ~ 12 months 
–Coenzyme Q10 QE2 80 Change in total UPDRS 16 months 
 NINDS NET-PD FS-
Too  
213 Change in total UPDRS 12 months 
–Creatine  60 123I-β-CIT SPECT 
changes 
24 months 
 NINDS NET-PD FS-1  200 Change in total UPDRS 12 months 
Dopamine agonists 
–Pramipexole CALM-PD 82 123I-β-CIT SPECT 
changes 
46 months 
–Ropinirole REAL-PET 186 18F-DOPA PET changes 24 months 
–α-
dihydroergocryptine 
Pöpperl et al.  25 
123
I-IPT SPECT changes 52 weeks 
Glutamate antagonists 
–Riluzole Jankovic and Hunter  20 Change in UPDRS II and 
III 
6 months 
 Rascol et al.  108
4 





–Levodopa ELLDOPA  361 Change in total UPDRS 40 weeks 
MAO inhibitors 




 Tetrud and Langston  54 Time to symptomatic 
treatment 
3 years 
 SINDEPAR  101 Change in total UPDRS 14 months 
 Swedish Parkinson 
Study Group  




Study Group  
79 Change in total UPDRS 60 months 
–Lazabemide ROADS  321 Time to symptomatic 
treatment 
12 months 
–Rasagiline TEMPO  404 Change in total UPDRS 12 months 
Neuroimmunophilin ligands 
–GPI-1485 NIL-A phase II clinical 
trial  
300 Change in UPDRS motor 
score 
6 months 
 NINDS NET-PD FS-
Too  
213 Change in total UPDRS 12 months 
Neurotrophic factors 
–GDNF ICV GDNF Study 
Group  
50 Change in UPDRS motor 
score 
8 months 




Table 1.1 Summary of neurorprotection clinical trials in PD (Lohle et al., 2010).  
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1.1.2 Aetiology of PD 
Despite many years of research, the cause of PD remains elusive.  Studies have 
shown that genetic and environmental factors play a role in precipitating PD.  The 
discovery of PD in families (Gasser et al., 1998; Kitada et al., 1998; Kruger et al., 
1998; Polymeropoulos et al., 1997) and observation of familial aggregation of PD 
cases (Cordato et al., 2004; Sveinbjornsdottir et al., 2000) supports the theory of 
genetic factors playing a role in the aetiology of PD.  In fact, mutations in 15 genes 
(Table 1.2) have been associated with Parkinsonism including: 
 SNCA (Kruger et al., 1998; Polymeropoulos et al., 1997) coding a protein (α-
synuclein) which can form fibril like aggregates that are found in Lewy 
bodies (LBs) in familial and sporadic PD (Spillantini et al., 1997).  Mutations 
are shown to increase protein expression (Farrer et al., 2004) which is 
associated with enhanced protofibril formation (Miller et al., 2004). 
 Parkin (Kitada et al., 1998), and ubiquitin C-terminal hydroxylase-L1 
(UCHL-1) (Leroy et al., 1998) are both involved with the ubiquitin-
proteasome system which degrades unwanted proteins.  Studies with 
knockout (KO) mice suggest that mutations in Parkin may cause 
mitochondrial dysfunction and oxidative damage (Palacino et al., 2004).  
UCHL-1 deficient mice showed disturbed re-use of ubiquitin and a resultant 
accumulation of abnormal proteins in the brain (Saigoh et al., 1999). 
 LRRK2 (Paisán-RuIz et al., 2004; Zimprich et al., 2004) a tyrosine kinase- 
like protein, but the exact function is unknown.  Some LRRK2 mutations are 
associated with an increase in kinase activity (West et al., 2005) and others 
with decreased GTPase activity (Lewis et al., 2007) but it is not clear how 
this is involved in PD pathogenesis. 
 PINK1 (Valente et al., 2004; Valente et al., 2001), a mitochondrial protein 
whose function is not known but is shown to be important for neuroprotection 
against mitochondrial dysfunction and proteasome-induced apoptosis.  
PPINK1 mutations impair this protective effect (Valente et al., 2004; Valente 
et al., 2001).  
 DJ1 (Bonifati et al., 2003), is suggested to act as an anti-oxidant (Nagakubo 
et al., 1997) and mutation is associated with increased oxidative stress 
(Takahashi-Niki et al., 2004).  However DJ-1 mutations are rare in PD. 
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Overall, these genes express proteins that are involved in one or more 
pathological pathways in PD including mitochondrial dysfunction, ubiquitin 
proteasome system dysfunction and oxidative stress (see Section 1.1.4), reinforcing 
their contribution to cell death in PD.  Although genetic mutations have contributed 
greatly to the understanding of pathogenesis of PD, they do not explain the majority 
of sporadic PD cases.  Nevertheless, research in this area is on-going and it is 
possible that future investigations may uncover new susceptibility genes in sporadic 
PD.  
 
PARK Locus Gene Map Position Inheritance 
Well-validated loci/genes 
   
 PARK1/PARK4 SNCA 4q21 AD 
 PARK2 Parkin 6q25.2–q27 AR 
 PARK6 PINK1 1p35-p36 AR 
 PARK7 DJ-1 1p36 AR 
 PARK8 LRRK2 12q12 AD (incomplete penetrance) 
 PARK9 ATP13A2 1p36 AR 
Putative loci/genes 
   
 PARK3 Unknown 2p13 AD 
 PARK5 UCHL1 4p14 AD 
 PARK10 Unknown 1p32 Not clear 
 PARK11 GIGYF2 2q36–q37 AD (incomplete penetrance) 
 PARK12 Unknown Xq21-25 Not clear 
 PARK13 Omi/HTRA2 2p12 Not clear 
 PARK14 PLA2G6 22q13.1 AR 
 PARK15 FBXO7 22q12–q13 AR 
 
Table 1.2 Genes underlying monogenic parkinsonism.  







Genetic mutations account for less than 10% of the cases thus the disease is 
more commonly sporadic (90%; (Litvan et al., 2003)).  Parkin and PINK1 mutations 
are suggested to explain up to 50% of  early onset PD cases (less than 40 years old) 
though this only accounts for 1-2% of total PD cases (Hardy, 2010).  Therefore, 
some suggest that environmental agents are the main causal factor, and this is 
supported with the following evidence.  The ability of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) to induce neurochemical, pathological and clinical 
features similar to those of PD suggested that similar effects could be caused by 
other environmental neurotoxins (Di Monte et al., 2002).  In addition, most 
epidemiological studies have found increased exposure to pesticides to be associated 
with higher risk of PD (Gorell et al., 1998; Liou et al., 1997; Petrovitch et al., 2002; 
Seidler et al., 1996; Semchuk et al., 1992).  In fact, pesticides such as rotenone and 
paraquat induce loss of nigral dopaminergic neurons in rodents (Greenamyre et al., 
2003; Peng et al., 2004).  Well water consumption and living in rural areas 
associated with the agricultural industry have also been linked to an increased risk of 
PD (Gatto et al., 2009; Priyadarshi et al., 2001).  In addition, people chronically 
exposed to welding fumes exhibited PD-like clinical features (Jankovic, 2005) and 
this was attributed to the high levels of manganese in these fumes (Jankovic, 2005).  
Further, metals such as iron and copper accumulate in SN and contribute to the 
production of hydrogen peroxide during the enzymatic oxidation of dopamine and 
the conversion of hydrogen peroxide to hydroxyl radicals (Dexter et al., 1989b; 
Earle, 1968).  There is a large body of epidemiological evidence of a link between 
exposure to toxins and PD, providing good grounds for further investigating the 
effects of long term exposure to toxins.  Nevertheless, toxin exposure only increases 
the risk and does not cause PD in all exposed individuals, suggesting that some 
people may be more susceptible than others and this could be due to genetic factors.    
In view of the evidence, the theory that a combination of genetic and 
environmental factors leads to PD may be a plausible possibility.  Although the 
causal factors are still not fully understood, PD has well defined pathological 
hallmarks. 
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1.1.3 Pathology of PD 
The pathological hallmarks of PD are a loss of dopaminergic neurones in the 
substantia nigra pars compacta (SNpc) and presence of inclusion bodies termed 
Lewy bodies (LBs) in surviving neurons.  Inflammatory gliosis is also considered a 
hallmark of PD pathology (see Section 1.1.4.g). 
The main site of dopaminergic neuronal loss in PD is the SNpc leading to 
depletion of dopamine from terminals in the striatum.  The depletion of striatal 
dopamine causes motor symptoms of PD because the nigro-striatal pathway is a 
major component of the basal ganglia that controls voluntary movement.  Motor 
symptoms of PD do not manifest until approximately 50-60% of nigral dopaminergic 
cell bodies have degenerated and about 70-80% decrease of striatal dopamine content 
is reached (Agid, 1991; Fearnley et al., 1991).  This is due to compensatory 
mechanisms, acting to maintain normal function, which include increased dopamine 
turnover and an increase in post-synaptic dopamine D2 receptors in the striatum 
(Bezard et al., 2003).  As neuronal loss progressively increases, compensatory 
mechanisms eventually become unable to maintain normal basal ganglia function 
and clinical symptoms appear.  Neurodegeneration also occurs in other brain regions 
including locus coeruleus (LC), raphe nuclei (RN), dorsal motor nucleus of the vagus 
(DMNV), nucleus basalis of meynert (NBM), the olfactory system and in peripheral 
autonomic ganglia, although to a lesser extent (Javoy-Agid et al., 1984; Lang et al., 
1998; Zarow et al., 2003).  Degeneration in these areas may be responsible for the 
non-motor symptoms, for example anxiety and depression are linked to the loss of 
noradrenergic and serotonergic neurons in the LC and RN and dementia is believed 
to be the result of the degeneration of the cholinergic system (Calabresi et al., 2006; 
Hanagasi et al., 2005).  
Neuronal degeneration is accompanied by the formation of LBs.  LBs are 
intraneuronal proteinaceous cytoplasmic inclusions composed of various proteins 
includin ubiquitin and α-synuclein (Olanow et al., 2004).  In PD, LBs are found in 
the remaining neurones of SN but also in noradrenergic neurons of LC, cholinergic 
neurones of the DMNV and NBM and in the hypothalamus (den et al., 1960; 
Langston et al., 1978; Olanow et al., 2004).  The role of LBs in PD is not well 
understood.  Recent evidence showed that clinically healthy individuals with α-
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synuclein-immunoreactive LBs, incidental lewy body disease (ILBD) have reduced 
striatal Tyrosine hydroxylase (TH) and VMAT2 and nigal neuron loss, indicating 
that ILBD may be an early stage of PD (DelleDonne et al., 2008).  This suggests that 
LBs may be formed before clinical manifestation of the disease.  In addition, the 
increase of LB numbers in the SN is suggested to be associated with less surviving 
dopaminergic neurons (de la Fuente-Fernandez et al., 1998).  These findings may 
suggest that LBs contribute to or at least are an indication of pathogenic load on 
neurones, but some suggest that LBs may be protective to neurons by means of 
removing potentially toxic proteins (Olanow et al., 2004). 
Braak et al. analysed brains from PD patients and asymptomatic subjects with 
LB pathology, with varying spread of pathology using α-synuclein immunopositive 
Lewy neurites and LBs as a neuropathological marker and suggested a 
neuropathological staging procedure describing the progress of pathology in terms of 
topographical extent (Braak et al., 2003).  According to the authors, pathology starts 
at the dorsal motor nucleus of the vagal nerve (stage 1) gradually progressing in an 
ascending fashion to reach the neocortex at stages 5-6 (Figure 1.1).  The SN only 
starts to be affected at stage 3 but the symptomatic phase is suggested to start at 
stages 4-5 where severe neuronal loss occurs at the SN.  This may be an explanation 
of the progressive nature of PD.  However, this staging procedure received the 
criticism that it is based on the presence of α-synuclein not neuronal loss and on the 
assumption that pre-symptomatic patients with LBs will develop PD at a later stage 
(Linazasoro, 2007).  In addition, other studies showed evidence of cases that do not 
follow the stages described by Braak et al. since in some cases there was α-synuclein 
pathology in the SN but not in the LC and DMNV (Jellinger, 2008; Parkkinen et al., 
2005).    
LBs are clearly associated with degeneration of dopaminergic neurons.  
However, in PD, not all nigral neurons contain LBs (Halliday et al., 1990) suggesting 
that there may be differences in the pathogenic processes in neurons or that some 
neurons may take longer to form or do not form LBs.  It may also suggest a 
complexity in the pathogenesis leading to neurodegeneration in PD.  Death of nigral 
dopaminergic neurones is in fact a result of complex and interrelated pathogenic 




Figure 1.1 Neuropathological stages of PD. 
(A,B) PD neurodegenerative pathology spreads in an ascending pathway in the brain 
in 6 stages (Braak et al., 2004).  White arrows indicate the ascending pathology 
process.  
 
1.1.4 Mechanisms of cell death 
The exact mechanism by which nigral dopaminergic neurons undergo 
degeneration is still unknown.  Evidence indicates that mitochondrial dysfunction, 
oxidative and nitrative stress, inflammation, proteasomal system dysfunction, 
necrosis and apoptosis are all involved in cell death of dopaminergic neurons in PD 
as discussed below.  There is also cumulative evidence that excitotoxicity contributes 
to cell death in PD, but this awaits confirmation by direct evidence from PD brains 
(Olanow, 2007).  Nevertheless, the precise way and exact order in which these 
pathways lead to cell death remains to be solved.  
1.1.4.a Apoptosis and necrosis 
Necrosis is suggested as a possible cell death mechanism in PD (Jellinger, 
2000), although strong evidence supporting this has not been found.  Indirect 
evidence of the involvement of necrosis in dopaminergic cell death comes from the 
ability of dopaminergic neurotoxins to cause necrotic cell death in dopaminergic cell 
lines (Maruyama et al., 2000; Ochu et al., 1998).  Necrosis is a passive form of cell 
death characterised by loss of ATP, cell swelling, membrane and organelle 
degradation and ultimately cell lysis, causing release of cell content and damage to 
surrounding tissue (Levin et al., 1999).  Conversely, apoptosis is programmed cell 
death, characterised by morphological changes including cell shrinkage, nuclear 
condensation, and DNA degradation (Majno et al., 1995).  There is a large body of 
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evidence suggesting the involvement of apoptosis as a major cell death pathway in 
PD pathogenesis.  In-vitro, the dopaminergic neurotoxin 6-OHDA was found to 
induce apoptosis in PC-12 cells, and primary dopaminergic cells (Blum et al., 2001; 
Blum et al., 1997; Lotharius et al., 1999).  MPP
+
 treatment also induces apoptosis in 
PC-12 and VM culture cells (Hartley et al., 1994; Viswanath et al., 2001).  In 
addition, inhibition of apoptosis seems to prevent cell death.  Pre-treatment of PC-12 
cells with caspase inhibitors protected the cells from 6-OHDA induced apoptosis 
(Takai et al., 1998).  Overexpression of the anti-apoptotic protein bcl-2 also 
prevented 6-OHDA induced apoptosis (Offen et al., 1997; Takai et al., 1998).  
Moreover, animal studies have also provided evidence for the possible 
involvement of apoptosis in PD.  6-OHDA lesioning of rats induces apoptosis of 
nigral dopaminergic neurons (He et al., 2000; Zuch et al., 2000) as demonstrated by 
an increase in the terminal deoxynucleotidyl transferase-mediated dUTP nick end-
labeling (TUNEL) staining and morphological changes.  MPTP treated mice also 
showed evidence of apoptotic cell death including DNA fragmentation, JNK 
activation and bax mRNA upregulation (Saporito et al., 2000; Tatton et al., 1997; 
Vila et al., 2001b).  Additionally, ablation of the pro-apoptotic Bax gene as well as 
overexpression of bcl-2 were shown to provide protection against MPTP-induced 
nigral dopaminergic cell death in mice (Offen et al., 1997; Vila et al., 2001b; Yang et 
al., 1998). 
In post-mortem studies, morphological signs of apoptosis such as chromatin 
condensation and irregular nuclear morphology are evident in brains of PD patients 
(Anglade et al., 1997; Kingsbury et al., 1998; Tompkins et al., 1997).  In addition, an 
increase in the expression of the apoptotic markers bax and caspase-3 was observed 
in SN in PD (Hartmann et al., 2000; Tatton, 2000)  as well as an increase in the level 
of the anti-apoptotic protein bcl-2 (Mogi et al., 1996).  In a separate study, caspase-1 
and caspase-3 activity were significantly higher in the SN of PD patients compared 
to controls (Mogi et al., 2000).  Conversely, some studies failed to find evidence of 
apoptotic cell death in post mortem PD tissue (Jellinger, 2000; Vyas et al., 1997).  
This, however, maybe due to the use of less sensitive classical histochemical 
techniques.  
In summary, there is some evidence of the involvement of necrosis in PD but 
this has not been extensively studied.  On the other hand, although some groups 
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failed to find evidence of apoptosis in PD, there is a large body of evidence from in-
vitro, in-vivo and post mortem PD brains suggesting that cell death in PD is more 
likely apoptotic.  The exact pathway leading to apoptosis is unknown but oxidative 
and nitrative stress, mitochondrial dysfunction, inflammation, UPS dysfunction and 
autophagy are suggested to be contributory mechanisms. 
1.1.4.b Oxidative stress 
Oxidative stress is implicated as a major pathogenic pathway in dopaminergic 
neurodegeneration.  It is defined as the imbalance between production of ROS and 
endogenous anti-oxidant systems.  Many cellular reactions such as mitochondrial 
oxidative respiration and dopamine metabolism require the use of molecular oxygen 
for catalysis and energy production.  A consequence of these reactions is production 
of reactive oxygen species (ROS) such as superoxide anions, hydrogen peroxide, 
hydroxyl radicals, peroxy radicals which are all important for physiological functions 
(Imlay, 2003).  However, overproduction of ROS can lead to damage and destruction 
of DNA, proteins and membranes (Loh et al., 2006).  Interestingly, oxidative stress 
seems to increase with age as there is evidence of more oxidized proteins, including 
carboxyls and nitro-protein adducts in ageing brains (Cardoso et al., 2005; Mariani et 
al., 2005).  Elderly brains also have higher levels of 8-hydroxy-2-deoxy-guanosine 
(8-HDG), a marker of oxidized DNA, in both nuclear and mitochondrial DNA 
(Mariani et al., 2005).  This may be a predisposing factor to neurodegenerative 
disease involving oxidative stress.  In fact, dopaminergic neurons may be particularly 
subjected to oxidative stress due to production of free radicals during dopamine auto-
oxidation or metabolism (Lotharius et al., 2002; Perez et al., 2004).  Dopamine has a 
tendency to auto-oxidize into dopamine-quinone species, superoxide radicals, and 
hydrogen peroxide (Graham et al., 1978).  These molecules are either highly reactive 
molecules or can quickly generate free radicals.  However, dopamine metabolism 
alone cannot explain neurodegeneration in PD since other non-dopaminergic 
neuronal types also undergo degeneration (Ahlskog, 2005).  
Direct evidence of oxidative stress was found in post mortem PD brains where 
there was an increase in protein carbonyls, proteins with oxidised amino acids in the 
SN (Alam et al., 1997; Floor et al., 1998).  Increased levels of lipid peroxidation 
markers including malondialdehyde, cholesterol lipid hydroperoxides and 4-
hydroxy-2-nonenal have also been reported in the SN of PD brains (Dexter et al., 
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1989a; Dexter et al., 1994; Yoritaka et al., 1996; Zhang et al., 1999).  In addition, 8-
HDG is shown to be increased in the SN and striatum of PD patients (Alam et al., 
1997; Zhang et al., 1999). 
Endogenous antioxidants such as glutathione and vitamin E as well as 
antioxidant enzymes such as superoxide dismutase, catalase and gluthathione 
peroxidase exist in cells in order to balance the oxidative mechanisms.  For example, 
superoxide dismutase can decrease oxidative stress by metabolising the conversion 
of superoxide to H2O2 which is then transformed into water and oxygen by catalase 
(Lin et al., 2005).  Decreased levels of endogenous antioxidants contribute to the 
oxidative stress in cells.  In fact, levels of glutathione and its oxidized product, which 
act as antioxidants, were found to be decreased in SN of PD brains compared to 
control (Pearce et al., 1997; Sofic et al., 1992).  Levels of glutathione are also 
decreased in individualss with ILBD, which may be indicative of pre-symptomatic 
PD, to a level similar to that in advanced PD, suggesting that oxidative stress is an 
early event in the pathogenesis of PD (Dexter et al., 1994).    
In conclusion, there is considerable evidence to suggest oxidative stress as a 
pathogenic pathway in dopaminergic cell death.  Oxidative stress, in turn, may 
precipitate other cell death pathways.  It can affect performance of the ubiquitin-
proteasome system (UPS) by oxidation of proteins of the proteasome (Reinheckel et 
al., 2000; Shamoto-Nagai et al., 2003) and may increase the load on the UPS system 
by the accumulation of oxidatively damaged proteins within cells.  There is also 
evidence suggesting a link between mitochondrial dysfunction and oxidative stress.  
For instance, mice deficient in superoxide dismutase or glutathione peroxidase show 
higher vulnerability to the mitochondrial toxin MPTP (Klivenyi et al., 2000).   
Furthermore, ROS not only contribute to oxidative stress but also react with nitric 
oxide (NO) leading to the accumulation of reactive nitrogen species (RNS) which 
contribute to nitrative stress, another pathway implicated in cell death in PD.      
1.1.4.c Nitrative stress 
Nitrative stress occurs when there is an imbalance between (RNS) and the anti-
oxidant defence mechanisms.  Nitrative stress results from excessive formation of the 
free radical NO which reacts with ROS leading to the accumulation of RNS such as 
peroxynitrite (EstÉVez et al., 2002).  Peroxynitrite can directly cause oxidative 
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damage to several molecules or indirectly by forming other reactive radicals 
including hydroxyl radicals (EstÉVez et al., 2002).  Peroxynitrite can then oxidise or 
nitrate many vital macromolecules including tyrosine residues, thiols and DNA 
leading to DNA strand breaks, disruption of protein integrity and enzyme 
dysfunction (Beckman et al., 1996; Kennedy et al., 1997).   
Nitrative stress is suggested to be involved in the pathogenesis of PD and this 
is demonstrated by the evidence of accumulation of nitrated α-synuclein in LBs of 
post-mortem PD brains (Giasson et al., 2000; Good et al., 1998).  There is also 
evidence of nitrated α-synuclein in the SN of MPTP-treated mice (Schapira et al., 
2010).  In addition, 3-nitrotyrosine (3-NT), which results from protein nitration, was 
found to be increased in the ventral midbrain and striatum of MPTP-treated mice 
(Pennathur et al., 1999).  Further, presence of inducible nitric oxide synthase (iNOS) 
is evident in the SN of PD brains (Hunot et al., 1996).  iNOS produces high amounts 
of NO (Luo et al., 2000) and is induced in the brain in pathological situations such as 
inflammation, infection and ischemia and also in the aging brain (Licinio et al., 
1999).  In PD, iNOS is induced in glial cells, particularly in microglia (Hunot et al., 
1996; Knott et al., 2000b).  iNOS is induced in microglia following 
Lipopolysaccharide  (LPS) and MPTP treatment in rodents (Arimoto et al., 2003; 
Dehmer et al., 2000; Iravani et al., 2002; Iravani et al., 2005; Liberatore et al., 1999).   
Moreover, the tyrosine-nitration of mitochondrial complex-I resulting in its 
inhibition is suggested to be involved in the pathogenesis of PD (Murray et al., 
2003).  In fact, nitration of mitochondrial complex-I has been associated with a 
decrease in glutathione levels (Bolanos et al., 1996).  Further, nitration of striatal TH, 
enzyme involved in synthesis of dopamine, in MPTP-treated mice resulted in 
enzyme inactivation and consequently failure of dopamine synthesis (Ara et al., 
1998).  There is further indirect evidence of the involvement of nitrative stress in PD 
pathology as, for instance, nitric oxide synthase (NOS) inhibitors were shown to 
protect against LPS induced nigral cell death in rats (Iravani et al., 2002).  iNOS KO 
mice are also protected against MPTP toxicity (Liberatore et al., 1999). 
In summary, there is strong evidence to suggest the implication of nitrative 
stress as a pathogenic mechanism in PD.  However, it is not fully clear how nitrative 
stress is linked to the cascade of events leading to cell death in PD. 
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1.1.4.d Mitochondrial dysfunction 
Mitochondrial dysfunction has been implicated as one major pathogenic 
pathway in PD.  Mitochondria are the energy manufacturing entity in the cell and 
their dysfunction results in energy deficiency and activation of cell death pathways.  
Understanding the role of mitochondrial dysfunction in the underlying pathology of 
PD stems from studies of the MPTP-induced Parkinson-like syndrome in man 
(Langston et al., 1983) and non-human primates (Burns et al., 1983).  MPTP leads to 
dopaminergic cell death in humans via inhibition of mitochondrial complex I by 
inhibiting the enzyme nicotinamide dehydrogenase (NADH) (Singer et al., 1987) and 
by generating free radicals (Cleeter et al., 1992).  Inhibition of NADH, in turn leads 
to superoxide production and lipid peroxidation (Hasegawa et al., 1990a; Sriram et 
al., 1997).  This suggested that mitochondrial dysfunction may contribute to 
neurodegeneration in PD.  This concept is supported by evidence that other toxins 
which cause complex I inhibition such as rotenone, also lead to selective nigral 
dopaminergic cell death in rats and formation of inclusion bodies (Sherer et al., 
2003b).    
The involvement of mitochondrial dysfunction in PD is reinforced by evidence 
from post-mortem studies in idiopathic PD brains where there is a 30-40% decrease 
in mitochondrial complex I activity in SN (Janetzky et al., 1994; Mann et al., 1994; 
Schapira et al., 1990).  There is also a decrease in complex I proteins in the SN of 
individuals with PD (Mizuno et al., 1989).  Specificity of complex I deficiency was 
demonstrated by reduced histochemical staining of complex I subunits in PD but not 
other respiratory chain complexes (Hattori et al., 1991) in addition to the finding that 
it is the only complex affected by endogenous oxidative damage and reduced 
structural stability in PD (Keeney et al., 2006).  Recently, mitochondrial complex I 
impairment was observed in the frontal cortex of PD patients (Parker Jr et al., 2008).   
Additionally, complex I activity was decreased in platelet mitochondria from 
PD patients (Haas et al., 1995).  In fact, transfer of mitochondrial DNA (mtDNA) 
from platelets of PD patients to cells lacking mtDNA resulted in recipient cybrid 
cells with complex I deficiency, suggesting a genetic base to mitochondrial 
dysfunction (Gu et al., 1998; Swerdlow et al., 1996).  In fact, the cybrid cells showed 
higher ROS production and increased susceptibility to MPP
+ 
(Swerdlow et al., 1996).  
An increase in deleted nigral mtDNA was observed in post-mortem PD brains 
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(Bender et al., 2006).  Furthermore, the fact that genes causing familial PD encode 
mitochondrial proteins such as PINK1 and DJ-1 suggests that mutations in these 
genes may lead to PD via vulnerability or dysfunction of mitochondrial proteins 
(Schapira, 2008a).  In support of this concept, PINK1 KO mice displayed impaired 
mitochondrial function, and higher sensitivity to oxidants (Gautier et al., 2008) and 
DJ-1 mutations are associated with higher sensitivity to oxidative stress and greater 
nigro-striatal neurodegeneration following MPTP treatment (Kim et al., 2005). 
Mitochondrial dysfunction, in turn, may precipitate other pathological 
pathways.  Inhibition of complex I activity by MPTP in-vitro leads to increased 
production of peroxide radicals hence contributing to oxidative stress (Hasegawa et 
al., 1990b).  Also, defective mitochondrial complex I leads to higher vulnerability of 
cells to apoptosis due to the generation of free radicals and sensitisation of cells to 
the pro-apoptotic protein Bax (Perier et al., 2005).    
In view of the evidence, mitochondrial dysfunction is therefore an evident 
pathological mechanism in PD and may exacerbate other pathological pathways 
thought to be involved in dopaminergic cell death.  However, further work is 
required to establish the exact mechanism leading to cell death.     
1.1.4.e Ubiquitin proteasomal system impairment 
Failure of the ubiquitin-proteasome system (UPS) is also suggested to be 
involved in neuronal degeneration in PD.  The UPS is a protein degradation system 
for unwanted proteins including mis-located, mis-folded, mutant or damaged proteins 
(Ciechanover, 1998).  Proteins are first tagged with ubiquitin forming polyubiquitin-
protein conjugates (Hochstrasser, 1996; Pickart, 2000).  These tagged proteins are 
then identified and metabolised by the proteasomes (Brodsky et al., 1997; 
Hochstrasser, 1996; Pickart, 1997).  Failure of this system leads to accumulation of 
unwanted proteins within the neuron and may result in or contribute to cell death.  In 
fact, proteasome inhibition in neuronal cells in-vitro was found to be associated with 
the accumulation of ubiquitinated proteins, a pro-inflammatory response and 
apoptotic cell death (Canu et al., 2000; Rockwell et al., 2000). 
The link between failure of the UPS and PD was supported by the finding that 
LBs in PD accumulate ubiquitinated proteins involved in the UPS such as parkin, 
ubiquitin, and UCHL-1 (Olanow et al., 2004) and that mutations in genes involved in 
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protein processing and degradation including parkin, UCHL-1 and ubiquitin have 
been found in familial cases of PD (Bekris et al., 2010).  In addition, systemic 
administration of proteasomal system inhibitors in rodents resulted in nigral 
dopaminergic degeneration and formation of α-synuclein and ubiquitin positive 
inclusions (Bukhatwa et al., 2009; McNaught et al., 2004; Sun et al., 2006).  Direct 
evidence from post-mortem brains of PD patients has immerged to support a role of 
the failure of the UPS in the pathogenesis of PD.  A reduction of proteasomal α 
subunit expression was observed in SNpc dopaminergic neurons of sporadic PD 
patients compared to control (Bukhatwa et al., 2010b; St. P. McNaught et al., 2003).  
Further, proteasomal enzymatic activity was found to be reduced in SN from PD 
patients compared to control (Bukhatwa et al., 2010a; Olanow et al., 2006).   
In summary, there is evidence of impaired UPS function in PD which may 
result in accumulation and aggregation of damaged and misfolded proteins ultimately 
causing cell death.  This protein load on cells can also be caused by dysfunction of 
lysosomal degradation.   
1.1.4.f Autophagy 
Autophagy is normally part of the homeostatic system in cells, it is a 
mechanism for the degradation of unwanted proteins including long-lived proteins, 
aggregate-prone proteins and cytoplasmic organelles (Rubinsztein, 2006).  There are 
three types of autophagy, macroautophagy; in which proteins are sequestered into 
autophagosomes which then fuse with lysosomes, microautophagy; in which proteins 
are sequestered directly into lysosomes and chaperon mediated autophagy (CMA); in 
which target proteins are recognised by heat-shock cognate 70 (Hsc70), followed by 
transportation directly into the lysosomes (Yang et al., 2010).  A number of studies 
have shown that CMA is involved in alpha-synuclein degradation (Cuervo et al., 
2004; Vogiatzi et al., 2008; Webb et al., 2003).  In fact, inhibition of autophagy leads 
to the accumulation of mono-ubiquinated alpha-synuclein, which can trigger 
aggregation (Rott et al., 2008).  In addition, A53T and A30P mutants of alpha-
synuclein, which cause familial PD, were found to inhibit autophagy (Cuervo et al., 
2004) suggesting that these mutations may induce aggregation of alpha-synuclein 
through inhibition of autophagy.  Besides, inhibition of autophagy resulted in higher 
apoptosis in cell lines transfected with A53T or A30P mutants of alpha-synuclein 
than control cells (Yang et al., 2009).  Macroautophagy is involved in the 
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degradation of dysfunctional mitochondria.  Importantly, Parkin was found to 
contribute to mitochondrial turnover by facilitating macroautophagy of dysfunctional 
mitochondria (Narendra et al., 2008).  Therefore, Parkin mutation, present in familial 
PD, may lead to impairment of mitochondrial turnover and thereby contribute to cell 
death.  Deletion of PINK1 gene -involved in the regulation of mitochondrial function 
and mutations of which are present in some familial PD cases- is shown to induce 
autophagy of mitochondria (Dagda et al., 2009).  This suggests that autophagy is 
implicated in mitochondrial turnover and failure of this degradation mechanism may 
be linked to cell death in PD.  In conclusion, impairment of autophagy may lead to 
neuronal cell death via accumulation of aggregated proteins and dysfunctional 
mitochondria. 
On the other hand, some suggest that excessive activation of autophagy may 
also be pathogenic (Bredesen et al., 2006).  In support of this, in-vitro treatment with 
MPP
+
 is shown to increase autophagic vacuoles (Zhu et al., 2007) and 
overexpression of A53T mutant of α-synuclein leads to autophagic cell death in PC-
12 cells and nigro-striatal system (Kirik et al., 2002; Stefanis et al., 2001; Xilouri et 
al., 2009; Yang et al., 2009).  In PD there is evidence of abnormal levels of 
autophagic vacuoles compared to normal brains (Anglade et al., 1997; Zhu et al., 
2003).  However, this may be due to over activation of autophagy but it may also be 
due to inability of cells to clear these vacuoles.     
In light of the evidence, suboptimal activation or over-activation of autophagy 
may have detrimental effects on neurons.  There is cumulative evidence that 
disregulation of autophagy may contribute to cell death in PD, but solid direct 
evidence supporting this is still lacking.    
1.1.4.g   Inflammation   
There is considerable evidence of an inflammatory involvement in the 
pathology of PD.  Cytokines such as TNF-α, IL-1β and IL-6 are expressed at high 
levels in SN and CSF of PD patients (Mogi et al., 1994; Nagatsu et al., 2000).  These 
cytokines are thought to be responsible for many pathological and clinical 
manifestations of peripheral inflammatory diseases including rheumatoid arthritis 
and inflammatory bowel syndrome.  In fact, glial cells expressing IL-1β and/or TNF-
α were found in SN of PD patients (Boka et al., 1994; Hunot et al., 1999).  
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Furthermore, in post mortem brains of PD patients there is evidence of activation of 
microglia (McGeer et al., 1988).  Activated microglia are also seen in SN of humans 
exposed to MPTP (Langston et al., 1999).  Microglia are the resident 
immunocompetent phagocytic cells of the central nervous system which become 
activated in pathological events such as inflammation, infection and ischemia 
(Wojtera et al., 2005).  Activated microglia up-regulate cell surface receptors such as 
the macrophage antigen complex-I (MAC-1) and secrete pro-inflammatory cytokines 
such as IL-1β, tumor necrosis factor α (TNF-α), and NO, the overproduction of 
which can be neurotoxic (Nakamura, 2002).  On the other hand, moderately activated 
microglia can play a protective role, where they scavenge neurotoxins, engulf dead 
cells and debris and release trophic factors such as brain-derived neurotrophic factor 
(Aloisi, 1999; Aloisi et al., 1999; Batchelor et al., 1999; Nakamura, 2002).  Whether 
microglial activation protects or exacerbates neuronal loss remains debated (Hirsch 
et al., 2003) but there is a vast array of evidence supporting a toxic role of activated 
microglia and a role of inflammation in the degenerative process as discussed 
hereafter. 
Activated microglia in the SN in PD have been reported to express pro-
inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1, 
interferon IFN-γ (Boka et al., 1994; Mogi et al., 1994), iNOS (Nagatsu et al., 2000) 
and cyclooxygenase-2 (COX-2) (Knott et al., 2000a).  The pro-inflammatory 
cytokines TNF-α and IL-1 can trigger direct toxicity in neurons (Allan et al., 2001; 
Clarke et al., 2002) and can also potentiate an ongoing inflammatory response by 
enhancing microglial NO production (Hunot et al., 1999; Possel et al., 2000).  
Further, activated microglia release ROS and NO (Dringen, 2005; Hunot et al., 1996) 
in order to kill pathogens but these are also harmful to neurons and contribute to 
oxidative and nitrative stress in the brain. 
Further evidence that microglial activation can lead to neurodegeneration 
comes from studies of the lippopolysaccharide (LPS) model of PD, where nigral 
injection of LPS causes microglia and astrocyte activation and degeneration of 
dopaminergic neurons (Castano et al., 1998; Herrera et al., 2000; Iravani et al., 
2005).  LPS is a potent inducer of inflammation in the CNS (Goralski et al., 2004) 
and leads to dopaminergic cell death indirectly via activation of glial cells.  This is 
supported by evidence from in-vitro studies showing that, in the absence of 
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microglia, LPS does not cause dopaminergic cell loss (Iravani et al., 2005).  
However, in mixed neuron-glia cultures and neuron cultures with microglial-
conditioned media, LPS leads to neuronal death (Gao et al., 2002; Taylor et al., 
2003).  In addition, inhibition of iNOS attenuated LPS toxicity to neurons (Iravani et 
al., 2005).  Besides LPS; MPTP, rotenone and 6-OHDA animal models of nigral cell 
death in PD also display microglial activation in the SN (Cicchetti et al., 2002; 
Czlonkowska et al., 1996; Sherer et al., 2003a).  Whether inflammation is a primary 
event or secondary to neurodegeneration is still not known, though some evidence 
may suggest that inflammation is rather a precipitating factor.  For instance, in the 
rotenone model, microglial activation is seen before degeneration of dopaminergic 
neurones (Sherer et al., 2003a).  In contrast, other evidence supports the possibility 
that it is a secondary event since humans exposed to MPTP show activated microglia 
16 years after the last drug exposure (Langston et al., 1999).  Persistent microglial 
activation is also seen in primates years after MPTP treatment (Barcia et al., 2004; 
Langston et al., 1999).   
Astrocytes, another type of glia present in the SN are also involved in the 
inflammatory reaction associated with PD.  Astrocytes protect neurons from cell 
death by releasing neurotrophic factors such as GDNF and BDNF and by increasing 
activity of glutathione reductase (Chen et al., 2006; Ishida et al., 2006; Knott et al., 
2002).  In contrast, activated astrocytes may contribute to neuronal death as they 
were shown to release the cytotoxic compounds NO, glutamate and H2O2 in VM 
cultures (McNaught et al., 1999b).  Activated astroglia show an increase in the 
expression of glial fibrillary acidic protein (GFAP), enlarged cell body and processes 
(Eddleston et al., 1993).  In the SN of post-mortem PD brains there is evidence of 
astrocytes activation in some but not all cases of PD (Forno et al., 1992).  Activated 
astrocytes were also found in post-mortem brains of MPTP-exposed individuals 
(Langston et al., 1999).  In addition, astrocytic activation is also seen in animal 
models of PD such as MPTP treated monkeys (Kohutnicka et al., 1998; Liberatore et 
al., 1999) 6-OHDA lesioned rats (Gordon et al., 1997; Pasinetti et al., 1999; 
Rodriguez et al., 2001) and LPS lesioned rats (Castano et al., 1998; Herrera et al., 
2000).   
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Furthermore, evidence suggests that anti-inflammatory drugs may attenuate or 
prevent dopaminergic neurodegeneration indicating that the underlying mechanism 
of cell death is inflammatory in nature.  One epidemiological study found that 
NSAID use is associated with a 45% decrease in PD risk (Chen et al., 2003a).  
However, a later study found that NSAIDs use was associated with lower risk of PD 
in men but a higher risk in women (Hernan et al., 2006).  Interestingly, a lower risk 
of Alzheimer’s disease in NSAID users, or those suffering from diseases in which 
anti-inflammatory agents are routinely taken has been confirmed in more than 20 
studies (McGeer et al., 2007).  
Many investigations of anti-inflammatory agents have emerged with some 
promising in-vivo results. The tetracycline antibiotic derivative with anti-
inflammatory properties, minocycline, prevented nigral dopaminergic cell loss in the 
MPTP and 6-OHDA models (Du et al., 2001; He et al., 2001; Wu et al., 2002) and 
prevented iNOS up-regulation (Wu et al., 2002).  The anti-inflammatory 
glucocorticoid, dexamethasone, was shown to partially inhibit microglial activation, 
decrease release of pro-inflammatory cytokines and NO and to protect against 
dopaminergic neurodegeneration caused by MPTP and intra-nigral LPS (Castano et 
al., 2002).  A peroxisome proliferator-activated receptor-γ (PPARγ), pioglitazone has 
also shown neuroprotection against MPTP toxicity in mice (Breidert et al., 2002).  
The nonselective COX-2 inhibitor sodium salicylate has also shown neuroprotective 
activity in-vivo (Gao et al., 2003; Sanchez-Pernaute et al., 2004).  However, most 
anti-inflammatory agents tested have not reached the clinical stage and whether they 
will have an effect on progress of PD remains to be determined.  A recent phase II 
futility trial with minocycline in early onset PD patients recommended phase III 
trials to be conducted in order to determine whether minocycline would affect 
progression of the disease since it was well tolerated and improved the UPDRS score 
(investigators, 2008).   
In summary, there is a large body of evidence supporting the involvement of 
inflammation in PD pathogenesis.  However, it is still not known whether 
inflammation precedes or occurs as a result of neuronal degeneration.  Although 
clinical trials have not yet determined whether anti-inflammatory agents have 
neuroprotective activity in PD patients, pre-clinical data indicates that an anti-
inflammatory agent may have protective effects.  Inflammation is an important 
 45 
process in the brain, and it seems that if regulated properly, it is beneficial to neurons 
in case of injury by eliminating damaged neurons and promoting survival of those 
that have a possibility to survive (Marchetti et al., 2005).  However, inflammation 
can become a chronic uncontrolled process.  Therefore, studying regulatory factors 
of inflammation may help elucidate agents that would maintain protective effects but 
not deleterious ones.  One such factor may be the protein osteopontin (OPN), a 
protein released in inflammatory processes and promotes tissue repair and cell 
survival.  This may be a good candidate to investigate as a potential neuroprotective 
treatment for PD since it was recently shown to be expressed in the SN and its levels 
reduced in remaining dopaminergic neurons in PD (Iczkiewicz et al., 2006).  The 
properties of OPN and its potential for neuroprotection are explained in the following 
section and its effects in models of nigral cell death form the basis of this thesis. 
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1.2 OPN: a potential neuroprotective agent  
OPN, a phosphorylated glycoprotein first isolated from transformed cells as a 
60kDa protein in 1979 (Senger et al., 1979).  Subsequently, it was discovered by 
separate groups as a transformation association gene 2ar (Smith et al., 1987) and as a 
cytokine released by activated macrophages and lymphocytes and was named early 
lymphocyte activation gene 1 (Eta-1) (Patarca et al., 1989a).  Interestingly, as 
discussed below, OPN is shown to regulate inflammation, reduce nitrative and 
possibly oxidative stress, inhibit apoptosis and to be present in the brain.  Therefore, 
this protein may have multifactorial protective effects and will be investigated as a 
potential protective agent against the degeneration of dopaminergic neurones in PD.  
Structure, functions, and receptors mediating effects of OPN are described below. 
1.3 OPN structure  
OPN belongs to a family of proteins, all being expressed in bone or dentin and 
having the ability to bind at least one receptor from the integrin family, together 
termed SIBLING (small integrin binding ligand N-linked glycoproteins) (Fisher et 
al., 2001).  Proteins of this family are coded by genes situated on chromosome 4 in 
man.  They act as signal transducers to promote cell adhesion, motility and survival 
but each protein has specific roles (Bellahcene et al., 2008).  OPN is expressed as a 
34 kDa nascent protein by a single copy gene and is subject to substantial post–
translational modifications explaining the varying reported size (44 to 75 kDa) 
(Kasugai et al., 1991; Senger et al., 1989; Wrana et al., 1991).  It consists of 264 to 
301 amino acids depending on the species.  Moderate levels of sequence 
conservation (40%) between five species (rat, mouse, human, pig, cow) exist in the -
NH2 and -COOH terminal regions (Butler, 1995) suggesting functional importance of 
these sequences.  The amino acid serine shows the highest level of conservation 
(24% in all 6 species are conserved) and glutamic acid shows a relatively high level 
of conservation (17%), indicating the importance of sequences subject to kinase 
activities and phosphorylation (Butler, 1995).  In fact, OPN undergoes heavy post-
translational modifications which may regulate its function as explained henceforth. 
OPN is acidic in character, being rich in aspartic acid and glutamic acid 
(Butler, 1995; Chen et al., 1992; Prince, 1989).  It contains N- and O-glycosylation 
sites in addition to multiple consensus sites for possible Ser and Thr phosphorylation 
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(Christensen et al., 2005; Senger et al., 1994; Sørensen et al., 1995) suggesting 
possibility of tissue specific isoforms of OPN.  Conservation and juxtaposition of 
several serine and glutamic acid residues suggests that phosphorylation of the protein 
is important to its function (Butler, 1995).  This is supported by reports of different 
functions of the protein to be related to different phosphorylation patterns (Nemir et 
al., 1989; Singh et al., 1990).  In addtion, the degree of phosphorylation affects the 
effectiveness of mineralization (Gericke et al., 2005) and mineral induction (Salih et 
al., 2002). 
OPN contains a conserved polyaspartic acid motif which is suggested to bind 
the protein to hydroxyapatite and calcium ions (Butler, 1995; Gorski, 1992), an RGD 
(arg-gly-asp) integrin binding domain (Butler, 1995; Oldberg et al., 1986) and a 
second integrin binding sequence SVVYGLR (ser-val-val-tyr-glu-leu-arg) (Yokasaki 
et al., 2000) (Figure 1.2).  These are the main identified receptor binding sites of the 
protein.  The region consisting of about 50 amino acids bracketing the RGD 
sequence exhibits the highest level of sequence conservation, suggesting importance 
of this sequence to the function of the protein (Denhardt et al., 1993).  OPN also 
contains two consensus heparin binding domains (Prince, 1989).  Besides integrins, 
OPN also binds to the CD44 receptor but the exact binding domain has not been 
determined (Weber et al., 1996a).  Additionally, the protein is cleaved by thrombin at 
the RS (arg-ser) site, 7 amino acids away from the RGD site (O'Regan et al., 1999; 
Senger et al., 1994).  Thus thrombin cleavage may regulate the interaction with 
integrin receptors.  This concept is supported by evidence showing that thrombin 
cleavage enhances actions of OPN such as cell attachement and spreading (Senger et 
al., 1994) and that it is necessary for interaction with integrins α9β1 and α4β1  
(Bayless et al., 2001; Smith et al., 1996; Yokasaki et al., 2000).  OPN is also a 
substrate for cleavage by matrix metalloproteinase 3 (MMP-3) and MMP-7 at a 
limited number of sites including the GL sequence immediately before thrombin 
cleavage site (Agnihotri et al., 2001).  Cleavage by MMPs also enhances OPN 
mediated cell adhesion and migration (Agnihotri et al., 2001).  The COOH terminal 
half of the protein after thrombin cleavage contains a non RGD cell attachment site, 
identity and significance of which are unknown (van Dijk et al., 1993).  This 
attachement, however, was inhibited by RGD peptides and anti-αvβ3 antibody (van 
Dijk et al., 1993).  The secondary structure of OPN (Figure 1.2b) was predicted to 
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contain eight α-helices and six segments of β-sheets (Denhardt et al., 1993) but the 
full structure is yet to be solved.  In summary, OPN can bind many receptors and is 
subject to extensive post translational modifications that may influence its function 
and receptor-binding.  This may explain the multiple actions OPN is reported to 










Figure 1.2 OPN predicted structure and the main functional domains. 
(a) Amino acid sequence of homo sapiens OPN, Pubmed accession number, 
AAC28619.  (b) Mammalian OPN schematic structure predicted from amino acid 
sequence and secondary structure prediction methods.  Predicted and demonstrated 
post-translational modifications sites are shown on the structure.  OPN is cleaved by 
thrombin into two equivalent size fragments; the N-terminal contains 
hydroxyappatite (1) and integrin binding sites RGD; (2) and SVVYGLR; (3), and the 
C-terminal fragment contains consensus calcium; (4) and heparin; (5) binding 
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1.4 OPN function  
OPN is involved in cell adhesion and migration
 
by receptor interaction, leading 
to downstream signalling
 
events that include calcium mobilization, protein 
phosphorylation,
 
and regulation of gene expression (Denhardt et al., 1995).  OPN is 
expressed in many tissues where it is reported to play different roles as discussed 
hereafter.  The link between functions of OPN in different tissues is not very clear 
but overall it seems to exert effects related to its ability to bind calcium, regulate 
inflammation and support cell survival as summarised below.  
1.4.1 OPN in bone, kidney, heart and cancer 
OPN is one of the major non-collagenous proteins in bone and is secreted by 
osteoclasts, osteoblasts, osteocytes and chondrocytes (Denhardt et al., 1993).  In its 
phosphorylated form, OPN plays a critical role in remodelling of mature bones and 
negatively regulates bone calcification (Denhardt et al., 2001; Sodek et al., 2000).  
OPN null mice exhibit significantly less bone loss following ovariectomy compared 
to wild type controls (Yoshitake et al., 1999) suggesting a role of OPN in bone 
resorption.  It also promotes attachment of bone cells to bone matrices (Butler, 
1995).  In addition, OPN may play a role in regulating calcium phosphate crystal 
deposition.  Due to the abundance and distribution of aspartate and phosphorylated 
serine residues, it binds strongly to calcium phosphate crystals in mineralized tissues 
and inhibits crystal growth (Jono et al., 2000; Sodek et al., 2000).   
In the kidney, OPN is synthesised and secreted into urine by epithelial cells 
(Hudkins et al., 1999; Kleinman et al., 1995).  OPN is suggested to inhibit renal 
stone formation as it was shown to reduce growth and aggregation of calcium oxalate 
crystals in-vitro (Asplin et al., 1998; Shiraga et al., 1992).  OPN can also directly 
inhibit binding of calcium oxalate crystals to renal epithelial cells in culture (Lieske 
et al., 1995).  In addition, OPN null mice but not wild type mice develop significant 
intratubular deposition of calcium oxalate after induced hyperoxaluria (Wesson et 
al., 2003).  In the same study, in wild type mice, absence of calcium oxalate 
deposition was accompanied by up-regulation of OPN expression suggesting that 
OPN was expressed to protect against calcium oxalate deposition.   Additionally, 
OPN is upregulated in renal injury in a pattern that correlates with monocyte 
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infiltration (Padanilam et al., 1996; Pichler et al., 1994).  This suggests an 
involvement of OPN in the inflammatory response to kidney injury. 
OPN is not expressed in normal cardiac muscle tissue, but it is thought to 
promote tissue repair after inflammation by inducing myocardial fibrosis and 
remodelling (Liaw et al., 1998b; Murry et al., 1994a; Trueblood et al., 2001).  Its 
presence has been detected in association with injured tissue in disease states such as 
dilated cardiomyopathy, hypertrophic cardiomyopathy, and ventricular tachycardia.  
In atherosclerosis, OPN is expressed in plaques in smooth muscle cells, epithelial 
cells and infiltrating macrophages (Giachelli et al., 1995).        
OPN is implicated in many cancers including breast, colon, prostate, 
osteosarcomas and melanomas (Furger et al., 2001; Weber, 2001).  It is thought to 
contribute to metastasis formation by reducing nitrative and oxidative stress 
produced by host macrophages (Denhardt et al., 1994; Feng et al., 1995).  In support 
of this, down-regulating OPN has been shown to increase tumour sensitivity to 
macrophage cytotoxicity (Gardner et al., 1994).  In addition, its anti-apoptotic 
properties may contribute to anchorage independent tumour growth (Thalmann et al., 
1999).  Investigations using OPN null mice showed conflicting results.  Some studies 
showed that OPN does not have an effect on tumourgenesis (Chen et al., 2003b; 
Feng et al., 2000).  In contrast, other studies reported that OPN secreted by the 
tumour  promotes its growth whereas OPN secreted by macrophages causes 
macrophage chemo-attraction and contributes to the host’s tumour reducing actions 
(Crawford et al., 1998).  The varying results may be due to the difference in tumour 
cell type.  Different actions of OPN released from various cell types suggest that 
OPN’s function may be regulated at the post-translational level.  Differential actions 
of OPN in host and tumour cells, taken together with constitutive OPN expression in 
many other normal tissues suggest that OPN expression does not necessarily confer a 
tumorigenic phenotype.     
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1.4.2 OPN in immunity, inflammation and tissue repair 
There is a large body of evidence for the involvement of OPN in the immune 
system though the exact role is not yet clear.   
OPN is reported to induce activation and proliferation of immune cells and to 
play a role in different immune responses.  OPN is highly expressed by activated 
macrophages, lymphocytes and NK cells as well as macrophage and NK-derived 
cells (O'Regan et al., 2000).  OPN expression correlates with presence of these cells 
in inflammatory processes and declines as inflammatory infiltrates recede.  It plays a 
role in the migration and adhesion of T cells and macrophages and co-stimulates T 
cell proliferation in-vitro (Giachelli et al., 1998; Kawashima et al., 1999; Murry et 
al., 1994b; O'Regan et al., 1999; Patarca et al., 1989b).  OPN plays a role in cell 
mediated immunity where it supports a Th1 immune response and induces T cells 
and macrophages in culture to express Th1 but not Th2 cytokines (Ashkar et al., 
2000).  In-vivo, OPN null mice have an impaired Th1 immune response and are more 
vulnerable to infection by Herpes simplex and Listeria monocytogenes than their 
wild type controls (Ashkar et al., 2000).  However, in a different infection model, 
both wild type and OPN null animals had comparable responses to antibody 
challenge after inducing anti-globular basement membrane nephritis (Bonvini et al., 
2000).  Therefore, OPN may be involved in some but not all cellular immune 
reactions.  In addition, OPN is expressed in human and mouse granulomatous 
responses (Ashkar et al., 2000; Nau et al., 1997; O'Regan et al., 1999).  Studies in 
OPN null mice showed that absence of OPN makes infectious cells proliferate more 
aggressively in granulomas (Nau et al., 1999).  In humans with a defective IFN-γ 
receptor 1, OPN expression in mycobacterial granuloma is impaired but also the 
infection has a more severe course (Nau et al., 2000).  Moreover, OPN may also 
have a role in humoral immune responses since it activates B lymphocytes (Weber et 
al., 1996b) and induces them to express IgG and IgM (Lampe et al., 1991; 
Prud'Homme et al., 1983).  The above evidence suggests a role for OPN in humoral, 
cell mediated as well as granulomatous immunity. 
Additionally, OPN is suggested to regulate inflammatory cell function.  OPN’s 
production is induced by mediators which are expressed in the early stages of 
inflammatory response including tumour necrosis factor TNFα, vitamin D3 
(Denhardt et al., 1993; Patarca et al., 1993), interleukin (IL)-1β and IL-2 (Patarca et 
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al., 1993; Pollack et al., 1994).  Angiotensin II is also shown to induce OPN 
production by cardiac fibroblasts in rats with renovascular hypertension (Ashizawa et 
al., 1996).  The exact role of OPN in the regulation of inflammation is not yet 
clarified with both pro and anti-inflammatory reactions reported in different 
conditions as discussed below. 
There is evidence of pro-inflammatory effects from in-vitro and in-vivo studies 
suggesting that OPN is involved in critical inflammatory processes including 
recruitment of inflammatory cells such as macrophages, T cells and astrocytes 
(Ellison et al., 1999; Lampe et al., 1991; O'Regan et al., 1999) and in cytokine 
expression (Attur et al., 2000).  Additionally, OPN null mice studies support the role 
of OPN in inflammation.  In one study, OPN null mice with obstructed kidney 
displayed significantly lower number of infiltrating macrophages compared to wild 
type counter-parts (Ophascharoensuk et al., 1999).  In another study in mice with 
chemical induced squamous cell carcinoma, the number of macrophages was lower 
in OPN null mice compared to wild type controls (Crawford et al., 1998).       
Paradoxically, OPN also exhibits anti-inflammatory actions such as inhibition 
of NO production by macrophages as well as reducing oxidative stress levels (Guo et 
al., 2001; Hwang et al., 1994a).  OPN inhibits iNOS and NO release by macrophages 
in-vitro in a dose dependent manner (Rollo et al., 1996b).  In post-ischemic kidneys 
of OPN null mice, levels of iNOS and nitrotyrosine (an indicator of NO levels in 
vivo) were increased to a markedly higher level than in wild type post-ischemic 
kidneys (Noiri et al., 1999).  In addition, OPN has been demonstrated to be a 
negative feedback regulator of NOS in murine macrophages (Guo et al., 2001; Scott 
et al., 1998).  In these studies, NO stimulates expression of OPN which inhibits 
iNOS transcription and reduces NO production.  In rheumatoid arthritis and 
osteoarthritis, the synovial fluid of the affected joints shows increased OPN 
expression and OPN is reported to inhibit production of the pro-inflammatory 
cytokines NO and prostaglandin E2 (Attur et al., 2001; Petrow et al., 2000).  
Moreover, OPN also acts to decrease oxidative stress levels in injured tissue (Hwang 
et al., 1994a). 
In addition, OPN may also have a role in tissue repair as it helps recruit 
inflammatory cells, an action that is not only important for inflammation but also for 
healing and tissue repair.   In fact, studies in OPN null mice support a role of OPN in 
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tissue repair.  Following incisional wounds, OPN null mice showed less matrix 
organisation, more residual debris and altered collagen fibrillogenesis (Liaw et al., 
1998a).   
1.4.3 OPN in cell survival  
Evidence shows that OPN may have the ability of enhancing cell survival 
through its anti-apoptotic actions.  It inhibits apoptosis in smooth muscle, endothelial 
cells, epithelial cells, macrophages and pro-B cells amongst others (Weber, 2001).   
There is a large body of evidence from different tissue and cell types 
supporting the role of OPN in cell survival.   OPN was shown to protect endothelial 
cell lines from serum deprivation induced apoptosis (Rice et al., 2006).  Other 
studies demonstrated neuroprotective effects of recombinant OPN in in-vitro and in-
vivo models of ischemia (Doyle et al., 2008; Meller et al., 2005).  In neonatal rats 
subjected to hypoxia-ischemia, OPN reduced brain injury and improved neurological 
outcomes by inhibiting neuronal apoptosis (Chen et al., 2011).  Recently, OPN was 
shown to significantly increase survival and improve morphology of porcine retinal 
neurons from a transgenic mouse model of retinal degeneration (Del Río et al., 
2011). OPN has also been suggested to enhance macrophage survival and 
accumulation in the brain using in-vitro and in-vivo models of neuroAIDS, HIV 
infections of the CNS (Burdo et al., 2007).  In addition, OPN KO studies provided 
further evidence for the pro-survival effects of OPN.  Apoptosis of interstitial and 
tubular cells is increased in obstructed kidneys of OPN KO mice compared to their 
wild type equivalents (Ophascharoensuk et al., 1999).  In the same study, treatment 
of serum-starved renal epithelial cells with anti-OPN antibodies significantly 
increased apoptosis.  In a separate study, OPN null mice exhibited higher post-
ischemic apoptosis in kidney tubular cells compared to wild type controls (Persy et 
al., 2003). 
The exact mechanism of the pro-survival effects of OPN is not yet established 
but there have been studies in endothelial cell lines showing that OPN inhibits 
apoptosis by activating NF-kB via its αvβ3 receptor (Rice et al., 2006; Scatena et al., 
1998).  Another suggested mechanism is by increasing levels of the anti-apoptotic 
protein Bcl-XL within the cell and preventing dispersal of BCL-XL/S (Denhardt et al., 
1998; Khan et al., 2002).  Moreover, OPN was shown to increase survival of gastric 
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cancer cells by interacting with variant isoforms of CD44 and through activation of  
β1 integrins (Lee et al., 2007) and its presence constitutively within a breast cancer 
cell line was shown to inhibit apoptosis after chemotherapy treatment (Graessmann 
et al., 2006).  OPN showed a similar effect on dexamethasone-induced apoptosis in 
multiple myeloma cells which was inhibited by anti-CD44v6 antibodies (Caers et al., 
2006) suggesting that OPN may exert its anti-apoptotic actions through ligation with 
the CD44 receptor.  On the other hand, the neuroprotective effects of OPN against 
ischemia induced cell death in primary cortical neurons was inhibited by peptide 
integrin inhibiors, implying the involvement of integrin receptors in the protective 
actions (Meller et al., 2005).  Both in the stroke and retinal neurodegeneration 
models, OPN pro-survival effects were mediated through activation of PI3K/Akt pro-
survival pathway (Del Río et al., 2011; Meller et al., 2005).  
1.5 OPN in the CNS 
A comprehensive investigation of the distribution of OPN expression in the 
brain has not yet been undertaken, but there are various reports on its expression in 
specific areas or whole brain lysates.  Some have reported no expression of OPN 
protein in whole rat brain lysates using Western blotting (Satoh et al., 2008) or rat 
hippocampus using immunohistochemistry (Choi et al., 2007).  By contrast, others 
report evidence of OPN expression in the septal nucleus and ventral brain nuclei in 
the same species (Ellison et al., 1998).  In these laboratories, evidence of OPN 
expression was found in the SN of rats (Iczkiewicz et al., 2004) and marmosets 
(Iczkiewicz et al., 2006).  In mice, no OPN expression could be obtained in the 
hippocampus using immunohistochemistry (Wirths et al., 2010).  However, in the 
human brain OPN is expressed in hippocampal pyramidal neurons (Wung et al., 
2007) and dopaminergic neurons of the SN (Iczkiewicz et al., 2006).  In contrast, 
Western blot analysis of whole human brain lysates showed no OPN expression in 
normal brains (Satoh et al., 2008).  This may be due to the use of a whole brain 
lysate rather than SN only, which may have reduced the concentration of OPN below 
detection levels.     
OPN is up-regulated in a number of models of disorders of the CNS.  It is up-
regulated in response to status epilepticus in degenerating neurons and axons in the 
rat hippocampus (Borges et al., 2008).  In kainic acid induced seizures in rat, OPN 
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was up-regulated but localised to activated microglia (Kim et al., 2002).  It is also 
up-regulated in a mouse model of Alzheimer’s disease (AD) (Wirths et al., 2010) and 
in pyramidal neurons in brains of AD patients compared to age-matched controls 
(Wung et al., 2007).  OPN is transiently up-regulated in microglia and prolonged up-
regulation is seen in astrocytes, following transient forebrain ischemia in rats (Choi 
et al., 2007).  Up-regulation of OPN in CNS disorders suggests that it is either part of 
the homeostatic defence in the CNS or a deleterious agent with detrimental effects 
contributing to the disorder.  Some evidence suggests that OPN has a protective role 
in the CNS.  For example, OPN null mice showed greater thalamic 
neurodegeneration post ischemic stroke compared to wild type controls (Schroeter et 
al., 2006), suggesting that the role of OPN in ischemic injury is protective.  This 
concept is supported by the evidence of neuroprotective and pro-survival effects of 
OPN in models of ischemia (Section 1.4.3).  On the other hand, treatment of OPN 
null mice with OPN did not affect neurodegeneration or inflammation following 
status epilepticus (Borges et al., 2008).  
Additionally, evidence suggests that OPN is up-regulated in inflammatory 
paradigms centrally.  It is up-regulated in lysosomal storage disorders associated 
with inflammation, like Sandhoffs- and Tay-Sachs-disease (Myerowitz et al., 2002) 
and in rat cerebral cortex post traumatic injury where it co-localised with ED-1 
positive macrophages and activated microglia (von Gertten et al., 2005).  In 
cryolesioned rats, OPN expression was also up-regulated in the cerebral cortex where 
it co-localised with activated microglia and macrophages in addition to some neurons 
and astrocytes (Shin et al., 2005).  Expression of OPN was increased significantly in 
the scrapie-infected brains compared to controls and was mainly expressed in 
neurons but also in reactive astrocytes and some microglia (Jin et al., 2006).  In 
addition, OPN is discussed to act as a chemoattractant for astrocytes following 
ischemic injury (Ellison et al., 1999; Ellison et al., 1998; Wang et al., 1998).  
Further, systemic LPS injection in rats induced transient OPN expression in 
parenchymal astrocytes and microglia in the brain, supporting the suggested 
inflammatory role of the protein (Choi et al., 2003).   
The role of OPN in inflammation in the CNS was clarified by a number of 
studies.  OPN null mice with spinal cord injury display lower inflammation, larger 
tissue damage and impaired locomotor recovery suggesting a neuroprotective role of 
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OPN in inflammatory responses (Hashimoto et al., 2007).  Also, OPN null mice 
exhibited higher microglial activation and inflammatory gene expression following 
ischemic cortical stroke compared to wild type animals (Schroeter et al., 2006).  In 
another study, following transient forebrain ischemia in rat, OPN was up-regulated in 
microglia and astrocytes and secreted into the extracellular space by astrocytes 
suggesting a role in tissue repair (Choi et al., 2007).  This is in line with other reports 
of neuroprotective effects of OPN in models of stroke (Doyle et al., 2008; Meller et 
al., 2005).  On the other hand, in multiple sclerosis and its animal model 
experimental autoimmune encephalomyelitis, OPN is reported to be up-regulated 
mainly in microglia and macrophages and to increase survival and proliferation of T-
cells resulting in a harmful pro-inflammatory effect (Chabas et al., 2001; Hur et al., 
2007; Jansson et al., 2002; Kim et al., 2004).  This difference may be due to the 
difference in disease models as multiple sclerosis is a T-cell mediated autoimmune 
disease and the former two disorders are ischemia or injury mediated 
neurodegeneration.  The evident involvement of OPN in the regulation of 
inflammation in the brain suggests that it may play a role in regulating this process in 
PD.  Nevertheless, the effect of OPN on the inflammation in PD has not been 
previously investigated. 
1.6 Receptors with which OPN interacts  
OPN exerts its actions via integrin and CD44 receptors, which are ubiquitous 
multifunctional and multistructural transmembrane glycoproteins. 
1.6.1 Integrins 
Integrin receptors are involved in the regulation of many aspects of cell 
behaviour such as differentiation, adhesion, migration and apoptosis (Barczyk et al., 
2010).  They consist of α and β subunits which bind non-covalently to form the 
integrin receptor heterodimer (Figure 1.3).  So far, 18 α and 8 β subunits have been 
identified and they bind to form 24 combinations of integrin receptors (Jalkanen et 
al., 1986).  OPN can mediate cell-cell and cell-matrix interactions by binding several 
integrins.  Through the RGD domain, it binds αvβ3, αvβ1, αvβ5, α5β1 and α8β1 (Attur et 
al., 2000; Bayless et al., 1998; Denda et al., 1998; Hu et al., 1995; Liaw et al., 1994; 
Smith et al., 1996; Yue et al., 1994).  Whereas binding to α4β1 and α9β1 appears to be 
RGD-independent; binding is instead to the SVVYGLR sequence in OPN but only 
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after thrombin cleavage (Bayless et al., 2001; Smith et al., 1996; Yokasaki et al., 
2000).  In contrast, Barry et al., report activation of α4β1 by the full length protein 
(Barry et al., 2000).   
The interaction of OPN with integrin αvβ3 has been implicated in cell 
attachment and migration whilst interaction with αvβ1 and αvβ5 mediates adhesion but 
not migration (Giachelli et al., 1995; Liaw et al., 1995).  Integrins α4 and α5 may also 
mediate adhesion (Nasu et al., 1995) and α9β1 may induce cellular migration (Smith 
et al., 1998).  αvβ3 is the most characterised integrin receptor of OPN and some claim 
that OPN has the highest specificity for αvβ3 (Caltabiano et al., 1999).  αvβ3 integrin 
receptor appears to be important for OPN-mediated NF-KB induction and survival, as 
adding a neutralizing anti-β3 integrin antibody blocked NF-KB activity induced by 
OPN (Scatena et al., 1998).  In the same study, β1 integrin mediated laminin but not 
OPN induced cell survival, this is contradictory to reports of involvement of this 
particular integrin in OPN-mediated cell survival (Lee et al., 2007). 
Pinkstaff et al. have mapped the expression of many integrins’ mRNA 
expression in the rat brain (Pinkstaff et al., 1999).  They found no expression of 
integrin α4 (Igα4), Igαv, Igα8 mRNA in the SN.  The mRNA for Igβ1, Igβ5 and Igα5 
receptors was present in the SN.  Expression of Igα9 mRNA has not been 
investigated.  The group also report that they could not detect an mRNA signal for β3 
integrin, although they describe in the same paper unpublished Western blotting data 
suggesting presence of this integrin in the brain (Pinkstaff et al., 1999).  A more 
detailed investigation of the expression of these receptors in SN and their sub-







Figure 1.3 Integrin receptors. 
(a) Protein structure of the integrin receptor.  Integrin receptors are heterodimmers of 
non-covalently bound α and β subunits.  They mediate signals from outside of cell to 
the inside (outside-in) and from inside the cell to the outside (inside-out).  Adapted 
from (Gu et al., 2004). 
(b) Integrin dimmers that bind to OPN.  There are 7 integrin receptors known to bind 
OPN so far.  These are combinations of either αv or β1 integrins and α4, α8,α5 ,α9, β3 or 
β5.   
 
1.6.2 CD44 
CD44, the main receptor of hyaluronic acid, has several isoforms serving 
diverse functions.  The standard isoform CD44s is the most abundant and there exist 
many splice variants termed CD44v.  These are the result of combination of exons 6-
14 of the gene, which can be alternatively spliced and inserted into the extracellular 
domain (Figure 1.4) (Naor et al., 1997).  CD44 is expressed on many cell types 
including epithelial cells, keratinocytes, fibroblasts, leukocytes, macrophages and 
endothelial cells (Fox et al., 1993; Gunthert et al., 1991).  In fact, CD44 was shown 
to be expressed on dopaminergic neurons of the SN (Fuxe et al., 1996).  CD44 is 
involved in mediating cell-cell and cell-matrix interactions thereby facilitating cell 
adhesion (Aruffo et al., 1990), migration (Peck et al., 1996; Trochon et al., 1996), 
lymphocyte homing (Jalkanen et al., 1986; Streeter et al., 1988) and activation 
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angiogenesis (Trochon et al., 1996) and release of cytokines (Webb et al., 1990).  In 
addition, OPN is involved in CD44 mediated chemotaxis (Weber et al., 1996b).  
Further, CD44 expression in tumour cells is associated with tumour progression and 
invasiveness (Gunthert et al., 1991; Sy et al., 1991) probably through its ability to 
mediate cell migration.  In addition, CD44 is upregulated in proliferating cells 
including cells involved in tissue repair, morphogenesis, organogenesis and 
angiogenesis (Trochon et al., 1996; Underhill, 1992; Yu et al., 1997).     
Some evidence suggests that OPN binds variant isoforms of CD44 but not the 
standard CD44s.  Weber et al. (1996) showed that a splice variant of CD44 present in 
fibroblasts namely (CD44v7-v10) facilitates adhesion and migration to OPN (Weber 
et al., 1996a).  In addition, not only had v6 or v7 to be present in CD44 in order to 
bind OPN but also RGD independent interaction with β1 integrin is required 
(Katagiri et al., 1999).    OPN binding to both CD44v6 and RGD-binding integrins 
was shown to be essential for the proliferation and migration of 5TMM cells (Caers 
et al., 2006) and binding to CD44 is essential for migration of macrophages to injury 
site (Marcondes et al., 2008).  Furthermore, OPN inhibition of apoptosis in gastric 
cell lines; this action was dependant on the expression of CDDv6 and v7 isoforms 
and was inhibited by anti-integrin β1 antibody and RGD peptides.  In contrast, OPN 
has been shown to bind CD44 receptor variants (v6 and v7) by an RGD-independent 
mechanism (Denhardt et al., 2001; Weber et al., 1996a) inducing macrophage 
accumulation and engagement of the β3 integrin (Weber et al., 1996a).      
Integrin and CD44 receptors are known to mediate OPN effects in the 
periphery and some central systems but it is not known whether actions of OPN in 







Figure 1.4 Structure of CD44 gene and protein. 
(a) Schematic gene structure.  v1-v10 boxes represent the 10 variant exons.  Exon 18 
is spliced out to allow transmembrane (TM) domain to be followed by cytoplasmic 
domain.  (b) Protein structure.  CD44 has a highly conserved 21 amino acid 
transmembrane domain and 72 amino acid cytoplasmic domain.  The extracellular 
domain comprises of: a highly conserved amino terminal domain 80% homology, a 
relatively conserved (35-45% homology) membrane proximal domain containing 
several glycosilation sites and between these two regions is the region where the 
variant exons can be inserted producing variant isoforms of CD44 (CD44v).  
Adapted from (Isacke et al., 2002).  GAGs: glycosaminoglycans. 
 
1.7 OPN in PD  
OPN plays an important role in the inflammatory process.  It is up-regulated in 
the early stages of inflammation and has pro-inflammatory and anti-inflammatory 
actions.  Inflammation is an important element of the underlying pathogenesis of PD, 
and thus OPN has a potential involvement in the regulation of inflammatory 
pathology of PD.  Importantly, OPN effects may be age related, age being an 
established factor that increases risk of developing PD.  The anti-inflammatory 
actions of OPN, namely inhibiting NO release by macrophages, inhibiting NOS, and 
decreasing oxidative stress levels appear to decline with age (Guo et al., 2001; Rollo 
et al., 1996a; Scott et al., 1998) suggesting that replacing OPN in age related 
disorders such as PD may be neuroprotective. 
Recently, OPN was found to be present in the rat basal ganglia with highest 
levels in the SN, the main site of pathology in PD (Iczkiewicz et al., 2004).  Both 





(Iczkiewicz et al., 2005) where it co-localised with microglia, suggesting that OPN 
may be involved in regulating inflammation mediated neurodegeneration.  
Conversely, OPN expression was reduced following MPTP challenge in marmosets 
and was not co-localised with glia (Iczkiewicz et al., 2006).  These results may not 
be contradictory but instead reflecting different phases of OPN regulation.  This is 
because in the first study, OPN expression was investigated within five days of LPS 
lesioning while in the second study it was examined 18 months following MPTP 
treatment.  OPN was also found to be present in dopaminergic neurones in normal 
human brain (Iczkiewicz et al., 2006).  Importantly, in PD patients, protein 
expression was decreased in remaining dopaminergic neurones and was present in 
activated microglia (Iczkiewicz et al., 2006).  In a separate study, patients with PD 
had increased OPN expression in the SN and higher OPN levels in serum and CSF 
compared to controls and higher levels were associated with more severe symptoms 
(Maetzler et al., 2007).  In the same study, OPN deficient mice showed reduced 
degeneration of dopaminergic neurons following MPTP challenge compared to wild 
type animals (Maetzler et al., 2007) suggesting that OPN may have a detrimental role 
in PD.  These contradictory findings are not easily explained but both seem to point 
to a role of OPN in PD.  Moreover, a recent study showed that a single-nucleotide 
polymorphism of the OPN gene may be linked to susceptibility to LB diseases 
including PD (Maetzler et al., 2009).   
OPN has been shown to prevent apoptosis in different cell types, to be involved 
in cell regeneration and tissue repair and to modulate inflammation.  This supports 
the hypothesis that OPN may have neuroprotective properties in PD and this will be 





There is a large body of evidence suggesting the involvement of OPN in pro-survival 
mechanisms.  In addition, OPN seems to play a protective role in diverse tissues.  In 
kidney, OPN appears to protect against renal stone formation and in bone, it plays an 
important role in remodelling.  In the heart, this protein is shown to prevent tissue 
calcification and is suggested to promote tissue repair.  In addition, OPN promotes 
survival of tumour cells and has an important role in regulating inflammation both 
peripherally and centrally. 
  Based on evidence of the involvement of OPN in the regulation of 
inflammation and its pro-survival effects it was hypothesised that OPN protects 
dopaminergic neurons against toxin insults through anti-inflammatory effects, 
mediated via binding to Igαv, Igβ3, Igβ1 or CD44 receptors.  
1.9 Aims 
 To determine whether endogenous expression of OPN is intrinsically 
neuroprotective.  
 To determine whether OPN exogenous treatment is neuroprotective. 
 To investigate the role of glial cells in the neuroprotective effects of OPN. 
 To investigate the role of Igαv, Igβ3, Igβ1 and CD44 receptors in the 













2. Chapter 2 Materials and methods 
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2.1 Introduction 
The aims of this thesis were to investigate the neuroprotective effects of OPN 
in cell lines, to study whether its effects are related to the endogenous expression of 
the protein and then to investigate the effects of OPN in more complex paradigms; 
the VM primary culture and rat brains.  Initial studies were carried out in each 
experimental model to characterise it for the expression of OPN and receptors 
involved with its cell survival actions namely Igαv, Igβ3, Igβ1 and CD44.  Then, 
neuroprotection studies were carried out in the three characterised models to test the 
ability of OPN pre-treatment to protect dopaminergic cells from toxin induced cell 
death.  The methods used in these studies are outlined in detail below. 
2.2 Cell lines  
Five cell lines derived from different cell types from rat, mouse and human 
were used: Ntera-2, a human neurone committed teratocarcinoma cell line (Angulo et 
al., 1995); SK-NMC, a human neuroblastoma cell line with cholinergic 
characteristics (Biedler et al., 1973; Biedler et al., 1978); PC-12, rat 
pheochromocytoma cell line that differentiates into sympathetic-like neurons in 
response to nerve growth factor (NGF) and extracellular matrix molecules (Greene et 
al., 1987); N1E-115 cell line, mouse adrenergic neuroblastoma clone with highest 
levels of TH (Amano et al., 1972).  These cell lines were obtained from the 
American Type Culture Collection.  SH-SY5Y, a human catecholaminergic 
neuroblastoma cell line derived from SK-N-SH cell line established from a bone 
marrow biopsy (Biedler et al., 1973) was obtained from The European collection of 
cell cultures. 
2.2.1 Maintenance of cells 
SH-SY5Y, SK-NMC, N1E-115 and Ntera-2 cells were maintained in tissue 
culture flasks (NUNC, Thermo scientific, UK) in Dulbecco's Modified Eagle's Mediu 
(DMEM-Glutamax), supplemented with foetal bovine serum (FBS; 10%), penicillin 
(5mg/ml), streptomycin (5mg/ml) and Neomycin (10mg/ml) (PSN, 1%) in a 
humidified 5% CO2 chamber (Sanyo, UK) at 37˚C.  Medium was changed every two 
to three days and cells were detached using trypsin (0.25%) at about 80% confluence 
and seeded into new flasks in full growth medium.  PC-12 cells were maintained in 
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the same manner but the medium used was Kaighn’s nutrient mixture supplemented 
with horse serum (15%), FBS (2.5%) and PSN (1%).   
2.2.2 Cell counting 
An aliquot of the cell suspension (50μL) was added to Trypan blue solution 
(50μL; 0.5%) and live cells which do not take up the dye were counted using a 
haemocytometer (Neubauer, Germany) under TMS inverted microscope (Nikon, 
UK) at x0.25 magnification.  Cells were counted in four corner squares, each square 
has a surface area of 1mm
2




.  Since 
1cm3=1ml, the following equation was used to estimate the number of cells per 1ml: 
Cells per ml = The average count of cells per square x the dilution factor x 10
4
  
2.2.3  Cryopreservation of cells 
When cell cultures reached 80% confluence, they were detached with trypsin 
(0.25%) and centrifuged at 950g for 5min in a CR3i centrifuge (Jouan, DJB Labcare, 
UK).  Cells were re-suspended at 1.5-2x10
6
cell/ml in the cryoprotectant solution (full 
growth culture medium (Section 2.2.1) with FBS (40% ) and dimethyl sulfoxide 
(20%) and placed in cryo-vials (2ml; Corning Inc., UK) in a Mr Frosty freezing 
container (Nalgene, USA) at -70˚C for 24h then transferred to liquid nitrogen (-
200˚C). 
2.2.4 Thawing cells from cryoprotection 
Cryo-vials were removed from liquid nitrogen and directly placed in a 37˚C 
water bath for 1-2min.  Once thawed, the cryoprotectant solution containing the cells 
was slowly added to pre-warmed full growth medium (10ml; details in Section 2.2.1) 
and centrifuged at 950g for 5min (CR3i centrifuge, Jouan, DJB Labcare, UK).  After 
discarding the supernatant, cells were re-suspended in full growth medium and 
grown as described in Section 2.2.1.  
2.2.5 Preparing cells for immunostaining 
2.2.5.a Coating of coverslips 
Glass coverslips (13 mm diameter; Scientific Laboratories supplies, UK) were 
washed three times in ethanol (70%) then rinsed three times with distilled water.  
Coverslips were sterilised in an autoclave at 121˚C for 30min and air-dried, then 
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immersed in poly-D-lysine solution (0.01% in sterile distilled water) for 30min.  
Coverslips were rinsed twice with sterile distilled water to wash off the unbound 
coating material before use. 
2.2.5.b Growing cell lines for immunostaining 
For immunofluorescence, cells (1.5-2x10
5
cell/well) were grown on poly-D-
lysine coated glass cover slips in twenty four well plates (Nunc, Thermo scientific, 
Germany) in culture medium (0.5ml/well; Section 2.2.1).  At about 60% confluence, 
culture medium was discarded and cells washed twice with cold Dulbecco’s 
phosphate buffered saline (DPBS, pH 7.4; 0.5ml/well).  The cells were then fixed in 
cold paraformaldehyde (PFA, 0.4% in 0.1M Phosphate buffered saline (PBS)) for 
20min. 
2.2.6 Fluorescence immunocytochemistry in cell lines 
This technique was carried out in 24 well plates (0.5ml/well).  After fixation 
(Section 2.2.5.b), cells were washed twice with PBS (0.1M) and incubated with 20% 
blocking solution containing goat serum (20%), Triton-X 100 (0.05%)/0.1M PBS for 
one hour.  The cells were then incubated with primary antibodies (details in Table 
2.1) diluted in 1% blocking solution (goat serum, 1%; Triton-X 100, 0.05%/0.1M 
PBS) overnight at 4˚C followed by three 5min washes with PBS (0.1M).  Next, cells 
were incubated with the appropriate secondary antibodies (Table 2.2) conjugated 
with Texas red or Fluorescein for one hour in a darkened environment.  After three 
30min washes with PBS (0.1M), coverslips were mounted, in the dark, onto polysine 
slides (Menzel-glaser, Germany) using vectashield hardset mounting medium with 
4',6-diamidino-2-phenylindole (DAPI) a fluorescent stain that binds strongly to 
DNA.  A Zeiss Axioskop 40 microscope (Germany) was used to examine the cells.  
Specificity of antibodies was tested by omitting the primary antibody.  Figure 2.1 
shows typical TH and OPN staining in cell lines.   
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Figure 2.1 Typical TH and OPN Immunofluorescence in PC-12 cells. 
PC-12 cells show positive immunoreactivity to (a) OPN (green; ) in the 
cytoplasm and to (b) TH (red; ) in the cytoplasm.  DAPI counter stain is shown 
in blue.  (a’) Primary antibody omitted, fluorescein conjugated anti-mouse secondary 
antibody used.  (b’) Primary antibody omitted, Alexa Fluor conjugated anti-rabbit 
secondary antibody used.  Magnification x100, Scale bar = 20µm and is 



































Abcam, UK rat 1:100 CD44 receptor 
 









Jackson immunolabs, UK goat 1:200 
Texas Red conjugated anti-
rabbit IgG 
Vector Laboratories, UK goat 1:100 
 
Table 2.2 Secondary antibodies used in cell lines and their respective dilutions 
and details. 
Immunofluorescence (IF).  
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2.2.7 Western blotting 
2.2.7.a Preparing cells for Western blotting 
Cells were grown in full growth medium (35ml; Section 2.2.1) in 75 cm
2
 flasks 
until they reached approximately 60-80% confluence (Section 2.2.1).  Growth 
medium was removed and cells washed three times with DPBS (10ml).  Lysis buffer 
(600l; Tris-Hcl buffer 50mM, sodium dodecyl sulphate (SDS; 1%)) was then added 
to the flask and cells were collected by scraping using a sterile scraper (BD Falcon, 
UK).  The cell suspension was triturated ten times through a Needle (25G, 1.5’’) 
using a 1 ml syringe in order to ensure complete lysis of cells.  The cell lysate 
(600l) in an eppendorf tube (alpha laboratories, UK) was then heated at 94˚C in a 
standard heating block (VWR, UK) for 10min to linearise the proteins and then 
centrifuged at 75590g for 10min in a micro-centrifuge (Galaxy 14D, VWR, UK) and 
the supernatant was retained and stored at -70˚C until use.  Protein concentration 
was determined using the protein A280 Nano drop ND-1000 spectrophotometer 
assay (Labtech international, UK). 
2.2.7.b Nano drop protein A280 assay 
Samples (2μl) were loaded on the measurement pedestal of the Nano drop 
spectrophotometer and absorbance measured at 280nm three times for each sample.  
Lysis buffer (2μl) was loaded on the measurement pedestal and measured as ‘blank 
measurement’.  Protein concentration in (mg/ml) is calculated by the program using 
absorbance by bovine serum albumin (BSA) solution as a reference.  Figure 2.2 
shows a typical absorbance spectrum.  Accuracy and linearity of protein 
concentration measurement was checked by diluting BSA protein standard a series of 
dilutions (0.4-100mg/ml) and comparing the actual concentrations with measured 
concentrations (Figure 2.3).  The concentrations obtained for cell lines (10-25mg/ml) 
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Figure 2.2 Typical absorbance spectrum using the Nanodrop spectrophotometer 




        































Figure 2.3 BSA actual concentration vs. Nanodrop-measured concentration. 
BSA protein standard solutions of known concentrations (0.4-100mg/ml) were 
measured using the Nanodrop assay in order to compare actual concentration with 
measured concentration.   
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2.2.7.c Preparation of positive control  
Male Wistar rats were terminally anaesthetised with sodium pentobarbitone 
(100mg/kg, i.p.), the kidneys removed then snap frozen immediately at -45˚C in 
isopentane.  The tissue was homogenised using a motor pellet pestle (Sigma) in Lysis 
buffer (Tris base, 50mM; TritonX-100, 1%; NaCl, 150mM; EDTA, 5mM; PMSF, 
2mM and protease inhibitor cocktail set III, 5%) at a concentration of 1mg/4μl then 
centrifuged at 10.000g at 4˚C for 30min (Heraeus microcentrifuge, DJB labcare, 
UK).  The supernatant was decanted and stored at-70˚C until use. 
2.2.7.d Gel electrophoresis 
SDS-PAGE (Sodium dodecyl sulphate polyacrylamide gel electrophoresis) was 
used to separate the proteins.  The gel comprised of a stacking gel (acrylamide, 2%; 
N,N, Methylene-bis-acrylamide, 0.08%; SDS, 0.1%; TEMED, 0.1%; ammonium 
picosulphate, 0.05% and Tris, 125mM, pH 6.8) and a resolving gel (acrylamide, 
12.5% ; N,N, Methylene-bis-acrylamide, 0.42% ; SDS, 0.04%; TEMED, 0.77%; 
ammonium picosulphate, 0.1%  and Tris, 375mM, pH 8.8).  
Aliquots of cell lysates containing 100g protein or rat kidney homogenate 
(10µg protein) were added to loading buffer (Tris, 5mM, pH 6.8; SDS, 2.5%; 
glycerol, 50%; bromophenol blue, 0.1% and β-mercaptoethanol, 10%) at a ratio of 
1:5 (loading buffer : sample) and were loaded on 12.5 % SDS PAGE gels.  The gel 
was placed in a gel caster system (Biorad, UK) and electrophoresis was carried out 
for one hour at 120V in running buffer (SDS, 0.1%;  glycine, 384mM and Tris, 
49.5mM) using a GIBCO BRL power supply (Life technologies, UK).     
2.2.7.e Protein transfer 
A polyvinylidene difluoride membrane (PVDF, Biorad, UK) was pre-wet in 
methanol (100%), rinsed in water then blot buffer (Tris-base, 0.582%; SDS, 0.04%; 
Glycine, 0.294%; methanol, 20%) for 1 min and then sandwiched together with the 
gel in between two layers of four filter papers which were immersed in Blot buffer 
for 1min before use.  Proteins were transferred from the gel into the PVDF 




Membranes were incubated in 5% blocking solution (5% non fat dry powder 
milk in TBS-T: Tris buffer, 50mM pH 7.5; NaCl, 150 mM; Tween 20, 0.2%) 
overnight at 4˚C on a shaking platform to block non-specific binding, then incubated 
with primary antibody (mouse anti-OPN, Hybridoma Bank) at a dilution of 1:3000 in 
2.5% blocking solution (2.5% non fat dry powder milk in TBS-T) for 3hr at room 
temperature.  After three 10min washes in TBS-T, membranes were incubated for 
1hr at room temperature with horse radish peroxidase conjugated secondary antibody 
(vector goat anti-mouse antibody 1:2000 in 2.5% blocking solution).  The 
membranes were then washed a further 3 times in TBS-T and incubated with ECL 
plus Western blotting detection kit solution (Amersham Biosciences, UK) to 
visualise the bands.  Hyperfilms (Kodak
®
, UK) were apposed to the membranes for 
varying times (1s-5min) and developed in a Compact X4 film automatic developing 
machine (Xograph, healthcare Ltd, UK).  Typical results obtained for OPN are 
shown in Figure 2.4. 
 
                                           
                                      
 
Figure 2.4 Typical Western blot showing the expression of OPN in N1E-115 and 
PC12 cell lines. 
Cell lysates of N1E-115 and PC12 were tested for OPN expression using the Western 
blotting technique in the presence of positive controls (rat kidney).  Both N1E-115 
and PC12 cells showed a positive band for OPN.  
 
2.2.8 Estimation of cell death  
2.2.8.a LDH Assay 
Cell death was determined by measuring lactate dehydrogenase (LDH) leakage 
from cells using the membrane integrity assay kit (Promega, UK) as this enzyme is 
only released from dead cells.  Lysis buffer provided with the kit (2μl) was added to 
N1E PC12 KIDNEY 
OPN 70KDa 
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3 wells of cells (100µl) in 96 well plates (NUNC, Thermo scientific, Germany).  This 
buffer causes lysis of all cells and release of all LDH content hence it represents 
100% LDH leakage.  The cells were equilibrated to room temperature for 20min then 
assay buffer mix (100l) was added to each well.  The plates were shaken gently for 
11 seconds then incubated at room temperature for 10min.  Finally, stop solution 
(50l) was added to each well in order to stop the reaction.  Plates were read in a 
Spectramax Gemini XS (Molecular devices, UK), excitation 560nm emission 
590nm.  Background reading was taken from 3 wells containing medium only.  LDH 
leakage (% of control) was calculated relative to the cell lysis buffer which kills all 
cells and represents 100% LDH release, using the following formula. 
 












Figure 2.5 Typical results obtained with LDH assay in SH-SY5Y cells following 
treatment with different concentrations of H2O2. 
SH-SY5Y cells were treated with H2O2 (50-800uM), then LDH assay was performed 
24 hours later to assess cell death.  Maximal LDH leakage from lysis buffer treated 
cells is 100%.  Data are expressed as mean ± SEM (n=3).  *P <0.05, **P <0.01, 
***P<0.001 (one-way analysis of variance followed by Newman Keuls test).  
Reading from lysis buffer treated well - background 
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2.2.8.b  ATP assay 
Cell death after toxin treatment was determined by measuring ATP release 
from cells using Cell titer glo assay kit (Promega, UK).  Following equilibration of 
cells to room temperature for 30min, assay buffer mix (100 l) was added to each 
well (100l).  The plates were shaken vigorously for 2min on a rotor shaker (VX7, 
Janke&Kunnel, Germany) to induce cell lysis and release of ATP from cells.  Plates 
were incubated at room temperature for 10min to stabilise signal then read in 
Spectramax Gemini XS luminometer (Molecular devices, UK).  ATP release (% of 
untreated control) was calculated using the following formula. 
 












Figure 2.6 Typical results obtained with ATP content assay in SH-SY5Y cells 
following treatment with H2O2. 
Cells were treated with H2O2 (50-800µM), then ATP content assay was performed 
24 hours later to assess cell viability.  Control untreated cells were taken as 100% 
ATP release.  Data are expressed as mean ± SEM (n=3).  **P <0.01, ***P<0.001 
(one-way analysis of variance followed by Newman Keuls test). 
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2.2.8.c Data Analysis 
All experiments were performed in triplicates on three to four separate 
occasions.  Data were plotted as logarithmic values and a sigmoidal concentration-
response curve was established by employing non-linear regression (Graph Pad 
Prism 5, USA).  The software also determined the half maximal effective 
concentration (EC50). 
2.3 Primary ventral mesencephalic culture 
The ventral mesencephalic (VM) region of the foetal rat brain develops in the 
adult rat into the SN & VTA.  Unlike transformed neuronal cell lines, it contains 
precursors for all cell types present in the mature SN region including dopaminergic 
and Gamma-aminobutyric acid (GABA)-ergic neurons in addition to glial cells 
which differentiate when cultured in-vitro.   
2.3.1 Dissection of the ventral mesencephalon  
Time mated pregnant E14 Wistar rats (Harlan, UK) were kept under standard 
conditions (21˚C, 50% humidity, and 12hr light/dark cycle with free access to 
pelleted diet).  All procedures comply with UK Animal (Scientific Procedures Act) 
1986 and associated guidelines. 
Animals were culled by exposure to CO2 and E14 foetuses collected in DPBS 
on ice.  Subsequently, foetuses were dissected under a dissection microscope (x10 
magnification; Vickers Instruments, UK) by making a cut from the mouth to the VM 
flexure.  This was followed by two sagittal cuts to separate out the mesencephalic 
region, one anterior and one posterior to the peak of the flexure.  The ventral part of 
the mesencephalic segment was obtained by cutting caudally down each side of the 
ventricle (Figure 2.7).  Finally, meninges were carefully removed and the ventral 









Figure 2.7 Diagram of the E14 foetal VM region. 
 
2.3.2 Preparation of primary VM cultures 
The dissected ventral mesencephalons were washed three times with DPBS in 
a sterile falcon tube (15ml) then incubated with trypsin (0.25%) at 37˚C for 2min.  
The tissue was allowed to settle and supernatant removed.  Full growth medium 
(10ml; DMEM-GLUTAMAX, 10% FBS, 1% PSN) was then added to the tissue and 
centrifuged at 1369g for 1.5min (Jouan CR3i centrifuge).  The supernatant was 
discarded and tissue pellet re-suspended in fresh medium with a micropipette 
followed by trituration through a fire-polished glass Pasteur pipette (pore diameter ~ 
0.5mm) ten times to ensure full dispersal of cells.  Cells were counted using trypan 
blue in the same way as cell lines (Section 2.2.2), and were plated at a density of 
2x10
5
cell/well on poly-D-lysine coated coverslips in 24 well plates (full growth 
medium;0.5ml/well) and grown in a cell culture incubator (Sanyo, 37˚C, 5%CO2, 
100% humidity) until use. 
2.3.3 Peroxidase immunocytochemistry in VM cultures 
This technique was carried out in 24 well plates (0.5ml/well).  At day in-vitro 
(DIV) 3, 4 or 5, medium was removed and cells washed with cold DPBS then fixed 
with cold  PFA (4%/0.1M PBS) for 15min followed by two washes with PBS 
(0.1M).  Cells were incubated in H2O2 (0.03%/ 0.1M PBS) for 30min to block 
endogenous peroxidises.  After three 5min washes with 0.1M PBS (0.1M), cells were 
incubated with 20% blocking solution (20% goat serum, 0.05% Triton-X 100/0.1M 
PBS) for 1hr at room temperature.  Following that, cells were incubated with primary 




at room temperature.  After three 5min washes with PBS (0.1M), cells were 
incubated with appropriate biotinylated secondary antibodies (Table 2.4) diluted in 
0.05% Triton-X/0.1M PBS for one hour.  After a further three 5min washes in PBS 
(0.1M), cells were incubated with avidin: biotinylated enzyme complex (vectastatin 
ABC Kit) 1:200 in 0.1M PBS for one hour.  Following three 5min washes in Tris-
HCL (0.05M, pH 7.4), cells were incubated with 3.3’-diaminobenzidene (DAB; 
0.05% in 0.05M Tris-HCL) before addition of H2O2 (0.01% final concentration) to 
each well and colour was allowed to develop for 3min.  The reaction was stopped by 
removal of DAB and addition of Tris-HCL (0.05M).  Coverslips were then immersed 
in Nissl stain: Cresyl violet (0.1%) for 3min to counter stain the cell nuclei.  Finally, 
cells on coverslips were sequentially dehydrated by dipping five times into 70%, 
95% and 100% ethanol before defatting in histoclear for 5min and mounting on 
coverslips using DPX mounting medium.  A Zeiss Axioskop 40 microscope was 
used to examine the cells.  Specificity of antibodies was tested by omitting the 










Figure 2.8 Typical TH staining in the primary VM culture. 
Primary VM cultures were fixed at DIV 5 and stained by immunoperoxidase for TH 
(a) and counterstained with Nissl stain.  Arrows show counterstained TH positive 
cells.  (b) primary antibody omitted, biotynilated anti-rabbit secondary antibody 





2.3.4 Cell counting 
Counting of immunopositive cells was carried out on three to four coverslips 
per culture and each experiment was performed in three to four separate cultures.  
Mounted stained cultures were analysed under Zeiss Axioskop 40 microscope at 
magnification x10 in a blinded manner.  The number of positively stained cells was 
counted in ten randomly selected areas on each coverslip using an eye piece grid 
(total area = 10mm
2
).  For characterisation of VM culture for TH and Glutamate 
decarboxylase (GAD), the percentage of positive cells per coverslip was found by 
counting the number of DAB stained cells in five randomly selected areas (total area 
= 5mm
2
) on each coverslip expressed as percentage of the total number of cells 
which was identified by counting the number of cresyl violet stained cells in the 
same area. 
2.3.5 Double labelling immunofluorescence in VM cultures 
This technique was carried out in 24 well plates (0.5ml/well).  After fixation, 
cells were washed twice with PBS (0.1M) and incubated with 20% blocking solution 
(20% goat serum, 0.05% Triton-X 100 in 0.1M PBS) for one hour.  The cells were 
then incubated with two primary antibodies (Table 2.3) for detecting the two desired 
antigens, diluted in a 1% blocking solution (1% goat serum, 0.05% Triton-X 100 in 
0.1M PBS) overnight at 4˚C.  On the next day, after three 5min washes with 0.1M 
PBS, cells were incubated with the relevant secondary antibodies (Table 2.4) 
conjugated with Alexa Fluor 594 or Fluorescin for 2hr in a darkened environment.  
After three 30min washes with PBS (0.1M), coverslips were mounted, in the dark, 
onto polysine slides using vectashield hardset mounting medium with DAPI.  A 
Zeiss Axioskop 40 microscope was used to examine the cells.  Specificity of 
antibodies was tested by omitting the primary antibody.  Figure 2.9 shows an 















Figure 2.9 Typical double immunofluorescence staining of TH and Igβ3 receptor 
in primary VM cells. 
 (a-c) Igβ3 positive cells were stained and visualised in red (Alexafluor 594, ) and 
TH positive cells were visualised in green (fluorescein, ).  The merged picture 
(c) shows co-localisation between TH and Igβ3 ( ) indicating that dopaminergic 
cells of the primary VM culture express Igβ3 receptor.  (d-e) Primary antibody 
omitted. (a) Alexafluor 594 anti-rabbit secondary antibody and (b) fluorescein 
conjugated anti-mouse antibody.  Magnification x40, scale bar = 60µm.  
Igβ3 TH merged 
a b c 
d e 
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rabbit - 1:50 Igβ1 receptor 
Anti-CD44 Abcam, UK rabbit - 1:100 CD44 receptor 
 
Table 2.3 Primary antibodies used in VM cultures with their respective details 
and dilutions. 
Immunoperoxidase (IP), immunofluorescence (IF).  
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Antibody Supplier Species Technique Dilution 
Biotynilated anti-
rabbit IgG 





goat IP 1:200 
Biotynilated anti-
mouse IgG 





goat IF 1:200 
Alexa Fluor 488 anti-
mouse IgG 
Invitrogen, UK donkey IF 1:200 
Alexafluor 594 anti-
rabbit IgG 
Invitrogen, UK goat IF 1:500 
 
Table 2.4 Secondary antibodies used in VM cultures and their respective 
dilutions and details. 
Immunoperoxidase (IP), immunofluorescence (IF). 
 
2.4 In-vivo methods 
The LPS model of nigral dopaminergic cell death was used to investigate 
neuroprotective properties of OPN in rats.  LPS produces dopaminergic cell loss in 
the SN via acute activation of glial cells and producing an inflammatory reaction at 
the SN (Herrera et al., 2000; Iravani et al., 2005).  Details of the methods used are 
decribed below. 
2.5 Animals 
Adult male Wistar rats (250-350g, Harlan, UK) were housed in pairs according 
to standard conditions (21-24˚C, 55-65% humidity with a 12hr light/dark cycle) and 
had free access to pelleted diet and water.  All experiments were performed under 
Animal (Scientific procedures) act 1986 and approved by King’s College Ethical 
Review panel, Project licence 70/6018. 
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2.5.1 The LPS model of inflammation in PD 
Male Wistar rats (250-300g) were anaesthetised with isoflorane (4% in 5%O2: 
95% CO2) and secured in stereotaxic frame (Kopf instruments, US).  The incisor bar 
was positioned 3.3 mm below the interaural line.  Anaesthesia was maintained using 
isoflorane (1.5-2%) and body temperature was maintained at 37˚C using a 
homeothermic blanket (Harvard instruments, US).  In order to expose the skull, the 
scalp of the rat was shaved, sterilised with ethanol (70%) and a vertical cut was made 
along the midline using a sterile disposable scalpel (No. 11, Swan-Morton, UK).  The 
bregma was located and immediately above SN a 1.5mm hole was drilled into the 
skull at co-ordinates -48mm anterior and +2.0mm lateral to bregma (Paxinos and 
Watson, 1986).  A Hamilton syringe (70IRN; Scientific laboratory supplies, UK) 
(10l) mounted on the stereotaxic frame was placed over the hole and the needle 
(26s; Hamilton, Scientific laboratory supplies, UK) was slowly lowered into the 
brain, 7.6mm below the dura into the SN.  LPS (5μg/μl; 2l) or vehicle (0.9% saline; 
2l) was slowly injected over 2min.  The needle was left in-situ for a further 4min 
after injection before being slowly withdrawn.  The skull was then swabbed with 
ethanol (70%) and the wound closed using absorbable sutures (Ethicon-coated vicryl, 
Johnson’s & Johnson’s, UK).  After surgery, the rats were injected with a glucose 
solution to prevent dehydration (5ml i.p. of 5% glucose/0.9% sodium chloride).  The 
rats were allowed to recover from anaesthesia before being returned to their home 
cages where they had access to mashed diet.  All animals were weighed regularly and 
those that had lost 10% of their body weight were given mash until they start gaining 




























































Figure 2.10 The number of TH positive cells in the SN one week following LPS 
intra-nigral injection. 
(a) TH immunopositive cells in the sham lesioned SN.  (b) TH immunopositive cells 
in the LPS lesioned SN.  (c) TH cell counts in the SN comparing the sham lesioned 
and LPS lesioned SN (n=3-6/group).  Magnification x5, scale bar = 400μm and is 
representative of both images. **P<0.01 (one-way ANOVA followed by Newman 








2.5.2 Immunohistochemistry in rat brain tissue 
2.5.2.a Tissue preparation 
Animals were deeply anaesthetised using pentobarbital (130mg/kg i.p.).  The 
thoracic cavity was exposed and animals were transcaridally perfused through the 
left ventricle with ice cold 0.1M PBS (0.1M; 100ml per animal).  Subsequently, 
brains were removed, post fixed in PFA (4%/0.1M PBS) for five days then 
cryoprotected in sucrose (30% in 0.1M PBS with 0.05% sodium azide) and kept at 
4˚C until use.   
When the tissue had equilibrated, it was mounted on a sliding microtome 
(Leica, Germany) and sectioned coronally through the SN according to the rat brain 
atlas of Paxinos and Watson (1986).  Free-floating sections of 30μm thickness were 
collected in 24 well plates filled with cold PBS (0.1M) with sodium azide (0.05%) 
for long term storage at 4˚C. 
2.5.2.b Peroxidase immunohistochemistry in free-floating sections 
This technique was carried out in 24 well plates (1ml/well).  Sections were 
incubated for 30min in H2O2 (0.3%/0.1M PBS) to block endogenous peroxidises.  
Non specific binding was blocked by incubating the sections with 20% blocking 
solution (20% goat serum, 0.1% Triton-X 100/0.1M PBS) for one hour.  After two 
10min washes with PBS (0.1M), the sections were incubated with primary antibodies 
(Table 2.5) diluted in 1% blocking solution (1% goat serum, 0.1% Triton-X 
100/0.1M PBS) overnight at room temperature.  After two 10min washes in 0.1M 
PBS, sections were incubated with biotinylated secondary antibodies (Table 2.6) 
diluted in 0.05%Triton-X/0.1M PBS for one hour.  The sections were washed twice 
(10min) in 0.1M PBS followed by incubation in the Avidin Biotin complex (1:200) 
for one hour then washed twice in Tris-HCL (0.05M).  For visualisation of results, 
sections were incubated with DAB (0.05% in 0.05M Tris-HCL; Ph 7.4) for 5min 
then H2O2 (0.01% final concentration) was added and the sections incubated for 2-
5min.  The reaction was terminated by removing DAB and washing sections three 
times (10min) in Tris-HCL (0.05M).  Sections were mounted onto polysine slides 
and dried overnight.  Finally, slides with mounted sections were dehydrated through 
series of ethanol solutions (70%, 96%, 100%), cleared in histoclear (15min) and 
coverslipped with glass coverslips (22x50cm; VWR,UK) using DPX mounting 
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medium.  A Zeiss Axioskop 40 microscope was used to examine the sections.  An 
example of typical results obtained for GFAP immunoperoxidase staining in the 













Figure 2.11 Typical GFAP immunoperoxidase staining in the rat SN. 
(a,b) GFAP immunostaining in the SN of a naive rat brain.  Magnifications x5 and 
x20  respectively, scale bars = 200μm, 100μmrespectively.  Insert in (b),  GFAP 
positive cell.  Magnification x100, scale bar = 10µm.  (c) Primary antibody omitted, 
biotinylated anti-mouse secondary antibody used. Magnification x20, scale bar = 
100µm. 
 
2.5.2.c Quantification of positive staining 
Cell counts were performed for the following markers: TH, OX-6 and ED-1.  
Three SN tissue sections from each animal were viewed using Zeiss Axioskop 40 
microscope at magnification x20 and cell counts performed manually in a blind 
manner.  For TH, immunopositive cells were counted from the whole SNpc but for 
OX-6 and ED-1, immunopositive cells were counted in five random areas of the SN 
using an eye piece grid (total area =1.25mm
2






images were taken using an Olympus BX-61 microscope at magnification x1.25, 
then optical density (OD) of staining in the SN measured using Image J software. 
2.5.2.d Double immunofluorescence staining in SN tissue sections 
This technique was carried out in 24 well plates (1ml/well). SN sections were 
incubated for an hour with 10% blocking solution (5% goat serum, 5% donkey 
serum, 0.05% Triton-X 100 in 0.1M PBS).  Then, sections were incubated with two 
different primary antibodies raised in different species (Table 2.5) diluted in 1% 
blocking solution (0.5% goat serum, 0.5% donkey serum, 0.05% Triton-X 100 in 
0.1M PBS) overnight at 4˚C.  On the next day, after two 10min washes with PBS 
(0.1M), cells were incubated with the relevant secondary antibodies (Table 2.6) 
conjugated with Alexa Fluor 594 (red) or Alexa Fluor 488 (green) for 2hr in a 
darkened environment.  After three 30min washes with PBS (0.1M), coverslips were 
mounted, in the dark, onto polysine slides using vectashield hardset mounting 
medium with DAPI.  A Zeiss Axioskop 40 microscope was used to examine the 
sections.  Specificity of antibodies was tested by omitting the primary antibody.  




                                  
 
 
Figure 2.12 Typical double immunofluorescence labelling of TH and Igαv in the 
SN. 
(a-c) Igαv positive cells are stained in red ( ) and TH positive cells are stained in 
green ( ).  The merged picture (c) shows co-localisation between TH and Igαv 
( ).  (d-e) Primary antibody omitted, (a) Alexafluor 594 anti-rabbit secondary 
antibody and (b) fluorescin conjugated anti-mouse antibody used.  Magnification 
x40, scale bar= 40µm and is representative of all images. 
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mouse 1:500 1:200 






mouse 1:200 - 






mouse 1:200 1:100 
MHC Class II Ia 





























rabbit 1:50 1:25 Igβ1 receptor 
Anti-
CD44 
Abcam, UK rabbit 1:100 1:50 CD44 receptor 
 
Table 2.5 Primary antibodies used in-vivo with their respective details and 
dilutions. 
Immunoperoxidase (IP), immunofluorescence (IF). 
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goat IP 1:200 
Alexa Fluor 488 anti-
mouse IgG 
Invitrogen, UK donkey IF 1:200 
Alexa Fluor 954 anti-
rabbit IgG 
Invitrogen, UK goat IF 1:500 
 
Table 2.6 Secondary antibodies used in-vivo with their respective details and 
dilutions. 
Immunoperoxidase (IP), immunofluorescence (IF). 
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Reagents  Source  
30% Acrylamide/bis soulution, 37.5:1 Bio-Rad, Hertfordshire, UK 
Ampicillin  VWR international, Lutterworth, UK 
Cell titre glo Luminescent cell viability 
assay 
Promega, Southampton, UK 
Cryospray  
Bright instrument CO Ltd.Cambridgeshire, 
UK 
Cytot Tox-ONE TM Homogenous 
membrane integrity assay 
Promega, Southampton, UK 
DPX mounting medium BDH, VWR international, Lutterworth, UK 
Dulecco’s modified eagle medium(DMEM)-
Glutamax 
Invitrogen, Paisley, UK 
Enhanced chemiluminescence (ECL) plus 
Blotting detection system  
Amersham Biosciences, Buckinghamshire, 
UK 
EmlaTM Cream BSU, KCL, UK 
F- 12k nutrient mixture, kaighn’s medium Invitrogen, Paisley, UK 
Foetal bovine serum Invitrogen, Paisley, UK 
Horse serum Invitrogen, Paisley, UK 
G-418- Sulphate solution PAA laboratories  Ltd., Yeovil, UK 
GFP fusion topo expression kit Invitrogen, Paisley, UK 
Histoclear  Fisher Scientific, Leicestershire, UK 
Isofluorane  BSU, KCL, UK 
Iso-Pentane BDH, VWR international, Lutterworth, UK 
Kodak hyperfilm GE Healthcare Ltd., Buckinghamshire, UK  
FuGENE 6 transfection reagent Roche, Burgess Hill, UK 
Methanol  BDH, VWR international, Lutterworth,UK 
MG-132 Calbiochem, Nottingham, UK 
LPS Calbiochem, Nottingham, UK 
Plasmid Midi Kit Qiagen, Crawley, UK 
 90 
Precision Plus protein standard Bio-Rad, Hertfordshire, UK 
Proteasome inhibitor cocktail set III Calbiochem, Nottingham, UK 
PSN Invitrogen, Paisley, UK 
PVDF membrane Bio-Rad, Hertfordshire, UK 
QIAprep Spin Mini kit Qiagen, Crawley, UK 
RNeasy Mini Kit Qiagen, Crawley, UK 
Sodium pentobarbitone (Euthatal®) Merial, Dundee, UK 
Standard Avidin biotin complex (ABC) Vector laboratories, Peterborough, UK 
Sterile water PAA laboratories  Ltd., Yeovil, UK 
Sucrose Merck Biosciences Ltd., Nottingham,UK 
Tris-(hydroxymethyl) methylamonium 
chloride (Tris-HCL) 
BDH, VWR international, Lutterworth,UK 
Trypsin (1x) Invitrogen, Paisley, UK 
Vectashield® Hard Set mounting medium 
(with/without Dapi) 
Vector laboratories, Peterborough, UK 
 
Table 2.7 List of chemicals, drugs and reagents used. 
Chemicals and reagents not listed in this Table were all obtained from Sigma-








3. Chapter 3 OPN does not prevent 
toxin induced cell death in 
dopaminergic neuronal cell lines 





OPN possesses many of the properties required for an effective neuroprotective 
agent in PD including anti-inflammatory, anti-apoptotic and anti-oxidant properties 
(Chapter 1).  Protective actions of OPN have been demonstrated in models of other 
diseases ranging from stroke to renal injury and these effects are thought to be 
related to actions of the protein on integrin and CD44 receptors (Chapter 1).   
Particularly relevant to PD, OPN is present in the SN of normal rats, 
marmosets and in man (Iczkiewicz et al., 2004).  Importantly, levels of OPN are 
decreased in remaining dopaminergic neurones of the SN in PD compared to age-
matched controls and following MPTP challenge in marmosets (Iczkiewicz et al., 
2006), suggesting that this protein could be intrinsically protective.  The protective 
properties of OPN are decreased in aged mice compared to younger animals (Rollo et 
al., 1996a) and this has significance to the age dependent prevalence of PD.  When 
the current studies were started, it was not known whether OPN possesses protective 
properties against injury to dopaminergic cells in culture or whether endogenous 
OPN imports protective effects, or influences the action of exogenous OPN. 
The key question is whether endogenous OPN expression is sufficient to 
significantly alter the sensitivity of neurons to toxic insult and whether exogenous 
OPN can exert any additional effect in protecting cells.  A further significant 
question is whether the protective effects of OPN are mediated through integrin or 
CD44 receptors located on dopaminergic cells.  It is known that full length OPN can 
bind to a number of integrin receptors notably Igαv, Igβ3, Igβ1 as well as the CD44 
receptor and that these are involved with cell survival actions of the protein (Caers et 
al., 2006; Lee et al., 2007; Lin et al., 2001; Scatena et al., 1998).   
A range of dopaminergic cell lines are available, and these potentially offer a 
means of answering these questions but whether they differ in basal OPN expression 
has not been investigated.  These cell lines can be used to manipulate OPN 
expression through transfection and subsequently to determine the effects of 
introducing OPN expression in an OPN null cell line.  Cell lines are the simplest 
system to start this investigation. 
Therefore, in these studies, a variety of cell lines commonly used in PD 
research (SH-SY5Y, SK-NMC, N1E-115, PC-12 and NTera-2) were used to 
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investigate the protective properties of full length OPN and whether these are 
mediated via the receptors previously shown to mediate pro-survival actions of the 
protein (Igαv, Igβ3, Igβ1 and CD44).  Cell lines were characterised for OPN 
expression and cells not normally expressing OPN were transfected to express the 
protein.  Then, the effects of endogenous expression of OPN or exogenous treatment 
with OPN on the toxic effects of MPP
+
 and H2O2 were investigated. 
3.1.1 Hypothesis 
It was hypothesized that:  
 Endogenous OPN expression is neuroprotective and its absence renders cells 
more sensitive to toxic insult. 
 Exogenous OPN treatment is protective in toxin treated cell lines because of 
the presence of Igαv, Igβ3, Igβ1 and CD44 receptors.    
3.1.2 Aims 
In order to test the hypothesis, the potential protective properties of OPN were 
investigated in: cell lines endogenously expressing OPN, cells not expressing it and 
cells transfected with OPN.  Detailed aims of the studies were:  
 To characterise SH-SY5Y, SK-NMC, N1E-115, PC-12 and NTera-2 cell 
lines for their dopaminergic phenotype. 
 To characterise SH-SY5Y, SK-NMC, N1E-115, PC-12 and NTera-2 cell 
lines for their OPN, Igαv, Igβ3, Igβ1 and CD44 expression profile. 
 To determine the susceptibility of OPN-null and OPN-positive (SH-SY5Y, 
N1E-115 and SH-SY5Y-OPN
+
) cells to toxin-induced cell death. 
 To investigate the effect of exogenous OPN treatment on toxin-induced cell 




 To investigate whether protective effects of OPN are mediated via Igαv, Igβ3, 
Igβ1 or CD44 receptors.  
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3.2 Methods 
Cell lines represent an important method for studying neuroprotective agents 
and investigating mechanistic aspects.  They allow performance of many 
manipulations such as gene over-expression or silencing, investigating 
pharmacological effects of inhibitors and agonists or testing fragments of the protein 
for activity relatively simply.  Neuronal cell lines were used in this chapter to 
produce in-vitro models of dopaminergic cell death using the non-specific toxin that 
works by inducing oxidative stress H2O2 and the mitochondrial complex I inhibitor 
MPP
+
.  Methodology used to achieve the aims of this chapter is detailed below. 
3.2.1 Cell lines 
Five different cell lines, SH-SY5Y (human neuroblastoma), SK-NMC (human 
neuroblastoma), N1E-115 (mouse neuroblastoma), PC-12 (rat pheochromocytoma) 
and Ntera-2 (human embryonal carcinoma) were grown as described in Section 2.2.1  
They were initially characterised for their TH, OPN and Igαv, Igβ3, Igβ3 and CD44 
receptors phenotype, before assessing neuroprotective properties of OPN. 
3.2.2 Immunofluorescence 
Immunofluorescence staining was used to characterise five cell lines (SH-
SY5Y, SK-NMC, N1E-115, Ntera-2 and PC-12) for their TH, OPN, Igαv, Igβ3, Igβ3 
and CD44 receptors phenotype as described in detail in Section 2.2.6.  Briefly, cells 
were incubated with blocking solution (20% Goat serum, 0.05% Triton-X100/ 0.1M 
PBS) for one hour then incubated with primary antibodies (Table 2.1) diluted in 1% 
goat serum/0.05% Triton-X100/0.1M PBS overnight at 4˚C.  After two washes in 
0.1M PBS, cells were incubated with the appropriate secondary antibodies (Table 
2.2) diluted in 0.1M PBS for one hour at room temperature.  A Zeiss Axioskop 









3.2.3 Western blotting 
Western blotting was performed in order to confirm the OPN phenotype of cell 
lines as described in Section 2.2.7.  Briefly, aliquots of cell lysates (15µl) containing 
100g protein were loaded on SDS gel (12.5%).  After electrophoresis, proteins were 
transferred from the gel into a PVDF membrane.  Membranes were incubated in 
blocking solution (5% non-fat dry powder milk in TBS-T: Tris buffer 50mM pH 7.5, 
NaCl 150 mM, Tween 20 0.2%) overnight at 4˚C then incubated with mouse anti-
OPN antibody (Hybridoma Bank; 1:3000) in blocking solution (2.5%) for three 
hours at room temperature.  After three 10min washes in TBS-T, membranes were 
incubated for 1hr at room temperature with horse radish peroxidase conjugated goat 
anti-mouse antibody (1:2000) in blocking solution (2.5%).  Bands were visualised as 
described in Section 2.2.7.   
3.2.4 Transfection of SH-SY5Y cells with OPN DNA 
SH-SY5Y cells which do not endogenously express OPN, were transfected 
with an OPN expressing vector or a control vector expressing green fluorescent 
protein (GFP). 
3.2.4.a DNA cloning for transfection  
Plasmid DNA designed with a human OPN insert 
(pEXP/pcDNA3.1/IOH13923; 1μl; Invitrogen) (Figure 3.1) or green fluorescent 
protein insert (GFP) (pcDNA3.1/NT-GFP; Invitrogen) (Figure 3.2) was incubated on 
ice with competent cells (XL1-Blue: Top10 strain; 20μl) for 30min.  The cells were 
then heat-shocked in a water bath for 90sec at 42˚C to transform the cells then 
transferred back on ice for 2min.  Luria-Bertani medium (80μl) was added to the mix 
and incubated at 37˚C for 45min.  Transformation mix (8µl) was plated onto pre-
warmed plates (37˚C) of Luria-Bertani agar with ampicillin (100μg/ml) and 
incubated overnight at 37˚C.  The next day, small single clones were selected 
randomly and inoculated into Luria-Bertani medium (3ml; containing ampicillin, 
100μg/ml) and incubated overnight at 37˚C on a shaking platform.  Cells were 
harvested by centrifugation (2700g for 5min) and the DNA purified using Qiagen 
Medi-prep kit by following manufacturer instructions.  A sample of the resulting 
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DNA was sent for sequencing at the molecular biology unit, King’s College London 
where the sequences of human OPN DNA and GFP were confirmed. 
 
Figure 3.1 Schematic map of pcDNA3.1 vector with OPN insert (IOH13923) 













Figure 3.2 Schematic map of pcDNA3.1 vector with GFP insert, used for 
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3.2.4.b Determination of the concentration of geneticin for selection 
The vector used for this transfection (pcDNA3.1) confers geneticin resistance 
to the successfully transfected cells.  Selection of transfected cells in all experiments 
was carried out over two weeks.  In order to determine the geneticin concentration 
which kills naïve (non transfected) cells remaining after each transfection, the 
following experiment was carried out before starting transfection. 
SH-SY5Y cells were plated in three 6 well plates at 2x10
5
cell per well, allowed 
to adhere overnight, then changed to media (DMEM-Glutamax, 10%FBS) containing 
geneticin (100-800µg/ml).  Cells were grown for two weeks with geneticin media 
changed every two days.  Using observation under the inverted microscope (Nikon 
VMS, UK), the smallest concentration of geneticin which caused total cell death in 
two weeks was found to be 300µg/ml (data not shown).  This concentration was used 
for further transfection experiments. 
3.2.4.c Optimisation of transfection conditions 
Fugene 6 transfection reagent (Roche) was used according to manufacturer 
directions where it was mixed with OPN or GFP DNA in serum and antibiotic free 
media (DMEM-Glutamax) at three different concentration ratios (Fugene:DNA, 1:6; 
2:6 and 4:6) and incubated for 15min.  SH-SY5Y cells were seeded into 6 well plates 
at a fixed density (4x10
5
 per well) as described in Section 2.2.1.  After 24hrs, when 
the cells reached about 30% confluence, the transfection mix was added to the wells 
and spread by swirling the plates and left for 72hr to allow transfection of cells.   
The cells were detached with trypsin and re-seeded into new 6 well plates at a 
density of 2x10
5
cell/well overnight then changed to selection media containing 
geneticin (300µg/ml), with selection media changed every two days to maintain 
geneticin concentration.  Control non-transfected SH-SY5Y cells were grown in a 
separate 6 well plate in the same manner.  After two weeks all the cells in the control 
(non-transfected) plate were dead, while transfected cells survived.  When surviving 
transfected cells reached about 80% confluence the heterogeneous population was 
lysed and Western blotting performed to determine the expression of OPN as 
described in Section 2.2.7.  The heterogeneous population obtained via transfecting 
conditions that resulted in the most expression of OPN (Fugene:DNA = 2:6) (Figure 
3.3) was subsequently used.   
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3.2.4.d Selection of stably transfected SH-SY5Y clones 
The transfection process was repeated as in Section 3.2.4.c using optimum 
transfecting conditions (Fugene:DNA = 2:6) and after 72hr exposure to DNA, cells 
were detached with trypsin, re-plated at 2x10
5 
on 6 well plates and grown in media 
containing geneticin (300µg/ml) until clones appeared.  Clones were picked using 
cloning cylinders (Sigma) and transferred to single wells of 24 well plates.  When 
clones reached confluence in the wells, they were transferred into separate T75 flasks 
and allowed to grow.  Expression of OPN protein was confirmed by Western blotting 
and fluorescence immunocytochemistry (Figure 3.4).  Control transfection was 
performed in the same manner using the GFP expressing vector and transfection was 










Figure 3.3 Typical Western blot showing OPN expression in different 
heterogeneous populations of OPN- transfected SH-SY5Y cells. 
SH-SY5Y cells transfected with OPN or control (GFP) using different transfection 
conditions: three different concentration ratios of Fugene:DNA (1:6; 2:6 and 4:6) 
were lysed and separated on a 12% SDS PAGE and tested for OPN expression. 














                
 
                
 
Figure 3.4 Characterisation of SH-SY5Y clones over-expressing OPN. 
(a) Western blot analysis demonstrating over-expression of OPN protein in SH-
SY5Y transfected clones.  Clones 1-3 showed a positive band for OPN at 60KDa.  β-
actin was used as a loading control.  (b-cc) Immunofluorescence confirmation of 
transfected clones.  OPN transfected SH-SY5Y clone 1 shows positive 
immunoreactivity for OPN (b, ) and GFP transfected control clone shows green 
fluorescence from the expressed GFP protein (c, ).  Magnification x40, scale bar 
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3.2.5 Determination of the EC50 concentration of MPP
+
 and H2O2  
Cells were plated into 96 well plates at 1-2 x 10
4
cell/well in full growth 
medium (100µl/well) as described in Section 2.2.1.  After 24hrs, medium was 
changed to serum free medium (DMEM-Glutamax supplemented with 100IU/ml 
penicillin and 100µg/ml streptomycin; 100µl) and after a further 24hrs treated with 
MPP
+
 (0.1-10mM), H2O2 (50-800µM) or vehicle (serum free medium) by adding 
stock solutions (10µl; 10x the desired concentration) to each well (90µl).  Cells 
treated with serum-free media only served as control.  Twenty four hours after toxin 
treatment, cell death was measured by LDH and ATP assays and EC50 values were 
determined by non-linear regression analysis as described in detail in  Section 
2.2.8.c. 
3.2.6 Neuroprotection assays 
Cells were plated into 96 well plates at 1-2 x 10
4
cell/well containing full 
growth medium (100µl/well) as described in Section 2.2.1.  After 24hrs, medium was 
changed to serum free medium (90µl).  In order to determine whether OPN exerted 
neuroprotective effects, the cells were pre-treated with OPN (1-1000ng/ml) or 
vehicle (serum free medium) 24hrs after plating by adding 10µl of stock solutions 
(10 times the desired concentration) to each well (90µl).  Recombinant human OPN 
(R&D systems, UK) was used for human neuroblastoma cell line SH-SY5Y and 
recombinant mouse OPN (R&D systems, UK) was used for mouse neuroblastoma 
cell line N1E-115.  After a further 24hr, cells were treated with MPP
+
 or H2O2 at 
their pre-determined EC50 concentrations (Section 3.2.5).  Control cells were 
incubated with OPN alone or toxin alone and untreated control cells were treated 
with serum free medium only.  Twenty four hours after toxin insult, LDH and ATP 
assays were performed to measure cell death  as described in Section 3.2.7. 
3.2.7 Quantification of cell death 
3.2.7.a LDH Assay 
Cell death was estimated by measuring LDH leakage using the Membrane 
integrity assay (Promega).  The assay was performed as per manufacturer protocol 
(Section 2.2.8a).  Briefly, an aliquot of the assay mix (100µl) was added to each well 
and plates were shaken for 11sec then incubated at 37˚C for 10min.  Stop solution 
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(50µl) was added to each well to stop the reaction then fluorescence was measured in 
a Gemini XS plate reader plate reader at 260/290nm. 
3.2.7.b ATP Assay 
Cell death was estimated using a different assay which gives a measure of the 
ATP content of cells (The Cell titre glo assay; Promega).  The assay was used as per 
manufacturer protocol (Section 2.2.8b).  Briefly, both cells and assay mix were 
equilibrated to room temperature for 30min then an aliquot of the assay mix (100µl) 
was added to each well and plates shaken rigorously for 2 min to induce cell lysis in 
order for the ATP to be released from cells.  Luminescent signal was allowed to 
stabilise for 5min and luminescence read on a Gemini XS plate reader.   
3.2.8 Statistical analysis 
Assays were performed as triplicates on three to four occasions (n=3-4).  Data 
obtained for determination of EC50 concentration of toxins were analysed by one-
way ANOVA followed by Newman Keuls test.  Data from neuroprotection studies 
were analysed by two-way ANOVA followed by Newman Keuls test.  GraphPad 
Prism 5 was used to analyse the data. 
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3.3 Results 
3.3.1 Characterisation of cell lines 
Five cell lines; SH-SY5Y, SK-NMC, N1E-115, PC-12 and Ntera-2 were 
characterised for TH, OPN, CD44 receptor and Integrins Igαv, Igβ3, Igβ1 expression 
by immunofluorescence staining.   
3.3.1.a TH 
All cell lines except Ntera-2 showed positive TH immunostaining; which was 
diffuse and cytoplasmic in nature (Figure 3.5).  PC-12 and N1E-115 showed intense 
TH staining while SH-SY5Y and SK-NMC showed faint TH staining (Figure 3.5).     
3.3.1.b OPN 
Only N1E-115 and PC-12 cell lines expressed OPN protein, showing punctate 
cytoplasmic immunofluorescence staining (Figure 3.5).  By contrast, SH-SY5Y, SK-
NMC and Ntera-2 cells did not show positive immunoreactivity to OPN. 
3.3.1.c Integrin and CD44 receptors 
All cell lines expressed all integrin subunits investigated (Igαv, Igβ3, Igβ1) 
(Figure 3.6).  Integrin positive immunoreactivity appeared as punctate cytoplasmic 
staining.  Intensity of integrin receptors staining was similar in all cell lines 
(Figure3.6). 
All cell lines showed positive immunoreactivity for the CD44 receptor and this 
appeared as diffuse cytoplasmic staining (Figure 3.6).  SH-SY5Y, SK-NMC, N1E-
115 and Ntera-2 cells showed faint staining while PC-12 showed intense 
















Figure 3.5 TH and OPN expression in SH-SY5Y, N1E-115, SK-NMC, PC-12 
and Ntera-2 cell lines. 
Representative photomicrographs showing TH immunoreactivity (red; a-e), OPN 
immunoreactivity (green; a’-e’) and DAPI (blue) in SH-SY5Y, Ntera-2, N1E-115, 
SK-NMC and PC-12 cell lines respectively.  Intense TH staining,  faint TH 
staining, OPN staining.  (Magnification x100, Scale bar = 10μm and is 




























































Figure 3.6 The expression of Igαv, Igβ3, Igβ1 and CD44 receptors in SH-SY5Y, 
N1E-115, SK-NMC, PC-12 and Ntera-2 cell lines. 
Representative photomicrographs showing integrin receptors immunoreactivity (red); 
Igαv (a-e,  ), Igβ3 (f-j, ), Igβ1 (i-o, ), CD44 immunoreactivity (green; p-t, 
) and DAPI (blue) in SH-SY5Y, Ntera-2, N1E-115, SK-NMC and PC-12 cell 























































 TH OPN Igαv Igβ3 Igβ1 CD44 
SH-SY5Y + - + + + + 
Ntera-2 - - + + + + 
N1E-115 + + + + + + 
SK-NMC + - + + + + 
PC-12 + + + + + + 
 
Table 3.1 Summary of the expression of TH, OPN and receptors (Igαv, Igβ3, 
Igβ1 and CD44) in SH-SY5Y, Ntera-2, N1E-115, SK-NMC and PC-12 cells.  
– represents no staining, + denotes positive staining.  
 
3.3.2 Western blotting confirmation of OPN expression in cell lines 
Expression of OPN was confirmed using Western blotting.  N1E-115 and PC-12 
cells expressed OPN protein while SH-SY5Y, SK-NMC, and Ntera-2 cells did not 
(Figure 3.7).  This confirmed the results obtained by immunofluorescence staining 
(Section 3.3.1).   
 
 
                                                                 
                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
 
 
Figure 3.7 OPN expression in SH-SY5Y, N1E-115, SK-NMC, PC-12 and Ntera-
2 cell lines. 
Cell lysates of SH-SY5Y, N1E-115, SK-NMC, PC-12 and Ntera-2 were tested for 
OPN expression by Western blot.  Rat kidney homogenate was used as a positive 











































3.3.3 Choice of cell lines 
Cells were chosen based on four different criteria: expression of TH, OPN, 
OPN receptors and neuronal phenotype.  First, in order for cell lines to be a suitable 
model of the vulnerable dopaminergic neurons which degenerate in PD, they should 
be neuronal and dopaminergic.  Second, cells should contain the putative mechanism 
to respond to protective actions of OPN i.e. express receptors involved in the cell 
survival actions of OPN (Igαv, Igβ3, Igβ1 and CD44) (Scatena et al., 1998; Caers et 
al. 2006; Lin et al., 2000; Lee et al., 2007).  In addition, the aim of this chapter was 
to determine whether endogenous OPN expression affected the ability of 
exogenously added OPN to protect them from toxin insults, hence different cell lines 
should differ in their OPN expression phenotype.   
All cell lines except Ntera-2 cells were TH positive (Table 3.1) but only SH-
SY5Y, SK-NMC and N1E-115 are neuronal.  The five cell lines showed positive 
immunoreactivity to all receptors tested.  However, they varied in their OPN 
expression profile with only N1E-115 and PC-12 cells showing positive expression 
(Table 3.1). 
Two dopaminergic, neuronal cell lines; mouse neuroblastoma N1E-115 cells 
which express OPN endogenously and human neuroblastoma SH-SY5Y which do 
not show positive expression of OPN were chosen for further studies.  SH-SY5Y cell 
line was chosen over SK-NMC as the former is more widely used in PD research and 
is more easily maintained.   
In addition, SH-SY5Y cells were transfected with OPN DNA (SH-SY5Y-
OPN
+
) in order to investigate the effect of introducing expression of the protein, or 
with a control vector expressing GFP (SH-SY5Y-GFP
+
).  The transfection process 
induced higher growth rate in both SH-SY5Y-OPN
+









3.3.4 The effect of OPN expression on the response to MPP+ 
In order to establish the effect of OPN expression on MPP
+





 cells were treated with 
MPP
+ 




(0.1-10mM) induced a concentration-dependent increase in cell death in 
all cell lines as measured by the ATP assay (Figure 3.8).  For SH-SY5Y and N1E-
115 cells, cell death was observed between 1 and 10mM.  Similarly, for SH-SY5Y-
OPN
+
 cell death was observed between 0.1 and 10mM and for SH-SY5Y-GFP
+
 
between 2 and 10mM (Figure 3.8).  Maximal cell death of 100% was observed for 
SH-SY5Y, N1E-115 and SH-SY5Y-OPN
+
 and 89% for SH-SY5Y-GFP
+
 (Figure 
3.8), although the latter value is not statistically different to that in the other cell lines 
(one-way ANOVA followed by Newman Keuls test). 




 (2±0.1mM) was higher 
than that in SH-SY5Y (1.5±0.14mM) but the EC50 value of MPP
+
 was also higher in 
control transfected SH-SY5Y-GFP
+
 (3±0.4mM) and not different to SH-SY5Y-
OPN
+
 (Table 3.2).  In addition, no significant difference was seen between EC50 
values of MPP
+
 in OPN expressing N1E-115 cells (2±0.22mM) or non OPN 




 (0.1-10mM) induced a concentration-dependent increase in cell death as 
measured by LDH leakage from cells (Figure 3.9).  Basal LDH release was between 
20-28% of lysis buffer control but was not significantly different in various cell lines 
(one-way ANOVA followed by Newman Keuls test).   
For SH-SY5Y and N1E-115 cells, cell death was observed between 1 and 




 cell death was observed 
between 0.1 and 10mM (Figure 3.9).  Maximal cell death of 75%, 76%, 74% and 





respectively (Figure 3.9), although value are not statistically different (one-way 
ANOVA followed by Newman Keuls test). 
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The LDH assay showed no difference in EC50 values of MPP
+
 between OPN 
expressing N1E-115 cells (1±0.11mM) and non OPN expressing SH-SY5Y cells 





(3±0.02mM) was higher than that in SH-SY5Y and N1E-115 cells (Table 3.4).  
However, the EC50 value of MPP
+
 was also higher in control trasfected SH-SY5Y-
GFP
+
 (3±0.2) and not different to SH-SY5Y-OPN
+















Figure 3.8 The effect of MPP
+






(a-d) Cells were treated with MPP
+
 (0.1-10mM) for 24hr.  Cell death was measured 
by ATP assay.  Control untreated cells were taken as 100% ATP release.  Data are 
expressed as mean ±SEM (n=3) and were analysed by non-linear regression.  ** P 
















-2 -1 0 1control
























-2 -1 0 1control
























































































Figure 3.9 The effect of MPP
+






(a-d) Cells were treated with MPP
+
 (0.1-10mM) for 24hr.  Cell death was measured 
by LDH assay.  Maximal LDH leakage from lysis buffer treated cells is 100%.  Data 
are expressed as mean ±SEM (n=3) and were analysed by non-linear regression.  * P 














 EC50 (mM) by 
ATP assay 
1.5±0.14 2±0.22 2±0.1 3±0.4 
MPP
+
 EC50 (mM) by 
LDH assay 
2±0.33 1±0.11 3±0.02 3±0.2 
Table 3.2 EC50 concentrations of MPP
+





 obtained by ATP and LDH assays. 
Data are expressed as mean ±SEM (n=3).  * P <0.05, compared to SH-SY5Y-OPN
+
; 
** P <0.01, compared to SH-SY5Y-OPN
+
; # P<0.01 compared to SH-SY5Y-GFP
+
; § 
P<0.001 compared to SH-SY5Y-OPN
+; ∆ p<0.001 compared to SH-SY5Y-GFP+ 
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3.3.5 The effect of OPN expression on the response to H2O2 





 cells were treated with 
H2O2 (50-800µM).  
ATP assay 
H2O2 (50-800µM) induced a concentration-dependent increase in cell death in 
all cell lines as measured by the ATP assay (Figure 3.10).  For SH-SY5Y cells, cell 
death was observed between 200 and 800µM H2O2 and N1E-115 between 50 and 
800µM (Figure 3.10).  Similarly, in SH-SY5Y-OPN
+
 cell death was observed 
between 100 and 800 µM and in SH-SY5Y-GFP
+
, between 200 and 800µM (Figure 





 respectively (Figure 
3.10), although values were not statistically different (one-way ANOVA followed by 
Newman Keuls test).  
The EC50 concentration of H2O2 in SH-SY5Y cells (417±29µM) was 
significantly higher than that in N1E-115 (268±44 µM) and SH-SY5Y-OPN
+
 
(361±44 µM) (Table 3.3).  However, the EC50 concentration of H2O2 in SH-SY5Y-
OPN
+
 cells was not significantly different to that in SH-SY5Y-GFP
+
 (352±25 µM). 
LDH assay 
H2O2 (50-800µM) caused a concentration-dependent increase in cell death in 
all cell lines as measured by LDH leakage from cells (Figure 3.11).  Basal LDH 
release was between 15-26% (Figure 3.11) but was not statistically different in cell 
lines (one-way ANOVA followed by Newman Keuls test).  H2O2 induced LDH 
leakage different to baseline at concentration 300µM in all cell lines (Figure 3.11). 
In all cell lines, cell death was observed between 300 and 800µM (Figure 
3.11).  Maximum cell death of 71%, 85%, 100% and 96% was measured at 800µM 




 respectively (Figure 





) was higher than that in SH-SY5Y (P<0.05; one-way ANOVA followed by 
Newman Keuls test).  There was no difference in EC50 values of H2O2 in all cells 





































(a-d) Cells were treated with H2O2 (50-800µM) for 24hr.  Cell death was measured 
by ATP assay.  Control untreated cells were taken as 100% ATP release.  Data are 
expressed as mean ±SEM (n=3) and were analysed by non-linear regression.  * P 
<0.05, ** P <0.01, *** P <0.001 compared to control (one-way ANOVA followed 























































































































































(a-d) Cells were treated with H2O2 (50-800µM) for 24hr and cell death was measured 
by LDH assay.  Maximal LDH leakage from lysis buffer treated cells is 100%.  Data 
are expressed as mean ±SEM (n=3) and were analysed by non-linear regression. * P 
<0.05, ** P <0.01, *** P <0.001 compared to control (one-way ANOVA followed 
by Newman Keuls test). 
 









H2O2 EC50±SEM (µM) 
by ATP assay 
417±29 268±44 361±44 352±25 
H2O2 EC50±SEM (µM) 
by  LDH assay 
367±79 333±22 361±19 340±40 
 





 measured by ATP and LDH assays.  
Data are expressed as mean ±SEM (n=3).  *P <0.05 compared to N1E-115; # P 
<0.05 compared to SH-SY5Y-OPN
+
 (one-way analysis of variance followed by 













































































































3.3.6 The effect of OPN expression on the response to exogenous OPN 
treatment in MPP
+
 treated cell lines 
In order to determine the effect of OPN expression on the ability of OPN to 
protect against MPP
+





 cells were pre-treated with OPN (1-1000ng/ml) in serum free 
medium or serum free medium alone prior to challenge with MPP
+
 at pre-determined 
EC50 concentrations (Table 3.2).  OPN treatment alone did not have any effect on 
cell viability of all cell lines (ATP and LDH assays) (Figures 3.12, 3.13).  All toxins 
induced significant cell death (approximately 40-60%) as determined by LDH 
leakage and ATP content assays (Figures 3.12, 3.13).  However, pre-treatment with 
OPN (1-1000ng/ml) did not have a protective effect against toxin-induced cell death 































Figure 3.12 The effect of OPN treatment on MPP
+





 cells as measured by 
ATP assay. 
(a-d) Cells were treated with OPN (1-1000ng/ml) 24hr prior to challenge with MPP
+
 
at appropriate EC50 concentrations (Table 3.2).  Control untreated cells were taken as 
100% ATP release.  Data are expressed as mean ±SEM (n=3).  * p<0.01, ** p<0.001 
compared to control (two-way ANOVA followed by Newman Keul’s test). 
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Figure 3.13 The effect of OPN treatment on MPP
+





 cells as measure by LDH 
assay. 
(a-d) Cells were treated with OPN (1-1000ng/ml) 24hr prior to challenge with MPP
+
 
at appropriate EC50 concentrations (Table 3.2).  Maximal LDH leakage from lysis 
buffer treated cells is 100%.  Data are expressed as mean ±SEM (n=3).  * p<0.01 
compared to control (two-way ANOVA followed by Newman Keul’s test). 
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3.5.7 The effect of OPN expression on the response to exogenous OPN 
treatment in H2O2 treated cell lines 
The effect of OPN expression on the ability of OPN to protect against H2O2 





using H2O2 at the pre-determined EC50 concentrations (Table 3.3).  OPN (1-
1000ng/ml) treatment alone for 24hrs did not alter LDH leakage or ATP content of 
cells (Figures 3.14, 3.15).  Treatment with H2O2 for 24hrs caused significant cell 
death of about 40-50% as measured by LDH leakage.  Pre-treatment of all cells with 
OPN (1-1000ng/ml) did not induce any changes to toxin–induced cell death (Figure 
3.15).  This was confirmed by ATP content assay, where treatment with H2O2 caused 
significant cell death of 40-50% but pre-treatment with OPN (1-1000ng/ml) did not 









































 cells as measured by 
ATP assay. 
(a-d) Cells were treated with OPN (1-1000ng/ml) 24hr prior to challenge with H2O2 
at the relevant EC50 concentrations (Table 3.3).  Control untreated cells were taken as 
100% ATP release.  Data are expressed as mean ±SEM (n=3).  *p<0.01, ** p<0.001 
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 cells as measured by 
LDH assay. 
(a-d) Cells were treated with OPN (1-1000ng/ml) 24hr prior to challenge with H2O2 
at the appropriate EC50 concentrations (Table 3.3).  Maximal LDH leakage from lysis 
buffer treated cells is 100%.  Data are expressed as mean ±SEM (n=3).  * p<0.01 
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It was hypothesized that endogenous OPN expression confers intrinsic 
protection to cell lines and that exogenous OPN treatment protects cell lines against 
toxic insult via binding to Igαv, Igβ3, Igβ1 or CD44 receptors.  In order to test this 
hypothesis, cell lines were characterised for OPN, Igαv, Igβ3, Igβ1 and CD44 
expression.  Then, the susceptibility of OPN-null and OPN-positive cells to toxin-
induced cell death was compared.  Finally, the effect of exogenous OPN treatment on 
toxin-induced cell death in OPN-null and OPN-positive cells was investigated.   
3.4.1 Choice of cell lines suitable for addressing the hypothesis 
Characterisation of OPN and receptors phenotype   
The TH phenotype of the cell lines used was confirmed.  SH-SY5Y, N1E-115, 
SK-NMC and PC-12 cells, but not Ntera-2, expressed TH.  This is in agreement with 
previous reports, where SH-SY5Y, N1E-115, SK-NMC and PC-12 cells but not 
Ntera-2 were dopaminergic in character (Amano et al., 1972; Markey et al., 1980; 
Stallcup, 1979).   
The presence of OPN protein in N1E-115 and PC-12 cell lines was 
demonstrated by immunofluorescence and Western blotting techniques whereas SH-
SY5Y, SK-NMC and Ntera-2 cells did not express OPN.  This is the first time OPN 
expression has been investigated in these cell lines.  On the other hand, αv and β3 
integrin receptor subunits were expressed by all five cell lines.  This is consistent 
with previous studies where SH-SY5Y, Ntera-2 and PC-12 were reported to express 
the αv integrin subunit (Choi et al., 1994; Gibson et al., 2005; Lin et al., 1993) and 
PC-12 cells were positive for β3 (Tomaselli et al., 1990).  While (Linnala et al., 
1997) found no positive immunostaining for αv and β3 integrin subunits in 
undifferentiated SH-SY5Y, (Choi et al., 1994) reported detectable levels of the αvβ3 
integrin heterodimer in these cells using immunoprecipitation (Choi et al., 1994; 
Linnala et al., 1997).  Importantly, this is the first report of the expression of αv and 
β3 integrins in N1E-115 and SK-NMC cell lines.  All cell lines showed positive 
immunostaining for the β1 integrin receptor subunit and this is not surprising, as the 
largest subgroup of integrin heterodimers is formed by β1 integrin.  Indeed, there 
have been previous reports on the expression of β1 integrin by all five cell lines 
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(Amendola et al., 2001; Amy et al., 2004; Cherubini et al., 2005; Chuluyan et al., 
2000; Chuluyan et al., 1998; Gibson et al., 2005; Miyashita et al., 2004; Tomaselli et 
al., 1990; Wang et al., 2006).  In addition, all cell lines expressed detectable levels of 
the CD44 receptor.  Weak expression of this receptor was reported in SH-SY5Y cells 
using reverse transcriptase-polymerase chain reactions and flow cytometry (Gross et 
al., 1995; Yan et al., 2003).  In another report, 11% of SHSY5Y cells expressed 
CD44H which is the standard or haematopoietic isoform (Gross et al., 1994).  In the 
present study, the antibody used to detect the CD44 receptor recognises all isoforms 
of this receptor as it is raised against the conserved trans-membrane domain.  This 
antibody was used because it is still not established which CD44 isoforms mediate 
OPN’s pro-survival effects (Chapter 1).  The presence of CD44 receptor has not 
previously been investigated in the other four cell lines before.  
In summary, all cell lines expressed Igαv, Igβ3, Igβ1 and CD44 and therefore, in 
terms of receptor expression criterion, they were all suitable for addressing the aims 
of this Chapter.   
Choice of cells 
The criteria set for choosing cell lines suitable for addressing the aims of this 
chapter are explained in Section 3.3.3.  In summary, it is preferable that cells chosen 
are neuronal and dopaminergic in character, cell lines need to express Igαv, Igβ3, Igβ1 
and CD44 receptors and either express OPN endogenously or be non-OPN 
expressing.  OPN expressing N1E-115 cells were chosen over PC12 cells as the 
former cells are neuronal while the latter are not.  Non-OPN expressing SH-SY5Y 
cells were chosen over NTera-2 as the latter are not dopaminergic.  Both non-OPN 
expressing SH-SY5Y and SK-NMC cells meet all the criteria and thus are both 
suitable candidates, but SH-SY5Y cells were preferred as they are more commonly 
used in PD research and easier to maintain.   
Therefore, OPN-expressing N1E-115 and non-OPN expressing SH-SY5Y cells 
were selected for further tudies as they differ in their OPN expression profile but also 
meet all the criteria set for addressing the aims of these studies.  In summary, both 
cell lines are: neuronal, dopaminergic and express Igαv, Igβ3, Igβ1 and CD44 
receptors.  SH-SY5Y cells were transfected to express OPN protein (SH-SY5Y-
OPN
+
) in order to investigate the effect of introducing OPN expression on their 
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 were therefore used for further investigation.   
3.4.2 Endogenous OPN expression does not affect the sensitivity of cell 
lines to toxin-induced cell death  
MPP
+
 and H2O2 have been reported to induce apoptotic cell death in cell lines 
at concentrations similar to those used in the present study: MPP
+
 (1.5-3 mM), H2O2 
(361-417µM) (Dennis et al., 2003; Fall et al., 1999; Gomez et al., 2001; King et al., 











 cell lines.  MPP
+
 (at the highest 
concentration; 10mM) did not induce maximal LDH leakage in any of the cell lines, 
although at this concentration the ATP assay showed total cell death.  This reflects 
the fact that maximal LDH leakage in the assay procedure is defined by the effect of 
adding a lysis buffer which induces complete necrosis and release of total LDH 
content of the cells.  So, MPP
+
 exposure may have initiated apoptosis in all cells but 
not necrosis and therefore LDH release was not complete.   
There was no difference in the potency of MPP
+
 to induce cell death in OPN 
expressing N1E-115 cells or non-OPN expressing SH-SY5Y cells when measured by 
ATP or LDH assays.  By contrast, MPP
+
 was less potent in inducing cell death in 
SH-SY5Y-OPN
+
 than in SH-SY5Y and N1E-115 cells.  However, MPP
+
 was also 
less potent in inducing cell death in control transfected SH-SY5Y-GFP
+
 cells, 
indicating that this is an effect of the transfection process.  In conclusion, 
endogenous OPN expression did not affect the sensitivity of cells to MPP
+
 toxicity.   
H2O2 





 cell lines.  It also did not 
cause maximal LDH leakage and this may be due to the same reasons outlined for 
MPP
+
.  At the highest concentration used (800µM), H2O2 caused more cell death in 
OPN transfected and control transfected cells compared to non-transfected SH-SY5Y 
and N1E-115 cells, suggesting that again this is an effect of the transfection process. 
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H2O2 was more potent in inducing cell death in N1E-115 cells than in SH-
SY5Y cells suggesting that OPN expression may render cells more vulnerable to 
H2O2 toxicity, as measured by the ATP assay.  However, the potency of H2O2 in SH-
SY5Y-OPN
+
 cells was not different to that in SH-SY5Y-GFP
+
 suggesting that this 
does not reflect OPN expression but rather the nature of the cells.  Unlike the ATP 
assay, the LDH assay showed no difference between cells in the potency of H2O2.  
The ATP assay may be more sensitive to the pro-oxidative effects of H2O2 as the 
ATP content of cells may be affected by the effect of oxidative stress on 
mitochondria.   
In summary, endogenous OPN expression in N1E-115 cells and the 
introduction of OPN expression in SH-SY5Y-OPN
+
 cells did not alter their 
sensitivity to toxin induced cell death.  Therefore, endogenous OPN expression does 
not confer protection against toxic insult.  Although OPN transfection did not seem 
to be protective in this study, it is noteworthy that, in both assays potencies of MPP
+
 
or H2O2 in SH-SY5Y- OPN
+
 are not different to those in SH-SY5Y-GFP
+
 control.  
This shows that transfection with OPN does not confer a higher vulnerability to cells, 
suggesting that introducing expression of this protein in cells is not in itself harmful. 
3.4.3 Exogenous OPN treatment does not protect cells from toxin 
induced cell death 
Exogenous OPN treatment alone did not alter cell viability in any of the cell 
lines.  As expected, MPP
+
 and H2O2 induced a significant increase in death in all cell 
lines.  However, exogenous OPN treatment 24hrs prior to toxic challenge did not 
protect any cell line from cell death as measured by either ATP or LDH assays.  This 
shows for the first time that exogenous OPN treatment does not protect cell lines 
against toxic insult regardless of the OPN expression phenotype.  In addition, OPN 
did not protect cells although they expressed Igαv, Igβ3, Igβ1 and CD44 receptors 
which have been previously shown to mediate protective actions of OPN (Caers et 
al., 2006; Lee et al., 2007; Lin et al., 2001; Scatena et al., 1998).  This could be due 
to a number of reasons.  First, pro-survival actions of OPN may not be mediated 
through Igαv, Igβ3, Igβ1 and CD44 receptors in these cell lines.  In fact, none of the 
integrin receptor subunits bind to OPN by themselves but need to form dimeric 
complexes for a functional receptor unit to be present and to bind OPN (Chapter 1).  
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For instance, Igβ1 associates not only with αv but with four other α receptor subunits 
(α5, α8, α4 and α9), one or more of these may be necessary for the protective effects of 
OPN but may not be present in the cell lines.  In addition, the antibody used to detect 
CD44 receptors in this study detects all CD44 isoforms as it binds to the conserved 
trans-membrane domain.  There are differing reports as to which CD44 isoform OPN 
binds (Chapter 1).  Since it is not known which isoforms of CD44 are expressed in 
these cell lines, they may well be lacking an isoform essential for mediating the 
protective effects of OPN.  Importantly, interaction of OPN with different receptors 
may have different functional consequences (Katagiri et al., 1999; Liaw et al., 1995; 
Yue et al., 1994).  This suggests that OPN may require a different mechanism 
through different receptors that may not be present in these cell lines.     
Second, recombinant OPN, added exogenously to cell lines, is not 
phosphorylated (Ashkar et al., 1993b) and can undergo autophosphorylation on 
tyrosine residues in-vitro in the presence of ATP or GTP (Ashkar et al., 1993a).  
Endogenous OPN on the other hand, has 58 consensus potential phosphorylation 
sites for various protein kinases and depending on tissue type, it is phosphorylated on 
many sites (Ashkar et al., 1993b).  In-vivo, some phosphorylation is indeed 
extracellular (Krane et al., 1962) suggesting that recombinant OPN exogenously 
added to cultures could be phosphorylated.  However, it was beyond the scope of this 
study to determine the phosphorylation state of OPN expressed by these cell lines or 
the in-vitro phosphorylation of exogenous OPN.  The phosphorylation state of OPN 
is important as it may be crucial to its function by determining whether it interacts 
with cells or the ECM (Ek-Rylander et al., 1994; Nemir et al., 1989) and by 
enhancing its binding to integrin receptors via the RGD domain.  In fact, the GRGDS 
integrin binding sequence in OPN is located only 3 residues away from tyr150, a 
highly conserved residue in mammalian OPN.  Tyr150 is also flanked by the 
thrombin cleavage sites and this is a potential site for autophosphorylation, that may 
alter binding to integrin receptors.  Phosphorylation of Ser147; located within the 
GRGDS integrin binding sequence, may also regulate the interaction between OPN 
and receptors on cells (Denhardt et al., 1995).  Moreover, phosphorylation of OPN 
varies in different tissues, for instance milk OPN versus bone OPN (Keykhosravani 
et al., 2005), indicating that phosphorylation may regulate OPN’s function.  OPN 
secreted from JB6 mouse cells is non-phosphorylated, but that secreted from 
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tumorigenic JB6 cells is phosphorylated (Chang et al., 1991), suggesting that 
phosphorylation of the protein is also dependent on the physiological state of the cell.  
Therefore, phosphorylation of endogenous OPN in N1E-115 and SH-SY5Y 
neuroblastoma cell lines may be different to that in other cell types and this may 
explain lack of protection.  The phosphorylation state of OPN expressed by 
transfected SH-SY5Y-OPN
+
 is not known and may also be the reason why no 
protection to the cells was seen.   
Third, OPN is subject to proteolytic cleavage by thrombin (Senger et al., 1989) 
and MMPs (Agnihotri et al., 2001), which may regulate its function.  Cleavage by 
both thrombin and MMPs occurs at close proximity to the integrin recognition 
sequence RGD (Agnihotri et al., 2001; Smith et al., 1996; Yokasaki et al., 2000).  In 
fact, proteolytic cleavage may alter the binding affinity to integrin receptors as one 
study showed that cellular adhesion to full length OPN mediated via α5β1 and α9β1 
was minimal and while thrombin cleavage enhanced adhesion, cleavage by MMPs 
inhibited it (Yokosaki et al., 2005).  In addition, thrombin cleaved OPN induces 
greater cell attachment than the full length protein (Senger et al., 1994), suggesting 
that cleavage is involved in regulating OPN actions.  In certain cells such as 
melanoma cells, cell binding occurs only with the thrombin cleaved OPN (Smith et 
al., 1998).  On the other hand, OPN full length had a greater anti-apoptotic effect on 
neutrophils than the thrombin cleaved protein (Sharif et al., 2009).  Furthermore, a 
recent study showed for the first time that OPN is also cleaved by caspase-8 and that 
mutating OPN to be resistant to this cleavage renders it more efficient in suppressing 
hypoxia/regeneration induced cell death (Kim et al., 2009).  Therefore, the 
processing of OPN in the neuronal cell lines environment may be different to that in 
other environments where it was previously shown to be protective. 
In summary, neuronal cell lines used in this study may not have the required 
receptors to mediate pro-survival actions of OPN, and/or OPN may not be modified 
by these cell lines to function as a protective molecule.  OPN is found in many 
tissues serving diverse functions and it is possible that post-translational 
modifications of OPN are different in different cell types.  Post-translational 
modifications of OPN were different in proliferating versus mineralizing osteoblasts 
(Kasugai et al., 1991; Kubota et al., 1989) and normal versus transformed kidney 
cells (Nemir et al., 1989).  OPN produced by tumor cells seemed to be functionally 
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different compared to OPN produced by host macrophages (Crawford et al., 1998).  
These diverse functions may also be explained by a different receptor repertoire in 
different cell types.   
Additionally, the cell line model provides a continuous supply of ‘mono-typic’ 
neuronal cells with dopaminergic characteristics but they lack the complexity of the 
real picture, where there are different cell types most notably glial cells which release 
neurotrophic factors that support neuronal function.  OPN has anti-inflammatory 
actions and it is involved in tissue remodelling and regeneration (Denhardt et al., 
1993; Scatena et al., 2007; Weber et al., 1996b) and hence may need more 
physiologically relevant systems to exert its protective actions.  Therefore, primary 
culture and in-vivo models will be used in further studies to investigate the potential 
neuroprotective effects of OPN. 
3.4.4 Conclusion 
In conclusion, these data confirm the toxic effect of MPP
+
 and H2O2 in SH-
SY5Y and N1E-115 cell lines.  They also showed, for the first time, that endogenous 
OPN expression does not confer altered vulnerability to toxins and that exogenous 
OPN treatment does not protect cell lines against toxic insult.  This makes the 
situation difficult as we started from the hypothesis that differential OPN expression 
in cell lines may have different effects but this was not the case and even exogenous 
OPN addition was not protective in the cell lines.  Therefore, the next step should be 











4. Chapter 4 OPN prevents toxin 
induced dopaminergic cell death in 




4.1 Introduction  
In the previous chapter, OPN did not protect dopaminergic neuronal cell lines 
against toxin-induced cell death despite the presence of Igαv, Igβ3, Igβ1 and CD44 
receptors.  This was surprising as it was previously shown that OPN has properties of 
a potential protective agent mediated through these receptors (Chapter1).  In 
addition, a study was published as this work was progressing showing the ability of 
an RGD containing peptide fragment of OPN to inhibit toxin induced cell death in 
primary VM culture (Iczkiewicz et al., 2010).  There are a number of reasons why 
this might occur as discussed in Chapter 3.  In brief, post-translational modifications 
affecting OPN function are different in various cell types and processing of OPN 
protein in the cell lines used in those studies may not support a pro-survival function.  
Also, the pro-survival effects of OPN may be mediated via receptors, other than Igαv, 
Igβ3, Igβ1 and CD44, which are not expressed in the cell lines used.  However, in 
light of the newly published findings of neuroprotective effects of an RGD 
containing fragment of OPN in primary culture (Iczkiewicz et al., 2010), there may 
be other potential reasons for this apparent discrepancy.   
First, the fragment found to be protective was based on the concept that the 
RGD binding domain was essential for activity through an action on integrin 
receptors whereas the intact protein is associated with multiple potential 
neuroprotective effects and these may not require the integrin interaction or may 
require additional interactions.  It is possible that such alternative mechanisms may 
not be present in cell lines but can be found in primary VM culture.  Second, the 
cleavage of OPN at the thrombin cleavage site immediately adjacent to portion of the 
molecule that interacts with integrin receptors enhances its binding to integrin 
receptors (Smith et al., 1998).  Thus the full length protein may not possess the 
protective effects previously seen with a fragment, but this has never been tested in 
PD models.  In fact, the concept that the OPN fragment acts through an integrin 
mechanism is purely based on association, and the presence of these receptors in 
primary VM culture has never been investigated.  In addition, no previous study has 
investigated whether integrin receptor antagonists can prevent the protective effect of 
OPN in VM culture. 
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Another important difference between cell lines and primary VM culture is the 
presence of glial cells.  This may be extremely important since a key activity of OPN 
is in the regulation of inflammatory processes (Chapter 1).  As a consequence, OPN 
may affect the response of glial cells to toxic insults, but whether OPN alters glial 
cell activation or number in VM cultures has not been previously investigated.  
Based on studies on the effects of OPN on inflammatory cells in the periphery, a 
direct effect through integrin or CD44 receptors might be anticipated.  But again no 
attempt has been made to look at this in relation to VM cultures or PD.  It is also not 
known whether inflammatory or dopaminergic cells in the VM culture express these 
receptors. 
4.1.1 Hypothesis 
It was hypothesized that OPN protects dopaminergic neurones of the primary 
VM culture against toxic insult and that this effect is mediated via an effect on glial 
cells through binding to integrin and/or CD44 receptors. 
4.1.2 Aims 
In order to test the hypothesis, studies were performed with the following aims: 
 To characterise the primary VM culture for dopaminergic and GABA-ergic 
neurones and glial cells. 
 To characterise the primary VM culture for the expression of OPN, Igαv, 
Igβ3, Igβ1 and CD44. 
 To investigate the effect of exogenous OPN treatment on MPP+ toxicity in 
VM culture. 
 To investigate the role of integrin and CD44 receptors in the protective 
actions of OPN. 




The embryonic ventral mesencephalon develops into the SN and the ventral 
tegmental area (VTA) in the adult rat.  When E14 VM tissue is cultured in-vitro, the 
cells differentiate into dopaminergic and GABA-ergic neurones and glial cells 
(Gilbert et al., 2003; Rodriguez-Pallares et al., 2008; Shimoda et al., 1992).  Specific 
dopaminergic toxins can be used to target dopaminergic cells in this culture, 
producing an in-vitro model of dopaminergic cell death (McNaught et al., 1999b; 
Rodriguez-Pallares et al., 2008).  This model was used to study neuroprotective 
effects of OPN against MPP
+
 toxicity and investigate the role of integrins and CD44 
and glial cells in the neuroprotective effects.  Details of methods used are described 
below. 
4.2.1 Dissection of the ventral mesencephalon 
Ventral mesencephalons were dissected from foetuses from E14 pregnant 
Wistar rats as described in section 2.3.1.  Briefly, foetuses were dissected under a 
dissection microscope (10x; Vickers Instruments, UK) by making a cut from the 
mouth to the VM flexure.  This was followed by two sagittal cuts to separate out the 
mesencephalic region, one anterior and one posterior to the peak of the flexure.  The 
ventral part of the mesencephalic segment was obtained by cutting caudally down 
each side of the ventricle.   
4.2.2 Preparation of primary VM cultures 
Primary VM cultures were prepared as described in detail in Section 2.3.2.  
Briefly, cells were plated at a density of 2x10
5
cell/well on poly-D-lysine coated 
coverslips in 24 well plates (0.5ml full growth medium/well) and grown in a cell 
culture incubator (Sanyo, 37˚C, 5%CO2, 100% humidity) until use. 
4.2.3 Characterisation of primary VM cultures 
Primary VM culture cells were characterised for the dopaminergic cell marker 
TH, a marker of GABA-ergic neurones; glutamate decarboxylase (GAD), a marker 
of microglia (OX-42) and a marker of astrocytes (GFAP).  At DIV 3, 4 or 5, medium 
was removed and cells washed with cold DPBS then fixed with cold PFA (4% in 
PBS) for 15min.  Following fixation, cells were stained using immunoperoxidase 
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cytochemistry for TH and GAD (Section 4.2.4), and counter-stained with Nissl stain 
as decribed in Section 4.2.4.      
4.2.4 Peroxidase immunocytochemistry in VM cultures  
Peroxidase immunocytochemistry was carried out in 24 well plates 
(0.5ml/well) as described in detail in Section 2.3.3.  Briefly, following incubation 
with 20% blocking solution (20% goat serum, 0.05% Triton-X 100 in PBS) for 1hr at 
room temperature, cells were incubated with primary antibodies (Table 2.3) in 1% 
blocking solution (1% goat serum in PBS) overnight at room temperature.  After 
three washes with PBS, cells were incubated with appropriate biotinylated secondary 
antibodies (Table 2.4) diluted in 1% blocking solution for one hour.  After incubation 
with avidin: biotinylated enzyme complex (vectastatin ABC Kit, Vector) colour was 
visualised with DAB and in characterisation experiments, cells were counterstained 
with Nissl stain (Section 2.3.3).   
4.2.5 Determination of the EC50 concentration of MPP
+
 in VM cultures 
VM cultures were grown on poly-D-lysine coated coverslips in 24 well plates 
as described in Section 2.3.2.  At DIV3, medium was changed to serum free medium 
(DMEM-Glutamax supplemented with 1% PSN; 500µl).  At DIV 4, an aliquot of 
medium (50µl) was removed from each well and 50µl of MPP
+
 (final concentrations: 
10-800µM) or vehicle (serum free medium) were added to wells.  At DIV5, medium 
was removed and cells washed three times in cold DPBS (0.5ml/well) then fixed in 
cold PFA (4%/ 0.1M PBS, 0.5ml/well) for 15min.  Cells treated with serum-free 
media only served as control.  Cells were then stained for TH expression as described 
in Section 4.2.4 and the number of TH positive cells counted as described in Section 
4.2.10.   
4.2.6 Neuroprotection Assays in VM cultures 
VM culture cells were grown on poly-D-lysine coated coverslips in 24 well 
plates as described in Section 2.3.2.  At DIV 3, medium was changed to serum free 
medium.  In order to determine whether OPN exerted neuroprotective effects, the 
cells were pre-treated with recombinant rat OPN (custom made, GenScript, USA; 1-
100ng/ml) diluted in serum free medium three days after plating (DIV 3) by adding 
an aliquot (50µl) of stock solutions (10 times the desired concentration) to each well 
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(450µl).  After a further 24hr (DIV 4), cells were treated with MPP
+
 at the pre-
determined EC50 concentrations as described in Section 4.2.5.  Control cultures were 
treated with either 1. Serum free only, 2. OPN only or 3. MPP
+
 only.  Twenty four 
hours after toxin insult (DIV 5), medium was removed and cells washed three times 
in cold DPBS (0.5ml/well) then fixed in cold PFA (4% in PBS; 0.5ml/well) for 
15min.  Cells were then stained for TH expression as described in Section 4.2.4 and 
the number of remaining TH positive cells counted as described in Section 4.2.10. 
4.2.7 Neuroprotection assays using a 15-mer fragment of OPN 
In order to investigate whether a small peptide sequence of OPN comprising 
the integrin binding domain RGD was responsible for the protective effect of OPN, a 
15-mer peptide sequence of OPN comprising the integrin-binding domain RGD 
(TVDVPDGRGDSLAYG) was custom-synthesised (Sigma-Aldrich, UK).    
Neuroprotection assays were performed as described in Section 4.2.6 but using OPN 
fragment (1-100ng/ml) instead of full length OPN. 
4.2.8 Neuroprotection assays in the presence of integrin inhibitors 
Neuroprotection assays were performed as described in Section 4.2.6 with the 
following modifications.  At DIV 3, 30min before adding OPN, non-selective 
integrin inhibitors (RGDS or GRGDSPK; Sigma-Aldrich, UK) shown previously to 
inhibit binding to integrin receptors (Dekkers et al., 2010; Onodera et al., 2005) were 
added at a final concentration range of 1-100nM.  OPN was then added and 24hr 
later, cells were treated with MPP
+
 as described in Section 4.2.5.  Control cultures 
were treated with either 1. Serum free only, 2. integrin inhibitor only or 3. MPP
+
 
only.  Cells were fixed at DIV 5, stained for TH expression (Section 4.2.4) and the 
number of remaining TH positive cells counted as described in Section 4.2.10. 
4.2.9 Double labelling fluorescence immunocytochemistry in VM 
cultures 
Double labelling fluorescence immunocytochemistry was employed to identify 
the cellular localisation Igαv, Igβ3, Igβ1 and CD44 receptors in VM cultures.  The 
cellss were stained for Igαv, Igβ3, Igβ1 or CD44 and a marker of either dopaminergic 
neurons (TH), astrocytes (GFAP), microglia (OX-42) or macrophages (ED-1).  This 
technique was carried out in 24 well plates (0.5ml/well) as described in Section 2.3.5.  
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Briefly, after incubation with 20% blocking solution (20% goat serum, 0.1% Triton-
X 100 in PBS) for one hour, the cells were incubated with a mixture of two primary 
antibodies (Table 2.3) for detecting the two desired antigens, diluted in a 1% 
blocking solution (1% goat serum, 0.1% Triton-X 100 in PBS) overnight at 4˚C.  On 
the next day cells were incubated with the relevant secondary antibodies (Table 2.4) 
conjugated with Alexa Fluor 594 or Alexa Fluor 488  for one hour in a darkened 
environment.  A Zeiss Axioskop microscope was used to examine the sections.   
4.2.10 Data and statistical analysis 
Immunoreactive cells were counted at x10 magnification in ten randomly 
selected areas per coverslip (total area=10mm
2
), with three to four coverslips per 
experiment as described in Section 2.3.4.  For characterisation of VM cultures, the 
number of TH positive or GAD positive cells were expressed as percentage of the 
total number of cresyl violet stained cells (Section 2.3.4).  Non-linear regression 
curve was fitted to log concentration-response data and EC50 concentration of MPP
+
 
calculated.   
Data are expressed as mean±SEM of three to four individual experiments (n=3-
4).  One-way ANOVA followed by Newman Keuls post hoc test was performed on 
MPP
+
 concentration-response data.  Data from neuroprotection studies were analysed 
by two-way ANOVA followed by Newman Keuls’ test.  P<0.05 was considered 




4.3.1 Characterisation of the VM culture 
VM cultures were characterised at DIV 3, 4 and 5 for the proportion of 
dopaminergic and GABAergic neurones by immunocytochemistry for TH and GAD 
respectively and compared to the total number of cresyl violet stained cells.  The 
composition of cultures was the same in all days: at DIV 3, 6% TH immunopositive 
cells and 51% GAD immunopositive, at DIV 4, 5% TH immunopositive cells and 
52% GAD immunopositive cells and at DIV 5, 5% TH immunopositive cells and 
53% GAD immunopositive cells (Figure 4.1).  TH and GAD staining was observed 
on cell bodies as well as processes.    













Figure 4.1 Characterisation of the VM culture.  
(a-b) Representative photomicrographs of VM cultures from DIV 3, 4 and 5 stained 
by peroxidase immunocytochemistry for TH (a) or GAD (b) and counter-stained with 
cresyl violet.   TH stained cell bodies,  GAD stained cell bodies.  
Magnification 20x, scale bar = 200μm and is representative of both images.  (c- e) 
TH positive and GAD positive cells were counted in cultures fixed at DIV 3 (c), DIV 
4 (d) or DIV 5 (e).  Data are expressed as % of cresyl violet stained cells, mean 





















































































































4.3.1.a Investigation of OPN and Igαv, Igβ3, Igβ1 and CD44 receptors expression 
in dopaminergic neurones of the VM culture 
The expression of OPN, Igαv, Igβ3, Igβ1 and CD44 receptors was determined in 
dopaminergic cells of the VM culture.  VM cultures were fixed at DIV 3 or 5 and 
stained for TH, OPN, Igαv, Igβ3, Igβ1 or CD44 using double-labelling 
immunofluorescence.  OPN and Igαv, Igβ3, Igβ1 and CD44 receptors were all 
expressed in VM culture cells (Figures 4.2, 4.3).  OPN staining appeared in the cell 
body, mainly in the cytoplasm and also on processes (Figure 4.2).  Igαv, Igβ3 and 
Igβ1 immunoreactivity appeared strongly in cell nuclei with fainter staining on the 
cytoplasm and few processes (Figure 4.3).  CD44 receptor immunoreactivity 
appeared in the whole cell body with fainter staining on processes (Figure 4.3). 
Double immunofluorescence labelling with anti-TH antibody showed that TH 
immunopositive cells expressed OPN (Figure 4.2) but also Igαv, Igβ3, Igβ1 and CD44 
receptors thought to mediate its pro-survival actions (Figure 4.3).  OPN and its 
receptors were also expressed on other cells that were not TH immunopositive 








Figure 4.2 OPN expression in TH immunopositive cells in VM cultures. 
Representative photomicrographs showing Immunofluorescence staining of TH 
(red), OPN (green) in VM culture cells.   OPN staining,  TH staining,  
co-localisation of OPN and TH,  OPN positive cell which is not TH positive.  
Magnification 20x, Scale bar = 50μm and is representative of all images.    
TH merged OPN 





































Figure 4.3 Expression of Igαv, Igβ3, Igβ1 and CD44 receptors in TH 
immuopositive cells in VM cultures.  
Representative photomicrographs showing Igαv, Igβ3, Igβ1 or CD44 receptor positive 
cells (red; a-d; ) TH positive cells (green; e-h; ), cells expressing both TH and 
receptor (i-l; ), cells expressing receptor but not TH (i-l; ) in VM cultures.  





















4.3.1.b Investigation of glial cell presence in the VM culture 
In order to determine the difference in cell composition between cell lines and 
primary VM culture, presence of glial cells in the VM culture was investigated at 
DIV 3.  Immunoperoxidase staining for glial cell markers showed presence of OX-42 
and GFAP positive cells (Figure 4.4).  OX-42 immunoreactivity appeared on round 















Figure 4.4 Expression of glial cell markers in VM cultures.  
Representative photomicrographs showing (a) OX-42 immunoreactivity ( ), (b) 
GFAP immunoreactivity (brown, ) in VM cultures, cells were counterstained 
with cresyl violet (blue).  Magnification x20, scale bar= 200µm and is representative 




4.3.1.c The expression of Igαv, Igβ3, Igβ1 and CD44 receptors in inflammatory 
cells in VM cultures 
The expression of Igαv, Igβ3, Igβ1 and CD44 receptors was investigated in 
inflammatory cells in the VM culture.  VM cultures were fixed at DIV 3 or 5 and 
immunostained for OX-42, GFAP or ED-1 and Igαv, Igβ3, Igβ1 or CD44 using 
double-labelling immunofluorescence.  Double immunofluorescence showed that 
OX-42 positive microglia, GFAP positive astrocytes and ED-1 positive macrophages 
expressed Igαv, Igβ3, Igβ1 and CD44 receptors, thought to mediate OPN’s pro-
survival actions (Figures 4.5-4.7).  Igαv, Igβ3, Igβ1 and CD44 receptors were also 
expressed on other cells that were not immunopositive for the inflammatory marker 
investigated (Figures 4.5-4.7).  In microglia, astrocytes and macrophages, Igαv, Igβ3 
and Igβ1 staining was localised to cell bodies and more intense immunoreactivity was 
observed in nuclei (Figures 4.5-4.7).  Integrin staining was not clearly seen on the 
processes of astrocytes.  CD44 staining was observed on cell bodies of microglia, 





               
               
               
               
 
Figure 4.5 Expression of Igαv, Igβ3, Igβ1 and CD44 receptors in OX-42 positive 
cells in VM cultures. 
Representative photomicrographs showing Igαv, Igβ3, Igβ1 or CD44 receptor 
immunoreactivity (red; a-d; ), OX-42 immunoreactivity (green; e-h, ), cells 
expressing both OX-42 and receptor (i-l; ) and cells expressing receptor but not 
OX-42 (i-l; ) in VM cultures.  Magnification x40, scale bar = 10μm and is 





















               
               
                 
               
 
Figure 4.6 Expression of Igαv, Igβ3, Igβ1 and CD44 receptors in GFAP positive 
cells in VM cultures. 
Representative photomicrographs showing Igαv, Igβ3, Igβ1 or CD44 receptor 
immunoreactivity (red; a-d; ), GFAP immunoreactivity (green; e-h; ), cells 
expressing both GFAP and receptor (i-l; ) and cells expressing receptor but not 
GFAP (i-l; ) in VM cultures.  Magnification x40, Scale bar = 10μm and is 
representative of all images.  



















               
               
               
                          
 
Figure 4.7 Expression of Igαv, Igβ3, Igβ1 and CD44 receptors in ED-1 positive 
cells in VM culture. 
Representative photomicrographs showing Igαv, Igβ3, Igβ1 and CD44 receptors 
immunoreactivity (red; a-d; ), ED-1 immunoreactivity (green; e-h; ), cells 
expressing both ED-1 and receptor  (i-l; ) and cells expressing receptor but not 
ED-1 (i-l; ) in VM cultures.  Magnification x40, Scale bar = 10μm and is 
representative of all images.  
  

















4.3.2 Determination of the EC50 concentration of MPP
+
 in VM cultures  
In order to determine the EC50 concentration of MPP
+
 in VM cultures, MPP
+
 
(final concentration, 0.1-800µM) was added to cells at DIV 4, the cells were fixed 
24hr later and the number of remaining TH immunopositive cells determined.  As 
expected, MPP
+
 produced a concentration-dependent loss of TH-positive neurones 
from VM cultures (Figure 4.8).  The EC50 concentration obtained was 20±16µM 
while the highest MPP
+
 concentration used (800µM) caused 89% dopaminergic cell 


































Figure 4.8 The effect of MPP
+
 on the number of TH-positive cells in VM 
cultures.  
VM cultures were treated with MPP
+
 (0.1-800μM) for 24hr.  Cells were 
immunostained for TH and the number of remaining TH-positive cells were counted 
and displayed as percentage of TH positive cells compared to untreated cells 
(=100%).  Data are expressed as mean ±SEM (n=4) and analysed by non-linear 
regression, EC50 = 20±16μM.  **p<0.01, *** p<0.001 compared to untreated control 





4.3.3 The effect of OPN treatment on MPP+ induced loss of 
dopaminergic cells in VM cultures  
In order to determine the effect of OPN pre-treatment on MPP
+
 induced TH 
positive cell loss in VM cultures, cells were treated with OPN (1-100ng/ml) 24hr 
prior to treatment with MPP
+
 at the pre-determined EC50 concentration (20µM).  
OPN treatment alone did not alter the number of TH immunopositive cells in VM 
cultures (Figure 4.9).  As expected, MPP
+
 treatment alone produced 48% loss of TH 
immunopositive cells.  However, pre-treatment with OPN (1-100ng/ml) significantly 
protected dopaminergic cells of the VM culture from MPP
+
 toxicity in a 
concentration-dependent manner (Figure 4.9).  Complete protection was achieved at 


















                    
                    
Figure 4.9 The effect of OPN treatment on MPP
+
 induced dopaminergic cell 
death in VM culture cells.  
VM cultures were treated with OPN (1-100ng/ml) 24hr prior to treatment with MPP
+
 
(20µM).  (a) TH immunoreactive cells were counted and displayed as percentage of 
TH positive cells compared to untreated cells (=100%).  Data are expressed as mean 
±SEM (n=3).  * p<0.01 compared to MPP
+
-only treated cells, # p<0.01 compared to 
untreated control (two-way ANOVA followed by Newman Keuls test).  (b-e) 
Representative photomicrographs showing TH immunostaining in (b) control, (c) 
OPN (10ng/ml) treated, (d) MPP
+
 treated and (e) MPP
+
 and OPN (10ng/ml) treated 
VM culture cells.  Arrows show dead cells.  Magnification x20, scale bar in (d) = 
200µM and is representative of all images.  Scale bar in (d’) = 50µM and is 
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4.3.4 Investigation of the mechanism of neuroprotection by OPN in VM 
cultures  
4.3.4.a The effect of a 15mer peptide fragment of OPN containing the RGD 
integrin binding domain on MPP
+
 induced dopaminergic cell death 
In order to investigate whether a small sequence of OPN comprising the 
integrin binding domain RGD was responsible for the protective effect seen in 
Section 4.3.3, a 15-mer peptide fragment comprising the integrin-binding domain of 
OPN was tested for neuroprotection in VM cultures.  Treatment with OPN fragment 
alone did not alter the number of TH positive cells present in the culture (Figure 
4.10).  As expected, treatment with MPP
+
 produced a 59% decrease in the number of 
TH positive neurones.  Pre-treatment with OPN fragment protected dopaminergic 
neurones from MPP
+
-induced cell death in a concentration-dependent manner, 













                     
                        
 
Figure 4.10 The effect of OPN treatment on MPP
+
-induced dopaminergic cell 
death in VM culture cells.  
VM cultures were treated with OPN fragment (1-100ng/ml) 24hr prior to treatment 
with MPP
+
 (20µM).  (a) TH immunoreactive cells were counted and displayed as 
percentage of TH positive cells compared to untreated cells (=100%).  Data are 
expressed as mean ±SEM (n=3).  # p<0.01 compared to untreated control, * p<0.01 
compared to MPP
+
-only treated cells (One-way ANOVA followed by Newman 
Keuls test).  (b-e) Representative photomicrographs showing TH immunostaining in 
(b) control, (c) OPN fragment (10ng/ml) treated, (d) MPP
+
 treated and (e) MPP
+
 and 
OPN fragment (10ng/ml) treated VM culture cells.  Arrows show dead cells.  
Magnification x20, scale bar in (d) = 200µM and is representative of all images.  





















































4.3.4.b The effect of integrin receptor inhibitors on neuroprotective effects of 
OPN 
To investigate whether protective effects of OPN shown previously (Section 
4.3.3) are mediated via integrin receptors, cells were incubated with non-selective 
peptide antagonists of integrin receptors, shown previously to inhibit binding to 
integrin receptors (Meller et al., 2005; Smith et al., 1996) before performing 
neuroprotection experiments.   
RGDS 
Integrin receptor antagonist RGDS alone did not alter the number of TH 
positive cells in the VM culture (Figure 4.11).  As expected, MPP
+
 (20µM) induced a 
58% loss of dopaminergic neurones, and treatment with OPN (10ng/ml) protected 
TH positive cells from MPP
+
 toxicity (Figure 4.11).  Treatment of cells with RGDS 
(1-100ng/ml) 30min before OPN (100ng/ml) prevented the protective effect of OPN 
in a concentration-dependent manner, with significant effects at 10ng/ml and 
100ng/ml (Figure 4.11).  In fact, complete inhibition was observed at 10ng/ml and 
100ng/ml (Figure 4.11). 
GRGDSPK 
Integrin receptor antagonist GRGDSPK alone did not have an effect on the 
number of TH positive cells in the VM culture (Figure 4.11).  As expected, MPP
+
 
(20µM) alone caused 67% loss of dopaminergic neurones, and treatment with OPN 
(10ng/ml) protected TH positive cells from MPP
+
 toxicity (Figure 4.11).  Treatment 
of cells with GRGDSPK (1-100ng/ml) 30min before OPN (1-100ng/ml) inhibited the 
protective effect of OPN in a concentration dependent manner, with significant effect 































Figure 4.11 Effects of integrin peptide inhibitors on the neuroprotective action 
of OPN 
VM cultures were treated with: (a) RGDS (1-100nM) or (b) GRGDSP (1-100nM) for 
30 min before treatment with OPN (100ng/ml).  After 24hr, cells were treated with 
MPP
+
 (20µM) and after a further 24hr, the number of TH positive cells was 
determined.  Data are expressed as mean ±SEM (n=3). * P<0.05 compared to 
control, $ P<0.05 compared to MPP
+
-treated cells, # P<0.05 comapred to OPN 
treated cells treated with MPP
+






























































































































































4.3.4.c The effect of OPN on the number of inflammatory cells in MPP+-treated 
VM cultures 
In order to determine whether protective effects of OPN against MPP
+
 induced 
TH positive cell death was mediated via an action on inflammatory cells, the effect 
of MPP
+
 and/or OPN treatment on the number of OX-42, OX-6, GFAP and ED-1 
positive cells was investigated. 
OX-42 and OX-6    
In untreated control cultures, the number of OX-42 positive cells was 117 
cell/10mm
2
 (Figure 4.12).  Treatment of the VM culture with OPN (10ng/ml) 





 (20μM) treatment also induced a similar increase in the number of OX-42 
cells in the VM culture (171 cell/10mm
2
).  Treatment of the VM culture with OPN 
(10ng/ml) 24hr before MPP
+
 (20μM) treatment caused an increase in the number of 
OX-42 positive cells (196 cell/10mm
2
) which was not different to that seen after 
OPN or MPP
+
 alone (Figure 4.12).  OPN and/or MPP
+
 treatment did not change the 
morphology of OX-42 positive cells (Figure 4.12).  No microglial activation 
occurred following any of the treatments, as no OX-6 positive staining was obtained 
for any treatment condition (Data not shown).   
GFAP 
Untreated control cultures contained 58 cell/10mm
2
 GFAP positive cells.  
Treatment of the VM culture with OPN (10ng/ml) or MPP
+
 (20μM) did not induce a 
change in the number of GFAP positive cells in the culture (Figure 4.13).  Similarly, 
treatment of the VM culture with OPN (10ng/ml) 24hr before MPP
+
 (20μM) did not 
affect the number of GFAP positive cells (Figure 4.13).  None of the treatment 
conditions changed the morphology of GFAP positive cells (Figure 4.13).     
ED-1 
In untreated control cultures, there was 163 cell/10mm
2
 ED-1 positive cells 
(Figure 4.14).  The cells appeared round and showed strong staining of cell bodies 
but not processes.  Treatment of the VM culture with OPN (10ng/ml) or MPP
+
 
(20μM) did not induce a significant change in the number of ED-1 positive cells in 
the culture or in morphology (Figure 4.14).  Similarly, treatment of the VM culture 
 149 
with OPN (10ng/ml) 24hr before MPP
+
 (20μM) did not affect the number or 
morphology of ED-1 positive cells (Figure 4.14).       













                   



















Figure 4.12 The effect of OPN on the number of OX-42 positive glial cells in 
MPP
+
-treated VM culture. 
VM cultures were treated with OPN (10ng/ml) or MPP
+
 (20µM), alone or in 
combination, OPN being added 24hr prior to MPP
+
.  (a) Cells were immunostained 
with anti-OX42 antibody and the number of OX-42 positive cells was determined.  
Data represent the number of OX-42 positive cells in 10mm
2
 and are expressed as 
mean ±SEM (n=3).  * P<0.05 compared to control (two-way ANOVA followed by 
Newman Keuls test).  (b-e) Representative photomicrographs showing OX-42 
immunostaining in (b) untreated control, (c) OPN treated, (d) MPP
+
 treated and (e) 
MPP
+
 and OPN treated VM cultures.  Magnification x20, scale bar = 200µM and is 


















































































                   











Figure 4.13 The effect of OPN on the number of GFAP positive glial cells in 
MPP
+
-treated VM culture.  
VM cultures were treated with OPN (10ng/ml) or MPP
+
 (20µM), alone or in 
combination, OPN being added 24hr prior to MPP
+
.  (a) Cells were immunostained 
with anti-GFAP antibody and the number of GFAP positive cells was determined.  
Data represent the number of GFAP positive cells in 10mm
2
 and are expressed as 
mean ±SEM (n=3).  Data were analysed using two-way ANOVA.  Representative 
photomicrographs showing GFAP immunostaining in (b) untreated control, (c) OPN 
treated, (d) MPP
+
 treated and (e) MPP
+
 and OPN treated VM cultures.  






































































              
                                                
             
 
Figure 4.14 The effect of OPN treatment on the number of ED-1 positive cells in 
MPP
+
 treated VM culture.  
VM cultures were treated with OPN (10ng/ml) or MPP
+
 (20µM), alone or in 
combination, OPN being added 24hr prior to MPP
+
.  (a) Cells were immunostained 
with anti-ED-1 antibody and the number of ED-1 positive cells was determined.  
Data represent the number of ED-1 positive cells in 10mm
2
 and are expressed as 
mean ±SEM (n=3).  Data were analysed using two-way ANOVA.  (b-e) 
Representative photomicrographs showing GFAP immunostaining in (b) untreated 
control, (c) OPN treated, (d) MPP
+
 treated and (e) MPP
+
 and OPN treated VM 
cultures.  Magnification x20, scale bar in (d) = 200µM and is representative of all 
























































OPN did not prevent MPP
+
 or H2O2 induced cell death in immortalised 
dopaminergic cell lines (Chapter 3), although a fragment of OPN has recently been 
shown to be neuroprotective in VM cultures (Iczkiewicz et al., 2010).  This has led 
to an investigation of OPN effects on dopaminergic neurones in primary VM culture.  
Therefore, in this study, it was hypothesized that OPN protects against toxin induced 
cell death in primary VM culture and that this effect is mediated via integrin 
receptors and CD44 and through an action on glial cells.   
4.4.1 Characterisation of the VM culture  
Between DIV 3 and 5, the VM cultures were comprised of approximately 5% 
TH immuopositive cells and 50% GAD immunopositive cells.  These results support 
previous reports of 2-5% TH immunopositive and 48% GAD immunopositive cells 
in VM cultures (Cheung et al., 1997; Gilbert et al., 2003; Johansson et al., 2003).  
The VM cultures also contained OX-42 positive microglia, GFAP positive astrocytes 
and ED-1 positive macrophages.  This confirms that primary VM cultures contain 
not only dopaminergic neurones but also other cell types most notably glial cells 
which may be critical for the protective effects of OPN.   
OPN binds to many integrin receptors and to the CD44 receptor in order to 
mediate a range of functions (Chapter 1).  Integrins αv, β3 and β1 as well as the CD44 
receptor have been shown to mediate pro-survival actions of OPN (Caers et al., 
2006; Lee et al., 2007; Lin et al., 2001; Scatena et al., 1998).  In this study, for the 
first time, dopaminergic neurones in VM culture were shown to express Igβ3, Igβ1 
and CD44 and the expression of Igαv was confirmed (Chao et al., 2003).  This 
demonstrates that dopaminergic neurones in VM culture express receptors that may 
mediate pro-survival effects of OPN.  Thus, they may provide an appropriate test bed 
for investigating neuroprotective effects of OPN.  In addition, dopaminergic neurons 
were shown to express OPN.  Although expression of OPN constituvely in cell lines 
did not affect their vulnerability to toxins (Chapter 3), a recent study in these 
laboratories showed different results in VM culture.  In this study, treating VM 
cultures with an anti-OPN antibody rendered dopaminergic cells more vulnerable to 
MPP
+
 and LPS toxicity, exacerbating more cell loss (Iczkiewicz et al., 2010).  In 
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fact, treatment of VM cultures with anti-OPN antibody alone induced dopaminergic 
cell loss (Iczkiewicz et al., 2010). 
4.4.2 OPN protects dopaminergic neurons in VM cultures from MPP+-
induced cell loss    
The susceptibility of dopaminergic neurones in VM culture to MPP
+
 was 
confirmed, as it produced a concentration dependent decrease in TH positive cell 
number with an EC50 = 20µM.  This concentration is comparable to the range used in 
previous studies (20-50µM) (Grammatopoulos et al., 2007; McNaught et al., 1999a; 
Outeiro et al., 2007).  It is noteworthy that the EC50 concentration of MPP
+
 in VM 
culture is about 100 fold lower than that in cell lines (2mM).  This suggests that cell 
lines may be different to primary neurones as they are more resistant to toxins and 
may thus be less sensitive to protective agents.   
Importantly, OPN (1-100ng/ml) pre-treatment of VM cultures prevented MPP
+
 
toxicity with complete protection of dopaminergic neurons at concentrations (10 and 
100ng/ml).  This is in line with a previous report of the ability of a 15-mer fragment 
of OPN to protect dopaminergic neurons against MPP
+
 toxicity (Iczkiewicz et al., 
2010).  However, these results are completely different to those obtained in SH-
SY5Y and N1E-115 cell lines despite the fact that they express Igαv, Igβ3 and Igβ1 
and CD44 receptors.  In fact, exogenous OPN treatment did not protect SH-SY5Y 
and N1E-115 cell lines from MPP
+
 or H2O2 induced cell death nor did transfection of 
SH-SY5Y cells with the protein (Chapter 3).  These findings perhaps indicate that 
the lack of protective effect in cell lines was due to differences between neuronal cell 
lines and VM culture.  It is possible that, as anticipated, presence of glial cells in the 
VM culture but not cell lines can affect regulation of OPN function and this is 
discussed in Section 4.4.4.  Also, post translational modifications of OPN such as 
phosphorylation and proteolytic cleavage may be different in VM culture, thereby 
facilitating interaction between protein and receptor and mediating protective 
mechanisms.  These post translational modifications have been shown to affect 




4.4.3 The role of integrin receptors in the neuroprotective effect of OPN 
Non-specific peptide inhibitors of integrin receptors (RGDS and GRGDSPK) 
prevented the protective effects of OPN in VM cultures exposed to MPP
+
.  This 
suggests that the protective effect of OPN was mediated through integrin receptors 
and this is in line with other studies where pro-survival effects of OPN were 
mediated via integrin receptors (Caers et al., 2006; Lee et al., 2007; Lin et al., 2001; 
Lin et al., 2000; Scatena et al., 1998).  The role of CD44 receptor in protective 
actions of OPN could not be investigated as there is no commercially available 
neutralising anti-CD44 antibody suitable for use in cells of rat origin.  In subsequent 
studies this could potentially be investigated using silencing RNA.  The fact that 
integrin inhibitors fully inhibited protection by OPN does not necessarily rule out a 
role for the CD44 receptor as binding to CD44 requires OPN to first bind Igβ1 
(Katagiri et al., 1999).  In the same study, however, binding to Igβ1 was not RGD 
dependent (Katagiri et al., 1999).   
In addition, a 15-mer fragment of OPN containing the RGD binding domain, 
which binds to αvβ3, αvβ1, αvβ5, α5β1 and α8β1 integrin receptors (Attur et al., 2000; 
Denda et al., 1998; Hu et al., 1995), retained the neuroprotective properties of OPN 
in the VM culture.  This is in line with the previous report of the protective effect of 
this fragment in MPP
+
 and LPS treated VM cultures (Iczkiewicz et al., 2010).  
However, the number of TH positive cells was lower than untreated control, 
indicating that MPP
+
 was still inducing some cell death in the presence of the 15-mer 
fragment of OPN.  Therefore, this segment of OPN did not fully protect 
dopaminergic neurones suggesting that other parts of the protein may be contributing 
to the pro-survival effects of OPN.  For instance the CD44 receptor, which binds a 
site of the protein, not included in the fragment, has been shown to mediate OPN-
induced cell survival in different cell lines (Lin et al., 2001; Lin et al., 2000).  In fact, 
unpublished data have shown a protective effect of a fragment of OPN containing the 
CD44 binding domain in toxin treated VM culture (Iczkiewicz et al. 2010).  In 
addition, binding to CD44 is suggested to regulate OPN binding to integrin receptors 
possibly via activating integrins through an outside-in mechanism and increasing cell 
survival (Lee et al., 2007).  Another possibility is that the full length protein may 
have enhanced binding to receptors via conformational changes to the protein 
binding site.    
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Inhibition of the protective effect of OPN against MPP
+
 toxicity by integrin 
antagonists and the positive effect of the RGD containing fragment of OPN suggests 
that protective effects of OPN protein are at least partially due to binding of integrin 
receptors.  Clearly, integrin receptors are involved in the neuroprotective effect of 
OPN in VM culture but whether this effect requires the involvement of glial cells is 
not yet clear.   
4.4.4 The role of glial cells in OPN-induced neuroprotection 
Immunohistochemical investigation showed that VM culture contains 
microglia, astrocytes and ED-1 positive macrophages.  This confirms results of 
previous studies showing that the VM culture comprises OX-42 and GFAP positive 
glia (Cheung et al., 1997; Gilbert et al., 2003).  In fact, in the present study, glial 
cells expressed receptors shown to mediate protective actions of OPN, Igαv, Igβ3, 
Igβ1 and CD44.  This suggests that OPN may have effects on these cells that 
contribute to neuroprotection, such as increased production of neurotrophic factors.         
Neither MPP
+
 nor OPN had an effect on the number of astrocytes or 
macrophages present in the VM culture.  This is the first investigation of OPN’s 
effect on these cells in VM cultures, while MPP
+
 was not previously reported to 
affect the number of GFAP positive astrocytes or ED-1 positive macrophages in VM 
culture.  OX-6 positive activated microglia could not be detected in the VM cultures 
under any treatment condition.  In one study, however, MPP
+
 induced an increase in 
the number of OX-6 positive microglia (Joglar et al., 2009) but this was after four 
days of MPP
+
 treatment.  Unlike the reported effects of MPTP in-vivo (Breidert et 
al., 2002; Chung et al., 2010), MPP
+
 did not have an effect on astrocytes or 
macrophages in VM culture suggesting that these glial cells may be immature and 
therefore may not act like mature glia in adult rat SN.     
MPP
+
 caused an increase in the number of OX-42 positive microglia in the VM 
culture in agreement with previous reports (Henze et al., 2005).  Interestingly, OPN 
also caused an increase in the number of OX-42 positive microglia in the VM culture 
and this is in line with previous reports of the ability of OPN to recruit inflammatory 
cells as part of its function (Ellison et al., 1999; Lampe et al., 1991; O'Regan et al., 
1999).  However, pre-treatment of cells with OPN 24hr before MPP
+
 treatment 
caused an increase in the number of microglial cells in the VM culture similar to that 
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caused by either agent alone.  It is therefore not clear whether this effect is produced 
by OPN, MPP
+
 or both.  It is possible that microglia reached maximal proliferation 
capacity so treatment with both agents could not have an additive effect.   
Although OPN protected the VM culture from MPP
+
 induced dopaminergic cell 
loss, it did not appear to affect the MPP
+
 induced increase in the number of 
microglial cells and may in fact be contributing to this increase.  Therefore, OPN 
may be acting directly on dopaminergic neurones instead, and this is supported by 
the fact that dopaminergic neurones in the VM cultures were shown to express 
receptors involved in OPN’s pro-survival actions.  However, although cell lines 
expressed these receptors, OPN did not protect them against toxin-induced cell death 
(Chapter 3) This may suggest that expression of receptors is not sufficient to allow 
protection by OPN, effects on glial cells or specific modification of OPN by VM 
cultures may also be necessary.   
It was previously shown that MPP
+
 induces iNOS up-regulation in VM cultures 
(Du et al., 2001).  Therefore, it is conceivable that OPN acts by decreasing NO levels 
from the VM culture by means of inhibiting up-regulation of iNOS as reported 
previously (Rollo et al., 1996b) but this requires further investigation.  Additionally, 
the increase in microglial cells caused by OPN treatment alone may be a protective 
action, since it was recently shown in unpublished studies from our laboratories that 
both OPN and MPP
+
 cause an increase in neurotrophic factors released by glial cells 
(GDNF and BDNF) in VM cultures (Broom, 2011, personal communication).  Glial 
cells in the SN determine the homeostatic control of the neuronal extracellular 
environment, provide support to neurones through the release of neurotrophic 
factors, protect neurones against toxic insult and have the ability to counteract 
oxidative stress (Hirsch, 2000; Montgomery, 1994).  In pathological situations, glial 
cells may play a protective role by releasing trophic factors such as GDNF or BDNF, 
cleavage of free radicals through glutathione peroxidase or catabolising dopamine by 
monoamine oxidase B or COMT.  They may also contribute to damage by releasing 
pro-inflammatory cytokines and promoting immune reactions (Barron, 1995; Hirsch, 
2000; Hirsch et al., 2003; McGeer et al., 1998; Vila et al., 2001a).  It is possible 
therefore that in this instance, OPN induced proliferation of microglia is not a 
harmful action particularly as it did not cause microglial activation or cause a 
decrease in the number of dopaminergic neurones present in culture.  It is difficult to 
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explain the increase in microglia produced by OPN and it is not easy to see why 
OPN would do this by itself.  Since OPN is induced as a response to injury or 
inflammation (Chapter 1), it may be that adding OPN alone to the culture sends 
signals that there is injury and hence microglial proliferation occurs.   
4.4.5 Conclusion 
In conclusion, these data confirm the toxic effect of MPP
+
 in VM culture cells 
and show for the first time the ability of OPN to protect dopaminergic neurones from 
this toxicity.  Protection was mediated via integrin receptors which are expressed on 
dopaminergic neurones and inflammatory cells, although the role of CD44 remains 
to be further investigated.  OPN induced proliferation of microglial cells but not 
astrocytes or macrophages and did not induce activation of microglia, so the exact 















5. Chapter 5 OPN prevents LPS 
induced nigral dopaminergic cell 





In the previous chapter, OPN was shown to protect against MPP
+
 induced 
dopaminergic cell loss in VM cultures and this was mediated via integrin receptors.  
The protective effect of OPN against MPP
+
 induced cell death was accompanied by 
an increase in the number of microglial cells, but as discussed in Chapter 4, it was 
difficult to determine their role in OPN’s protective effect.  OPN is involved in the 
regulation of inflammatory processes in the periphery and CNS (Chapter 1) and was 
previously shown to be up-regulated in the SN following supra-nigral LPS injection 
in rat (Iczkiewicz et al., 2005).  OPN may therefore be involved in regulating the 
inflammatory process in PD.  The obvious thing to do, perhaps, would have been to 
look more specifically into the role of glial cells using LPS in VM culture.  However, 
the ultimate objective of these studies was to determine whether full length OPN is 
protective in the brain.  In addition, a study was recently published using supra-nigral 
LPS injection in rats as a model of cell death in PD and in fact showing that a 15-mer 
peptide fragment of OPN is protective (Iczkiewicz et al., 2010).  However, it is not 
known whether full length OPN is equally protective since this has not been 
investigated previously in experimental models of dopaminergic cell death.  
Therefore, a more logical step is to focus on the LPS model to investigate the role of 
OPN in regulating inflammation, but to use it in the SN in-vivo.  Consequently, the 
rat LPS model of inflammation in PD was employed to investigate the effects of 
OPN on inflammatory mediated dopaminergic cell loss.   
Whether, in the intact rat SN, evidence can be found for integrin receptors 
which seem to be important for protection; Igαv, Igβ3, Igβ1 (Chapter 4 and Chapter 1) 
and CD44 (Chapter 1) is to be determined.  Although, Igαv and CD44 were 
previously shown to be expressed on dopaminergic neurons of the SN (Chao et al., 
2003; Fuxe et al., 1996), a full investigation of Igαv, Igβ3, Igβ1 and CD44 receptors 
and their cellular localisation within the rat SN has not been undertaken.  It is also 
not known whether expression of these receptors is altered following LPS lesioning 
in the SN and whether it is different in activated glia and infiltrating macrophages.  
This is an important issue, but from the studies described in Chapter 3, expression of 
these receptors on cells does not necessarily indicate that OPN is able to exert 
protective effects.         
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5.1.1 Hypothesis 
OPN protects against inflammation induced cell death of dopaminergic neurons 
and this is mediated through an interaction with Igαv, Igβ3, Igβ1 or CD44 receptors 
and an effect on glial cells. 
5.1.2 Aims 
In order to test this hypothesis, studies with the following aims were performed 
 To characterise normal rat SN for the expression of Igαv, Igβ3, Igβ1 and CD44 
receptors. 
 To confirm the dopaminergic cell loss and reactive gliosis in the LPS model 
of PD. 
 To determine the effect of LPS on the expression of Igαv, Igβ3, Igβ1 and 
CD44 receptors. 
 To determine whether OPN pre-treatment protects nigral dopaminergic 
neurones from LPS mediated degeneration. 
 To determine if the effects of OPN are mediated through changes in the 





OPN was investigated for neuroprotective effects in the LPS model of nigral 
cell death in PD.  LPS, a component of the outer membrane of gram negative 
bacterial cell wall, is an endotoxin and a potent inducer of inflammation (Burrell, 
1990).  Administration of LPS into rat SN produces significant loss of dopaminergic 
neurones due to rapid activation of glial cells (Herrera et al., 2000; Iravani et al., 
2005).  LPS was shown to cause a persistent and selective degeneration of the 
dopaminergic neurons of SN, having no effect on GABAergic or serotonergic 
neurons (Castano et al., 1998).  In addition, LPS induced toxicity is not via direct 
action on neurons but it works via activation of glial cells and inducing the release of 
pro-inflammatory cytokines such as TNF-α and IL-1β (Liu et al., 2000b).  This 
makes the LPS model a suitable model for studying inflammation mediated 
neurodegeneration.  In addition to the inflammatory reaction, LPS was shown to 
produce a reduction in glutathione levels in SN indicating that oxidative stress may 
also be a contributory factor in cell death (Dutta et al., 2008).  This model was 
previously used to investigate potential treatments for PD such as naloxone (Liu et 
al., 2000a) and minocycline (Tomás-Camardiel et al., 2004). 
5.2.1 Investigation of Igαv, Igβ3, Igβ1 and CD44 receptors expression in 
the normal rat SN 
In order to investigate the expression of Igαv, Igβ3, Igβ1 and CD44 receptors in 
the normal rat SN, a group of male Wistar rats (250-280g, n=5) were deeply 
anaesthetised with sodium pentobarbital (130mg/kg, i.p.).  The rats were 
transcardially perfused with 0.1M PBS followed by PFA (4%/0.1M PBS) and then 
brain SN sections prepared as described in Section 2.5.2a.  The expression of Igαv, 
Igβ3, Igβ1 receptors and CD44 in rat brain SN was investigated by immunoperoxidase 
histochemistry as described in Section 5.2.4 and double labelling 
immunofluorescence as described in Section 5.2.5.  All experiments were performed 
under Animal (Scientific procedures) act 1986 and approved by King’s College 
Ethical Review panel, Project licence 70/6018. 
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5.2.2 LPS rat model of PD 
Supra-nigral injection of LPS was performed in the rat brain as described in 
Section 2.5.1.  Briefly, male Wistar rats (250-300g, n=6 per group) were 
anaesthetised with isoflorane (4% in 5%O2: 95% CO2) and secured in stereotaxic 
frame (Kopf instruments, US).  LPS (5μg/μl; 2l) or vehicle (saline, 0.9%; 2l) were 
slowly injected over 2min at co-ordinates -4.8mm anterior, +2.0mm lateral and -
7.6mm ventral to bregma (Paxinos and Watson, 1986; Figure 5.1).  The needle was 
slowly withdrawn, wounds sutured and animals allowed to recover.  Rats were culled 
at three different time points (1, 3 or 7 days) following surgery and peroxidase 
immunohistochemistry was performed to determine the effect of supranigral LPS on 
the expression of TH, OX-6, GFAP and ED-1 as described in Section 5.2.4.  Double 
labelling immunofluorescence was employed to examine the cellular localisation of 
integrin and CD44 receptors after LPS lesioning as described in Section 5.2.5. 
5.2.3 Neuroprotection studies  
In order to test the neuroprotective effects of OPN in-vivo, recombinant rat 
OPN (custom made, GenScript; 100ng, 2µl) or vehicle (PBS, 2µL) were injected into 
the rat SN following the same surgical procedure described for the LPS model in 
Section 2.5.1 using co-ordinates -4.8mm anterior, +1.8mm lateral and -8.0mm 
ventral to bregma (Paxinos and Watson, 1986; Figure 5.1).  OPN or vehicle were 
injected either 2 or 24hr before supra-nigral LPS (5μg/μl; 2l) or vehicle (0.9% 
saline; 2l) injections performed as described in Section 5.2.2.  Rats were culled 1 
week after surgery and peroxidase immunohistochemistry was performed as 
described in Section 5.2.4 to investigate the effects of OPN pre-treatment on the 





















Figure 5.1 Schematic diagram of LPS and OPN injection co-ordinates. 
OPN was injected into the SN at co-ordinates -4.8mm anterior +1.8mm lateral and -
8.0mm ventral to bregma.  LPS was injected supra-nigrally at co-ordinates -4.8mm 
anterior, +2.0mm lateral and -7.6mm to bregma (Paxinos and Watson, 1986). 
 
5.2.4 Peroxidase immunohistochemistry in rat SN  
Peroxidase immunohistochemistry was used to characterise the normal and LPS 
injected SN for the expression of Igαv, Igβ3, Igβ1 and CD44 and to study the changes 
induced by LPS and OPN on the expression of TH, OX-6, ED-1 and GFAP.  
Peroxidase immunohistochemistry was performed as described in detail in Section 
2.5.2.  Briefly, SN sections were incubated with primary antibodies (Table 2.5) 
overnight at room temperature.  After two washes in 0.1M PBS, sections were 
incubated with biotinylated secondary antibodies (Table 2.6) for one hour.  The 
sections were then washed twice in 0.1M PBS followed by incubation in the Avidin 
Biotin complex (1:200) for one hour.  For visualisation of results, sections were 
incubated with DAB (0.05% in 0.05M Tris HCl; Ph 7.4) for 5min then H2O2 (0.01% 
final concentration) was added and the sections incubated for 1-5min.  Sections were 




5.2.5 Double labelling fluorescence immunohistochemistry in rat SN 
tissue sections 
Double labelling fluorescence immunohistochemistry was employed to identify 
the cellular localisation of Igαv, Igβ3, Igβ1 and CD44 receptors in the normal and LPS 
lesioned rat SN.  The sections were stained for Igαv, Igβ3, Igβ1 or CD44 and a marker 
of either neurones (Neuronal nuclei, NeuN), dopaminergic neurons (TH), astrocytes 
(GFAP), microglia (OX-42), activated microglia (OX-6) or macrophages (ED-1).  
The detailed method of this technique is described in Section 2.5.2.d.  Briefly, SN 
sections were incubated with two different primary antibodies raised in different 
species (Table 2.5) overnight at 4˚C.  On the next day, sections were incubated with 
a mixture of Alexa Fluor 594 (red) and Alexa Fluor 488 (green) secondary antibodies 
for one hour in a darkened environment.  After three 30min washes with 0.1M PBS, 
coverslips were mounted, in the dark, onto polysine slides (Menzel-glaser) using 
vectashield hardset mounting medium with DAPI.     
5.2.6 Data analysis 
TH 
The number of TH positive cells was manually counted from the whole SNpc 
(3 sections at the level of third nerve from each animal) in a blinded manner under 
magnification x20 using a Zeiss Axioskop microscope. 
Glial and macrophage markers 
The number of OX-6 and ED-1 positive cells was manually counted from 3 
sections of the SN per rat, in a blinded manner.  Immunopositive cells were counted 




Receptors and GFAP 
Optical density of immuonostaining was measured for sections stained with 
GFAP, Igαv, Igβ3, Igβ1 or CD44 relative to optical density of the background using 
ImageJ software.  Images for this were taken using Olympus BX-61 microscope at 
magnification x1.25.  Values are given in arbitrary units (AU). 
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5.2.7 Statistical Analysis 
Data are expressed as mean±SEM of experimental treatment groups (n=3-8).  
Data were analysed by two-way ANOVA followed by Newman Keuls test.  P<0.05 












5.3.1 Expression of Igαv, Igβ3, Igβ1 and CD44 receptors in the normal rat 
brain SN 
Igαv, Igβ3 and CD44 receptors were expressed in the SNpc and SN pars 
reticulata (SNpr) (Figure 5.2).  Staining of Igαv, Igβ3 and CD44 receptors appeared in 
the cell bodies located mainly in the SNpc and some in the SNpr.  Igβ3 stained 
smaller areas of cell bodies than Igαv and CD44.  Igβ1 receptor was expressed to a 
lesser extent in the SN and not consistently through the SN (Figure 5.2c).  Staining of 
Igβ1 receptor was also located in the cell bodies.  Antibodies for all receptors also 













Figure 5.2 Peroxidase immunostaining of Igαv, Igβ3 and Igβ1 and CD44 
receptors in the rat SN. 
Representative photomicrographs showing (a) Igαv positive cells, (b) Igβ3 positive 
cells, (c) Igβ1 positive cells and (d) CD44 positive cells in the SN.  Magnification x5, 
 receptor positive cells, scale bar = 1000µm (c) and is representative of all 
photomicrographs.  Inserts (a’-d’), magnification x40, scale bar = 50 µm (c’) and is 
















5.3.2 Cellular localisation of Igαv, Igβ3, Igβ1 and CD44 receptors in the 
SN 
Igαv positive staining appeared in cell nuclei with fainter staining in cell bodies 
(Figures 5.2-5.3).  Igβ3 positive staining appeared mainly in the cell nucleus with 
fainter staining over some of the cell body (Figures 5.2-5.3).  CD44 positive staining 
appeared over the whole cell body (Figures 5.2-5.3).  Igβ1 was not detected in the SN 
by immunofluorescence histochemistry.   
5.3.2.a Co-localisation of Igαv, Igβ3 and CD44 receptors with neurones of the SN 
Igαv, Igβ3 and CD44 receptors were expressed in almost all neurons of the SN 
as identified by NeuN co-staining (Figure 5.3).  Igαv, Igβ3 and CD44 receptors were 
also present in cells that were not NeuN positive suggesting that they are also 
expressed in non neuronal cells. 
5.3.2.b Co-localisation of Igαv, Igβ3 and CD44 receptors with Dopaminergic 
neurons of the SN 
Igαv, Igβ3 and CD44 receptors were present in TH positive neurons of the SN as 
shown by co-localisation of immunofluorescence staining of these receptors and TH 
immunoreactivity (Figure 5.4).  However, Igαv, Igβ3 and CD44 receptors were also 
expressed on other cells that were not TH positive. 
5.3.2.c Co-localisation of Igαv, Igβ3 and CD44 receptors with glial cells of the SN 
None of the receptor positive cells co-localised with GFAP positive astrocytes, 
although receptor positive cells were located in very close proximity to GFAP 
positive cells (Figure 5.5).  Co-localisation with microglial cells could not be 
investigated as OX-42 signal for resting microglia could not be detected using the 


















Figure 5.3 Immunofluorescence staining in SN sections showing co-localisation 
of NeuN positive neurons with Igαv, Igβ3 and CD44 receptors. 
Representative photomicrographs showing Igαv, Igβ3 or CD44 receptor positive cells 
(a-c; red,  ), NeuN positive cells (d-f; green, ),  cells expressing both receptor 
and NeuN (g-i, ) and cells expressing receptor but not NeuN (g-i; red, ) in 






























Figure 5.4 Immunofluorescence staining in SN sections showing co-localisation 
of TH positive neurons with Igαv, Igβ3 and CD44 receptors. 
Representative photomicrographs showing Igαv, Igβ3 or CD44 receptor  positive cells 
(a-c; red, ),  TH positive cells (d-f; green, ),  cells expressing both receptor 
and TH (g-i; ) and cells expressing receptor but not TH (g-i; red, ) in the SN.  
Magnification x100, scale bar = 50µm and is representative of all images. 
  





























Figure 5.5 Immunofluorescence staining in SN sections showing expression of 
GFAP and Igαv, Igβ3 and CD44 receptors. 
Representative photomicrographs showing Igαv, Igβ3 or CD44 receptor positive cells 
(a-c; red, ) and GFAP positive cells (d-f; green, ) in the SN.  No co-
localisation was found between GFAP and receptors (g-i).  Magnification x40, scale 
bar = 100µm and is representative of all images. 
  














5.3.3 Establishing the rat LPS model  
5.3.3.a Confirmation of TH positive cell loss and presence of gliosis following 
supra-nigral LPS injection 
In order to investigate the effect of supra-nigral LPS injection on dopaminergic 
neurons and inflammatory cells, rats were supra-nigrally lesioned with LPS (10μg) 
and sacrificed after 1, 3 or 7 days.   
As expected, LPS injection produced a significant loss (70%) of dopaminergic 
neurons after 24hrs compared to contralateral side, which remained until one week 
after surgery (Figure 5.6).  Immunohistochemical staining confirmed the reactive 
microgliosis produced by LPS (Figure 5.7).  Evidence of a reactive microgliosis is 
demonstrated by presence of activated (OX-6 positive) microglial cells on the 































Figure 5.6 Dopaminergic cell loss following LPS lesioning. 
Rats (n=6 per group) were lesioned with LPS (10µg) and culled after 1, 3 or 7 days 
post surgery.  (a-f) Representative photomicrographs showing TH immunoreactivity 
in intact (a-e) and lesioned (b-f) sides of the SN at the different time points.  
Magnification x5, scale bar = 1000µm and is representative of all images.  (g) The 
number of the remaining TH positive cells in the SN was counted.  Data are 
expressed as mean ±SEM.  *P<0.001 (two-way ANOVA followed by Newman 
























































































        






Figure 5.7 Microglioial activation in the SN following LPS lesioning. 
Rats (n=6 per group) were lesioned with LPS (10µg) and culled after 1, 3 or 7 days. 
(a-f) Representative photomicrographs of OX-6 staining in intact and lesioned sides 
of SN sections (a) 1 day, (b) 3 days and (c) 7 days post LPS injection.    














5.3.4 Supra-nigral LPS injection induces up-regulation of integrin and 
CD44 receptors in the SN 
In order to establish the effect of LPS on the expression of Igαv, Igβ3, Igβ1 and 
CD44 receptors in SN, sections from rats supra-nigrally lesioned with LPS (10μg) 
and culled at three different time points (1 day, 3 days or 7 days) were stained for 
Igαv, Igβ3, Igβ1 or CD44 by immunoperoxidase histochemistry and the degree of 
expression was represented by OD measurement.   
LPS lesion produced an increase in the expression of Igαv (significant effect of 
lesion, P<0.05 two-way ANOVA), but the OD in the lesioned side of SN was not 
significantly different compared to the contralateral side at individual time points 
(Newman Keuls test) (Figures 5., 5.12).  LPS injection induced a significant increase 
in the expression of Igβ3 receptor in the ipsilateral side compared to the contralateral 
side at all time points and was highest at 7 days post injection (Figures 5.9, 5.12).  
LPS injection also significantly increased Igβ1 expression in the ipsilateral side 
compared to the contralateral side at all time points but the increase of Igβ1 
expression  was highest at day 7 post lesioning (Figures 5.10, 5.12).  Expression of 
CD44 receptor was increased in the ipsilateral side compared to the contralateral side 
after LPS challenge in the SN at all time points (Figures 5.11, 5.12).  Examining the 
sections at higher magnifications reveals that, for all receptors, both the intensity of 
staining of cell bodies and processes is higher after LPS lesioning (Figures 5.8-5.12). 
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Figure 5.8 The effect of LPS on the expression of Igαv receptor in SN.  
Rats were lesioned with LPS (10µg) and culled after 1 day, 3 days or 7 days post 
lesioning.  Representative photomicrographs of Igαv staining in intact and lesioned 
sides of SN sections (a) 1 day, (b) 3 days and (c) 7 days post LPS injection.   
Igαv positive cell.  Magnification x1.25, scale bar = 3000µm and is representative of 
all images.  Insets, magnification x10, scale bar (c2) = 500µm and is representative of 



































































Figure 5.9 The effect of LPS on the expression of Igβ3 receptor in SN 
Rats were lesioned with LPS (10µg) and culled after 1 day, 3 days or 7 days post 
lesioning.  Representative photomicrographs of Igβ3 staining in intact and lesioned 
sides of SN sections (a) 1 day, (b) 3 days and (c) 7 days post LPS injection.   
Igβ3 positive cell.  Magnification x1.25, scale bar = 3000µm and is representative of 
all images.  Insets, magnification x10, scale bar (c2)  = 500µm and is representative 





































































Figure 5.10 The effect of LPS on the expression of Igβ1 receptor in SN 
Rats were lesioned with LPS (10µg) and culled after 1 day, 3 days or 7 days post 
lesioning.  Representative photomicrographs Igβ1 staining in intact and lesioned 
sides of SN sections (a) 1 day, (b) 3 days and (c) 7 days post LPS injection.   
Igβ1 positive cell.  Magnification x1.25, scale bar = 3000µm and is representative of 
all images.  Insets, magnification x10, scale bar (c2) = 500µm and is representative of 



























                              
 
















Figure 5.11 The effect of LPS on the expression of CD44 receptor in SN  
Rats were lesioned with LPS (10µg) and culled after 1 day, 3 days or 7 days post 
lesioning.  Representative photomicrographs of CD44 staining in intact and lesioned 
sides of SN sections (a) 1 day, (b) 3 days and (c) 7 days post LPS injection.   
CD44 positive cell.  Magnification x1.25, scale bar = 1000µm and is representative 
of all images.  Insets, magnification x10, scale bar (c2) = 500µm and is representative 
























































Figure 5.12 The effect of LPS on the expression of Igαv, Igβ3, Igβ1 and CD44 
receptors in SN  
Rats (n=6 per group) were lesioned with LPS (10µg) and culled after 1, 3 or 7 days 
post lesioning.  Optical density of receptor staining relative to background was 
measured for (a) Igαv, (b) Igβ3, (c) Igβ1 and (d) CD44 immunostaining in the SN.  
Data are expressed as mean ±SEM.  **P<0.01, ***P<0.001 compared to intact side; 
# P<0.05, ##P<0.01 compared to 1day lesioned side; $ P<0.05 compared to 3days 
















































































































































































































































































































5.3.5 Integrin and CD44 receptors are expressed on glial cells following 
LPS challenge in the SN    
In order to determine the effect of LPS on the cellular localisation of Igαv, Igβ3, 
Igβ1 and CD44 receptors in SN, sections from rats lesioned supra-nigrally with LPS 
(10μg) and culled at three different time points (1 day, 3 days and 7 days) were 
immunostained for Igαv, Igβ3, Igβ1 or CD44 and OX-6, ED-1 or GFAP.   
Integrins αv and β3 mainly stained nuclei and cell bodies while CD44 stained 
cell bodies and processes (Figure 5.12-5.14).  Double labelling immunofluorescence 
showed that Igαv, Igβ3, Igβ1 and CD44 receptors were expressed on some but not all 
OX-6 positive activated microglia, GFAP positive astrocytes and ED-1 positive 
macrophages (Figures 5.13-5.15).  There was no difference in the co-localisation of 




               
                         
                                       
                   
 
Figure 5.13 Immunofluorescence staining in SN sections showing expression of 
OX-6 positive microglia and Igαv, Igβ3 and CD44 receptors.  
Representative photomicrographs showing Igαv, Igβ3 or CD44 receptor  positive cells 
(a-c; red, ) , OX-6 positive cells (d-f; green, ),  cells expressing both receptor 
and OX-6 (g-i; ) and cells expressing OX-6 but not the receptors (g-i, ) in 

























                
              
                
 
Figure 5.14 Immunofluorescence staining in SN sections showing expression of 
GFAP positive astrocytes and Igαv, Igβ3 and CD44 receptors. 
Representative photomicrographs showing Igαv, Igβ3 or CD44 receptor  positive cells 
(a-c; red, ),  GFAP positive cells (d-f; green, ), cells expressing both receptor 
and GFAP (g-i, ) and cells expressing GFAP but not the receptors (g-i, ) in 






















              
 
              
 
              
 
 
Figure 5.15 Immunofluorescence staining in SN sections showing expression of 
ED-1 positive macrophages and Igαv, Igβ3 and CD44 receptors.  
Representative photomicrographs showing Igαv, Igβ3 or CD44 receptor positive cells 
(a-c; red, ), ED-1 positive cells (e-f; green, ) and cells expressing both 
receptor and ED-1 (g-i, ) and   cells expressing ED-1 but not receptor (g-i, ) 
in LPS lesioned SN.  Magnification x60, scale bar = 100µm and is representative of 
all images. 
  














5.3.6 The effect of OPN on nigral TH positive cell loss induced by LPS 
lesioning 
In order to investigate whether OPN treatment in the SN is protective against 
LPS toxicity, recombinant rat OPN (100ng, 2µl) or vehicle (PBS, 2µl) were injected 
2 or 24hrs into the SN before injecting LPS (10µg, 2µl) supra-nigrally.   
No significant effects on the number of TH-positive cells were observed in 
sham-lesioned and vehicle-injected rats nor in sham-lesioned and OPN-injected rats 
(Figure 5.16).  As expected, LPS produced a 50% (2hr study) and a 55% (24hr study) 
loss of TH positive cells in the lesioned SN compared to vehicle lesioned control 
(Figure 5.16).  However, OPN injection into the SN 24hr before LPS lesioning 
significantly protected against TH-positive cell loss in the SN and the number of TH 
positive cells was not different to control (Figure 5.16-e).  Injecting OPN only 2hrs 
before LPS lesioning provided similar protection to dopaminergic neurons (Figure 





























Figure 5.16 The effect of OPN on the number of TH –positive cells in SN of LPS 
or sham-lesioned rats.  
(a-d) Representative photomicrographs of TH immunoreactivity in the lesioned side 
of SN in (a) sham-lesioned and vehicle-injected rats, (b) sham-lesioned and OPN-
injected rats, (c) LPS-lesioned and vehicle injected rats, (d) LPS-lesioned and OPN-
injected rats.  Magnification x5, scale bar = 1000µm and is representative of all 
images.  (e) Number of TH-positive cells in the lesioned and intact SN following 
OPN or vehicle injection 2hrs before LPS or vehicle lesioning (n=3-8).  (f) Number 
of TH-positive cells in the ipsilateral and contralateral following OPN or vehicle 
injection 24hrs before LPS or vehicle lesioning (n=3-8).  Data are expressed as mean 
±SEM.  ***P<0.001 compared to sham-lesioned and vehicle-injected, ## P<0.01 
compared to LPS-lesioned and vehicle-injected rats (two-way ANOVA followed by 
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5.3.7 Effects of OPN on the inflammation produced by supra-nigral LPS 
injection 
5.3.7.a The effect of OPN on microglial activation following LPS lesioning 
In order to investigate the effect of OPN injection into the SN on the reactive 
gliosis produced by LPS lesion, SN sections from rats sham-lesioned and vehicle-
injected, sham-lesioned and OPN-injected, LPS-lesioned and vehicle-injected or in 
rats LPS-lesioned and OPN-injected were stained for OX-6; a marker for activated 
microglial cells.   
There was a small non-significant increase in the number of OX-6 positive 
microglia on the ipsilateral side of sham-lesioned and vehicle-injected rats and sham-
lesioned and OPN-injected rats compared to the contralateral side (Figure 5.17).  
This was mainly located around the injection site (Figure 5.17).  As expected, LPS 
produced a significant increase in the number of OX-6 positive microglia (24hr 
study, 150±10; 2hr study, 142±15) in the ipsilateral side compared to the ipsilateral 
side of sham-lesioned and vehicle injected control (24hr study, 6±2; 2hr study, 
24±20).  OX-6 positive cells displayed large cell bodies and shorter processes 
(Figure 5.17.c’).  However, OPN-injected 24hrs prior to LPS lesioning produced a 
significant decrease (58%) in the number of activated microglial cells compared to 
LPS lesioned vehicle injected rats (Figure 5.17-e).  When injected only 2hr before 
LPS lesioning, OPN also reduced the LPS-induced increase in the number of OX-6 
positive microglia by (72%) (Figure 5.17-f).  In OPN pre-treated SN, OX-6 positive 
cells appeared less activated with smaller cell bodies than LPS and vehicle injected 

































Figure 5.17 The effect of OPN on microglial activation produced by LPS in the 
SN.  
(a-d) Representative photomicrographs of OX-6 immunoreactivity in the lesioned 
side of SN in (a) sham-lesioned and vehicle-injected rats, (b) sham-lesioned and 
OPN-injected rats, (c) LPS-lesioned and vehicle-injected rats, (d) LPS-lesioned and 
OPN-injected rats.  Magnification x5, scale bar = 1000µm and is representative of all 
images.  Insets (c’,d’), magnification x40, scale bar = 50µm and is representative of 
both images.  (e) Number of OX-6-positive cells in the lesioned and intact sides of 
SN following OPN or vehicle injection 2hrs before LPS or vehicle lesioning (n=3-8).  
(f) Number of TH-positive cells in the lesioned and intact sides of SN following 
OPN or vehicle injection 24hrs before LPS or vehicle lesioning (n=3-8).  Data are 
expressed as mean ±SEM.  ***P<0.001 compared to sham-lesioned vehicle-injected, 
### P<0.001 compared to LPS-lesioned vehicle-injected rats (two-way ANOVA 
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5.3.7.b The effect of OPN on the number of ED-1 positive macrophages 
following LPS lesioning 
To study the effect of OPN injection into the SN on the macrophage infiltration 
produced by LPS lesion, SN section from the rats sham-lesioned and vehicle-
injected, sham-lesioned and OPN-injected, LPS-lesioned and vehicle-injected or in 
rats LPS-lesioned and OPN-injected were stained for a marker of macrophages (ED-
1).   
There was a small non-significant increase in the number of ED-1 positive 
macrophages in the ipsilateral side of sham-lesioned and vehicle-treated rats and 
sham-lesioned and OPN-injected rats compared to the contralateral side (Figure 
5.18).  These macrophages showed small cell bodies with few processes (Figure 
5.18.a’).  As expected, LPS produced a significant increase in the number of ED-1 
positive cells in the ipsilateral side compared to the sham-lesioned vehicle-injected 
control.  In these rats, macrophages displayed larger cell bodies (Figure 5.18.c’).    
OPN-injected 2hrs or 24hrs before LPS lesioning did not have an effect on the 
increase in the number of activated macrophages induced by LPS lesioning (Figure 
5.18).  OPN injection 2hrs or 24hrs before LPS lesioning did not alter the 





























Figure 5.18 The effect of OPN and LPS on macrophages in the SN.  
(a-d) Representative photomicrographs showing ED-1 immunoreactivity in the 
lesioned side of SN in (a) sham-lesioned and vehicle-injected rats, (b) sham-lesioned 
and OPN-injected rats, (c) LPS-lesioned and vehicle-injected rats, (d) LPS-lesioned 
and OPN-injected rats.  Magnification x5, scale bar = 1000µm and is representative 
of all images.  Insets (a’,c’), magnification x40, scale bar = 50µm and is 
representative of both images.  (e) Number of ED-1-positive cells in the lesioned and 
intact sides of SN following OPN or vehicle injection 2hrs before LPS or vehicle 
lesioning (n=3-8).  (f) Number of ED-1-positive cells in the lesioned and intact sides 
of SN following OPN or vehicle injection 24hrs before LPS or vehicle lesioning 
(n=3-8).  Data are expressed as mean ±SEM.  *P<0.05 compared to sham-lesioned 
vehicle-injected, **P<0.01 compared to contralateral side (two-way ANOVA 
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5.3.7.c The effect of OPN on the astrocytosis produced by LPS challenge 
In order to investigate the effect of OPN injection into the SN on the reactive 
astrocytosis produced by LPS lesion, SN sections from rats sham-lesioned and 
vehicle-injected, sham-lesioned and OPN-injected, LPS-lesioned and vehicle-
injected or in rats LPS-lesioned and OPN-injected were stained for a marker of 
astrocytes (GFAP) and optical density (OD) of staining was measured.   
There was no change in the OD of GFAP staining in the ipsilateral side of 
sham-lesioned and vehicle-injected rats and in sham-lesioned and OPN-injected rats 
compared to the contralateral side (Figure 5.19).  As expected, LPS induced a 
significant increase in the OD of GFAP immunostaining in the ipsilateral side 
compared to sham-lesioned vehicle-injected control.  GFAP positive cells displayed 
hypertrophic cell bodies with thicker processes compared to control (Figure 5.19.c’).  
OPN injected 2hrs or 24hrs before LPS lesion did not have an effect on the increase 
in the OD of GFAP immunostaining induced by LPS lesioning nor on the 







































Figure 5.19 The effect of OPN on the astrocytosis produced by LPS in the SN.  
(a-d) Representative photomicrographs showing GFAP immunoreactivity in the SN 
of (a) sham-lesioned and vehicle-injected rats, (b) sham-lesioned and OPN-injected 
rats, (c) LPS-lesioned and vehicle-injected rats, (d) LPS-lesioned and OPN-injected 
rats.  Magnification x1.25, scale bar = 3000µm and is representative of all images.  
Insets (a’,c’) from lesioned side, magnification x40, scale bar = 50µm and is 
representative of both images.  (e) OD of GFAP staining in the intact and lesioned 
side of the SN following OPN or vehicle injection 2hrs before LPS or vehicle 
lesioning (n=3-8).  (f) OD of GFAP staining in the intact and lesioned side of the SN 
following OPN or vehicle injection 24hrs before LPS or vehicle lesioning (n=3-8).  
Data are expressed as mean ±SEM.  *P<0.05 compared to sham-lesioned vehicle-
injected, **P<0.01 compared to sham-lesioned vehicle-injected (two-way ANOVA 
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In these studies, it was hypothesized that OPN is protective against 
inflammation induced death of dopaminergic neurons and that this is mediated 
through an interaction with Igαv, Igβ3, Igβ1 or CD44 receptors and an action on glial 
cells.  Initial studies were undertaken to examine the SN for Igαv, Igβ3, Igβ1 and 
CD44 receptors expression in normal and LPS-lesioned rats.  This was followed by 
an investigation into the effect of nigral OPN injection on LPS-induced 
dopaminergic cell loss, and the potential involvement of glial cells in the protective 
effect. 
5.4.1 Expression of Igαv, Igβ3, Igβ1 and CD44 receptors in rat SN 
Peroxidase immunohistochemistry investigation revealed that Igαv, Igβ3, Igβ1 
and CD44 receptors were all expressed in the SN.  These findings confirm previous 
reports of the expression of mRNA of Igαv and Igβ1 in this brain region (Pinkstaff et 
al., 1999).  The same group could not detect a signal for β3 integrin but they describe 
unpublished Western blot data suggesting its presence in whole brain lysates 
(Pinkstaff et al., 1999).  Ig αv mRNA and protein (Chao et al., 2003) and the CD44 
receptor (Fuxe et al., 1996) were shown to be expressed in the rat SN.  However, this 
is the first report of the expression of Igβ3 and Igβ1 protein in this brain region.   
The cellular localisation of Igαv, Igβ3, Igβ1 and CD44 receptors in the SN was 
investigated by double labelling immunofluorescence.  Igαv, Igβ3 and CD44 were 
expressed on neurones as there was co-localisation between these receptors and the 
neuronal marker NeuN.  In fact, Igαv, Igβ3 and CD44 receptors were found in all 
dopaminergic neurones of the SN as immunofluorescence results showed positive 
expression of Igαv, Igβ3 and CD44 receptors in TH-positive cells.  The 
immunofluorescent signal for Igβ1 was not different to negative control.  This may be 
due to lower sensitivity of the imunnofluorescence technique compared to 
immunoperoxidase histochemistry.  
Double labelling immunofluorescence showed no positive co-localisation of 
Igαv, Igβ3 and CD44 receptors with GFAP positive astrocytes in normal rat SN.  
However, there is a possibility that they co-localise with microglial cells but this 
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could not be investigated as resting microglial cells were not detected by 
immunofluorescence histochemistry due to lower sensitivity of this technique.  A 
possible alternative for future studies would be to use in-situ hybridisation to label 
receptors followed by immunoperoxidase histochemistry to stain for microglial cells 
in order to examine co-localisation. 
Presence of Igαv, Igβ3, Igβ1 and CD44 receptors, involved in cell survival 
actions of OPN in other systems (Caers et al., 2006; Lee et al., 2007; Lin et al., 2001; 
Scatena et al., 1998), suggests that the SN may contain the mechanism for mediating 
pro-survival actions of OPN.  However, it is not known whether expression of these 
receptors is altered in the LPS model of dopaminergic cell death, where OPN will be 
tested for neuroprotection.   
5.4.2 The effects of LPS challenge in the SN 
Supra-nigral LPS injection produced a significant loss of dopaminergic 
neurones from the SNpc compared to sham-lesioned control and this is in line with 
other reports (Herrera et al., 2000; Iravani et al., 2002; Iravani et al., 2005).  
Previous studies have confirmed that LPS induces dopaminergic cell death rather 
than a reduced expression of TH protein (Gao et al., 2002; Iravani et al., 2002). 
Supra-nigral LPS injection in the rat brain produced a significant increase in 
activated microglial cells, macrophages and astrocytes compared to sham-lesioned 
animals.  This confirms previous evidence of the pro-inflammatory effects of LPS in 
the rat SN (Herrera et al., 2000; Iravani et al., 2002; Iravani et al., 2005).  LPS 
causes microglia and astrocyte activation (Castano et al., 1998; Herrera et al., 2000) 
and induces the expression of iNOS and an increase in the generation of NO and 3-
NT from activated microglia (Arimoto et al., 2003; Gayle et al., 2002; Iravani et al., 
2002; Peng et al., 2005).  In addition, LPS leads to an increased expression of the 
pro-inflammatory cytokines TNF-α, IL-1α, IL-1β, and IL-6.  This inflammatory 
process accompanying nigral cell degeneration is also seen in PD (Chapter1), but it is 
still not clear whether inflammation is a cause and/or an effect. 
The expression of Igαv, Igβ3, Igβ1 and CD44 receptors increased following LPS 
lesioning in the SN.  Further investigation using double-immunofluorescence 
labelling showed evidence of expression of these receptors on some astrocytes, 
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activated microglia and macrophages present in the lesioned hemisphere of SN.  This 
suggests that the up-regulation of Igαv, Igβ3 and CD44 receptors is likely to be due to 
the expression of these receptors on proliferating glial cells and infiltrating 
macrophages resulting from the LPS injection.  This is the first time that the 
expression of these receptors was investigated in a PD model but up-regulation of 
integrins was observed in the temporal cortex in Alzheimer’s disease (Akiyama et 
al., 1991; Akiyama et al., 1990), in brainstem and cerebellum in mice infused with 
LPS (Kloss et al., 2001) and in multiple sclerosis lesions (Bo et al., 1996).  In these 
studies, integrin expression was increased in microglial cells.  The CD44 receptor 
was also upregulated in Alzheimer’s disease in GFAP positive astrocytes (Akiyama 
et al., 1993), in a rat stroke model in microglia and macrophages (Wang et al., 2001) 
and in a mouse model of multiple sclerosis in astrocytes (Haegel et al., 1993).  More 
importantly, CD44 expression was elevated in the SN of MPTP treated mice where it 
co-localised with infiltrating lymphocytes (Kurkowska-Jastrzebska et al., 1999).  The 
results obtained in the current study in addition to evidence from previous 
investigations indicate a possible role for integrin and CD44 receptors in the 
regulation of inflammation mediated neurodegeneration.  This, however, requires 
further detailed investigation as it may be relevant to neurodegenerative diseases, 
where there is evidence of inflammatory involvement, such as PD.  Integrin and 
CD44 receptors are known to bind many ligands and mediate various actions and 
may be mediating pro or anti-inflammatory effects.  In support of this concept, 
Laminin and fibronectin (both integrin ligands) exert opposite effects on the 
activation state of cultured microglia from the cerebral cortex and striatum (Chamak 
et al., 1991).  Therefore OPN may have a role in regulating the LPS induced 
activation of inflammatory cells through effects on integrin or CD44 receptors.      
5.4.3 The effects of OPN on LPS induced pathological changes  
This is the first report of the neuroprotective effect of OPN against LPS 
induced loss of dopaminergic neurons in the SNpc.  OPN injected into the SNpc 24hr 
or 2hr before supra-nigral LPS injection prevented dopaminergic neurone loss 
induced by LPS.  This is in line with a recent study showing that a 15-mer peptide 
fragment of OPN containing the RGD binding domain is also protective in LPS and 
6-OHDA lesioned rats (Iczkiewicz et al., 2010).  In the same study, intra-nigral 
injection of an anti-OPN antibody induced a significant loss of dopaminergic neurons 
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in the SN (Iczkiewicz et al., 2010).  In light of the evidence, OPN seems to be 
endogenously protective to dopaminergic neurons and when administered 
exogenously, provides protection against toxin induced cell death.      
OPN caused a significant reduction in the LPS induced microglial activation 
but did not affect the increase of astrocytes or macrophages.  This suggests that OPN 
may have protected dopaminergic neurons via preventing and/or attenuating the LPS 
induced microgliosis.  This suggestion is supported by studies in models of stroke 
and ischemic neurodegeneration where OPN was found to be protective, this was 
accompanied by anti-inflammatory actions suggesting that it may protect neurons 
through reduction in inflammation induced cell death.  In support of this concept, 
OPN KO mice displayed higher microglial activation and inflammatory gene 
expression in addition to higher secondary thalamic degeneration after cerebral artery 
occlusion compared to wild type animals (Schroeter et al., 2006).  In addition, 
following transient forebrain ischemia in rat, OPN was up-regulated in microglia and 
astrocytes but was also secreted into the extracellular space by astrocytes suggesting 
a role in tissue repair (Choi et al., 2007).  However, there are contradictory findings 
in multiple sclerosis and its animal model experimental autoimmune 
encephalomyelitis, where OPN is reported to be up-regulated mainly in microglia 
and macrophages and to increase survival and proliferation of T-cells resulting in a 
harmful pro-inflammatory effect (Chabas et al., 2001; Hur et al., 2007; Jansson et 
al., 2002; Kim et al., 2004).  This discrepancy, nonetheless, may be due to the 
difference in disease models as the former is an ischemia mediated 
neurodegeneration and the latter is a T-cell mediated autoimmune disease.     
The underlying protective mechanism of OPN may be accomplished by 
reducing nitrative stress.  OPN can reduce nitrative stress by reducing levels of NO 
and iNOS as it was shown to inhibit up-regulation of NO and to lower mRNA levels 
of iNOS in kidney cells stimulated with LPS (Hwang et al., 1994a; Hwang et al., 
1994b) and to inhibit production of NO in human osteoarthritis-affected cartilage 
(Attur et al., 2001).  Indeed, evidence of the presence of NO and iNOS exists not 
only in PD (Hunot et al., 1996) but also in the LPS lesioned rats (Iravani et al., 
2002).    Inhibition of NO up-regulation may be related to the evident reduction of  
activated microglial cell numbers in  rats injected with OPN before LPS lesioning in 
this study, since iNOS is mainly expressed in activated microglia (Arimoto et al., 
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2003; Dehmer et al., 2000; Iravani et al., 2005).  The lower levels of NO would in 
turn reduce the generation of harmful peroxynitrite which forms after interaction of 
NO with superoxide anion produced in activated microglia.  This suggested anti-
inflammatory mechanism is further supported by the up-regulation of mediators of 
OPN actions (Igαv, Igβ3, and CD44 receptors) on glial cells post LPS lesionin.  
Moreover, studies in VM culture showed that integrins protected dopaminergic cells 
via a glial dependant mechanism (Peluffo et al., 2007).   
A possible alternative explanation is that OPN may be acting directly on 
neurons which were shown here to express Igαv, Igβ3 and CD44.  This may be 
mediated through inhibiting apoptosis since there is a large body of evidence of anti-
apoptotic and pro-survival effects of OPN in different cell types including neurons 
(Chapter 1).  This, however, requires further investigation.  It is also possible that 
OPN works via induction of neurotrophic factor release from glial cells since in 
unpublished studies from these laboratories OPN induced GDNF and BDNF release 
in VM cultures (Broom, 2011, personal communication).  It is not excluded that 
OPN acts both directly on dopaminergic neurones and indirectly through an effect on 
glial cells.  The exact mechanism of neuroprotection by OPN in the LPS model is not 
yet clear and prompts further study, but it seems to be related to an effect on 
activated microglia.  Although OPN was shown to be neuroprotective in LPS 
lesioned rats, extensive investigations are still required to establish the exact role of 
OPN in PD. 
5.4.4 Conclusion 
In conclusion, these data confirm the dopaminergic cell loss and gliosis 
induced by LPS and show for the first time the ability of OPN protein to protect 
against LPS-induced dopaminergic cell loss.  This was mediated via attenuating the 
microgliosis produced by LPS probably via a more complex anti-inflammatory 
mechanism.  This is supported by the finding that OPN receptors were expressed on 
glial cells following LPS insult in the SN.  Other direct effects of OPN on 
dopaminergic neurons cannot be ruled out at this stage, especially since OPN 
receptors are also expressed on dopaminergic neurons.  The increase in the 
expression of integrin and CD44 receptors following LPS lesion indicates a possible 






















6. Chapter 6 General Discussion 
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6.1 Thesis hypothesis and Aims 
Based on previous reports of the involvement of OPN in the regulation of 
inflammation and its pro-survival effects, it was suggested that OPN may be a 
potential neuroprotective agent in PD.  As a consequence, it was hypothesized that 
OPN is protective against toxic insult when endogenously expressed or when 
dopaminergic cells are exposed to it exogenously.  It was also hypothesised that 
protective effects of OPN are mediated through an action on glial cells and via Igαv, 
Igβ3, Igβ1 and CD44 receptors.  Therefore, the aims of the studies described in this 
thesis were to investigate the protective effects of exogenous and endogenous OPN 
and to study the role of glial cells and Igαv, Igβ3, Igβ1 and CD44 receptors in its 
effects. 
6.2 Summary of results 
 Endogenous OPN expression in dopaminergic cell lines or transfection of cell 
lines to express OPN did not protect against toxin induced cell death, nor did 
pre-treatment with exogenous OPN. 
  OPN protected dopaminergic neurons in primary VM culture against MPP+ 
toxicity. 
  Protection by OPN in VM culture was mediated via integrin receptors and it 
was accompanied by an increase in the number of microglia. 
 OPN also protected dopaminergic neurons of the SN from LPS induced cell 
death and reduced the number of activated microglia following LPS 
challenge but did not affect macrophage or astrocyte numbers. 
 LPS induced an up-regulation of Igαv, Igβ3, Igβ1 and CD44 receptors in the 
rat SN and their expression on glial cells and macrophages. 
In conclusion, neither endogenous nor exogenous OPN conferred any 
protection to dopaminergic cell lines against toxic insult although they expressed 
Igαv, Igβ3, Igβ1 and CD44 receptors.  However, OPN protected dopaminergic 
neurons both in primary VM culture and in rat SN against toxin induced cell death 
and showed a role in regulating the inflammatory process.  Although the exact role of 
Igαv, Igβ3, Igβ1 and CD44 receptors and glial cells is still not clear from these 
studies, the results provided a platform for further investigation of OPN’s potential as 
a neuroprotective agent for PD. 
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The concept of employing endogenous molecules as neuroprotective agents is not 
novel.  Various endogenous substances including proteins, hormones and cytokines 
have also been studied in relation to neuroprotection in PD.  For example, estrogens 
showed neuroprotective properties in cell lines against oxidative stress (Singer et al., 
1998) and MPP
+
 toxicity (Gélinas et al., 2002).  They were also protective in 6-
OHDA and MPTP treated rodents (Kenchappa et al., 2004; Quesada et al., 2008) but 
no clinical trials have been undertaken to confirm their effectiveness.  Endogenous 
molecules involved in inflammatory regulation have also showed some positive pre-
clinical data but further investigations are still required.  For example, IL-10 was 
shown to protect dopaminergic neurons of the VM culture from LPS toxicity (Qian et 
al., 2006) and gene delivery of IL-10 into the rat striatum preserved dopaminergic 
neurons following 6-OHDA lesioning and reduced microglial activation (Johnston et 
al., 2008).  The endogenous peptide exendin-4 is a glucagon-like peptide 1 receptor 
agonist which has neurotrophic and antiapoptotic effects (Li et al., 2003; Perry et al., 
2002).  It showed neuroprotective effects in cultured cell lines and primary 
dopaminergic neurons (Li et al., 2009) but also in rats when injected 7 days after 
LPS or 6-OHDA lesioning (Harkavyi et al., 2008).  Exendin-4 has the advantages of 
safety and BBB permeability (Harkavyi et al., 2010) but whether it will show 
neuroprotection in clinical trials remains to be determined.  As discussed in Chapter 
1, neurotrophic factors have been explored as a potential neuroprotective treatment in 
PD.  The neurotrophic factor GDNF showed promising results in pre-clinical studies 
but more clinical trials are required to determine whether it shows efficacy in PD.  
Neurturin, a neurotrophic factor member of the GDNF family, has also been tested 
for neuroprotection.  Neurturin exhibited protective properties in VM cultures 
(Horger et al., 1998) and protected nigral dopaminergic neurons from 6-OHDA 
induced cell death (Horger et al., 1998; Rosenblad et al., 1999), medial forebrain 
bundle axotomy in rats (Tseng et al., 1998) and MPTP challenge in monkeys 
(Kordower et al., 2006).  Recently, a phase I clinical trial confirmed safety and 
efficacy of neurturin delivered via an AAV vector (CERE-120) into the putamen of 
PD patients (Marks Jr et al., 2008) and was followed by a phase II double blind 
randomised clinical trial using the same delivery method.  This trial did not meet its 
primary endpoint of efficacy but positive improvements were seen in a subgroup of 
patients who were followed for a longer period of time (Marks Jr et al., 2010).  Thus, 
neurotrophic factors have shown promise as neuroprotectants in PD but this has not 
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yet been translated into a proven clinical effect.  For this reason, OPN would seem to 
offer an alternative approach through endogenous mechanisms as shown in this 
thesis.  However, a lack of translation from the laboratory to the clinic has dogged 
the development of neuroprotective drugs and this raises questions about the 
experimental procedures that are used as discussed below.  In addition, a number of 
questions arise from findings in the current studies and they are also discussed 
below.    
6.3 Are cell culture and experimental models of dopaminergic cell 
death in PD suitable for testing neuroprotective agents? 
In these studies, OPN was investigated for protective effects using cell lines, 
primary VM culture and LPS lesioned rats.  Results obtained in cell lines did not 
agree with those in primary culture and rats, suggesting that this may be due to 
differences in models.  In addition, a number of agents such as those discussed in 
Section 1.1.1 showed protective properties in cultured cells and animals but when 
tested in man did not show the same effects.  Therefore, it is possible that these 
models do not closely mimic the complex pathology leading to neuronal 
degeneration in PD.  This is discussed below in relation to results obtained in the 
current studies. 
6.3.1 In-vitro models of nigral cell death 
In the present studies, OPN showed protective effects in the primary VM 
culture and in rats but not in dopaminergic cell lines.  Similar findings were 
previously reported, where neuroprotective agents that were effective in-vivo, did not 
have the same effect on SH-SY5Y cell lines (Kou et al., 2008; Presgraves et al., 
2004).  Conversely, other neuroprotective agents have showed neuroprotection in 
cell lines and subsequently in other models, for example dopaminergic agonists, 
MAO-B inhibitors, anti-oxidants and anti-apoptotic agents (Mandel et al., 2003; 
Schapira, 2008b).  Although factors related to OPN itself may be underlying this 
discrepancy as discussed in Chapter 3, it may also be due to the nature of cell lines. 
Cell lines constitute an important tool for screening potential new drugs for 
PD.  They offer the advantages of shorter experiment time and being less labour 
intensive than primary culture or animals.  Dopaminergic cell lines are an unlimited 
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source of mono-typic cells with similar functional and biochemical characteristics to 
dopaminergic neurons.  They can also be useful in studying mechanisms of action 
via pharmacological manipulations but also studying protein functions by 
overexpressing specific targets or silencing specific proteins.  However, these cell 
lines are obviously not authentic dopaminergic neurons and this already presents a 
number of issues.  For instance, SH-SY5Y cells are resultant of Ras mutation leading 
to chronic activation of MAPK/ERK signaling and therefore may exhibit different 
mechanisms of cell death to mature neurons (Abramova et al., 2002).  In addition, 
SH-SY5Y cells exhibit low dopamine synthesis enzymes and DAT (Presgraves et al., 
2004).  Therefore these cell lines may respond differently to exogenous stimuli from 
mature neurons.  In addition, cell lines are continuously dividing, meaning that the 
number of cells is increasing during the course of the experiment and this makes it 
difficult to distinguish whether the toxin or the protective agent are affecting cell 
death or proliferation rate (Datki et al., 2003).  By contrast, neurons in the brain are 
not able to divide with little ability of recovery from injury and are therefore highly 
vulnerable (Klöcker et al., 2001).  This questions how well can results from cell lines 
be representative of what might occur in brain neurons.  In addition, some cells of the 
dopaminergic neuroblastoma cell lines can lose their neuronal or dopaminergic 
characteristics especially at higher passage numbers.  This was overcome in these 
studies by using low passage numbers and regularly staining for the dopaminergic 
marker TH.  Furthermore, the EC50 of MPP
+
 was 100 fold greater in cell lines 
compared to primary dopaminergic neurons (Chapter 3) and this could be indicative 
of lower sensitivity of cell lines.  Indeed, cell lines previously showed lower 
sensitivity to both toxins and protective agents than primary mesencephalic neurons 
(Storch et al., 2000).  This maybe a result of the immortalisation process, suggesting 
that cell lines may be less accurate in predicting physiological outcomes in intact 
brains.   
Primary VM culture has some advantages over dopaminergic cell lines.  It 
offers authentic dopaminergic neurons which have not been genetically modified to 
become immortalised.  Also, these dopaminergic neurons are cultured within a more 
heterogenous, physiological environment with other cell types such as other neuronal 
and glial cells which are also present in the intact SN.  However, this culture also 
carries the limitations of low percentage of dopaminergic neurons (3-5%) and 
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increased vulnerability of neurons the longer they are cultured in-vitro.  The VM 
culture is also limited in terms of culture life span and passaging, rendering some 
useful manipulations, such as stable transfections, impossible to achieve.  In addition, 
the limited culture life span imposes neuroprotection assays with a very fast time-
course of cell death compared to the slow degeneration of neurons in PD.   
In the current studies, there was an interesting difference between primary VM 
culture and rat SN; Igαv, Igβ3, Igβ1 and CD44 were expressed on neurons and glia in 
VM culture but only on neurons in naive rat SN.  This may be due to the nature of 
the VM culture model as the cultured cells are embryonic in nature and in the process 
of development.  In fact, integrin receptors are expressed in developing cells due to 
their roles in survival, adhesion, migration and proliferation (Anthis et al., 2011).  
This may also be the case for the CD44 receptor as it is also involved in these vital 
processes.  Therefore, mature glial cells may stop expressing these receptors and 
only up-regulate them in the event of injury or inflammation when adhesion, 
migration and proliferation activities are required as was the case in this study.  
Consequently, although VM culture contains glial cells their phenotype may be 
different to mature glia in the SN.      
In summary, cell line or tissue culture models provide a good starting point to 
investigate properties of protective agents, though it remains difficult to interpret 
how data from in-vitro toxin models will relate to the complex pathophysiology of 
PD. 
6.3.2 In-vivo models of nigral cell death 
Testing neuroprotective candidates in animals may be more physiologically 
relevant than in-vitro systems.  However, none of the toxin-based animal models 
available mimic the exact pathophysiological features of PD and they all have 
advantages and shortcomings.  Therefore the choice of animal model is usually based 
on the type of investigation required.  Here, the LPS model was chosen since the 
objective of these studies was to look at inflammation mediated neurodegeneration 
for which LPS is the most suitable model.  The 6-OHDA model, for instance, could 
have also been used as it induces an inflammatory reaction (Cicchetti et al., 2002; He 
et al., 2001) but the mechanism of cell death is through accumulation of the toxin in 
dopaminergic neurons and subsequent oxidisation into hydrogen peroxide and 
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paraquinone which mediate cellular damage (Saner et al., 1971).  The following 
discussion focuses on the use of LPS and its relation to PD pathology.   
LPS is not directly toxic to neurons but induces degeneration via a reactive 
gliosis and inflammation (Gao et al., 2002; Taylor et al., 2003).  However, in PD, it 
is not known whether inflammation is a primary event or is secondary to neuronal 
degeneration (Chapter 1).  Although LPS can cause dopaminergic neuron loss from 
the SN and a reactive gliosis, its administration to the SN results in very acute cell 
death different to the progressive nature of neurodegeneration in PD.  In this study, 
significant dopaminergic cell death was seen 1 day after LPS administration and 
previously, significant cell death was observed as early as 16hr post lesioning 
(Iravani et al., 2002).  In addition, the destruction of the nigro-striatal system remains 
static up to 1 year post lesioning (Herrera et al., 2000).  This disadvantage, however, 
is common to most toxin based animal models with varying extents.  Systemic 
infusion of LPS may cause a more progressive cell death but it does cause 
widespread inflammation in the brain and may not be a model specific to PD (Qin et 
al., 2007).  Chronic administration of LPS into the SN over 2 weeks was shown in 
one study to produce progressive loss of dopaminergic neurons (Gao et al., 2002).  
This, however, may be a transient progression resulting from prolonged 
administration of toxin.  Besides, this model is not confirmed by other studies, thus 
not well established.  Another limitation, is the fact that inflammation following LPS 
lesion is a transient process (Herrera et al., 2000; Iravani et al., 2005) whereas in PD 
there is on-going inflammation (McGeer et al., 1988).  This, however, may not affect 
the present study as the experiments were carried out within a one week period while 
inflammation is still present.  Nevertheless, the pathological consequences of a 
transient inflammation might be different to that of an on-going one.   
In order to better predict the outcome of administering OPN to humans with 
PD, the primate MPTP model may be more suitable.  Non-human primates are more 
closely related to humans than rodents.  As opposed to LPS nigral injection, 
inflammatory gliosis following MPTP treatment in primates is ongoing (Barcia et al., 
2004; Langston et al., 1999).  In addition, previous studies have shown that 
following LPS insult there is up-regulation of OPN, while in PD and MPTP-treated 
marmosets OPN expression is decreased (Iczkiewicz et al., 2006).  This suggests that 
regulation of OPN in MPTP-treated marmosets is similar to that in PD.  However, 
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this may be because LPS was used in the early stage while MPTP treated monkeys 
were used after one year of MPTP challenge.  Noteworthy, the cell death process 
induced by MPTP, like LPS, is acute and there is lack of inclusion bodies (Halliday 
et al., 2009).  Overall, there is no animal or cell culture model that exactly mimics 
the pathophysiology of PD.  However, these in-vitro and in-vivo models represent 
valuable tools that can help study one or more biochemical aspects contributing to 
the complex process of cell death in PD, and provide a realistic, simple system to 
investigate protective agents before attempting clinical trials.   
6.4 Are integrin and CD44 receptors important potential targets for 
the treatment of PD? 
In the VM culture, OPN’s protective effect was inhibited by non-specific 
integrin blockers suggesting that interaction of OPN with these receptors is essential 
to achieve neuroprotection.  The CD44 receptor may also play a role, but this 
remains to be investigated.  In addition, OPN was previously shown to have pro-
survival effects in different cell and tissue types and this was mediated via integrins 
(Doyle et al., 2008; Meller et al., 2005), CD44 receptors (Caers et al., 2006) or both 
(Lee et al., 2007).  Although the role of integrin and CD44 receptors in the protective 
actions of OPN in rats was not investigated here, results from VM culture in addition 
to previous reports suggest that one or more of these receptors are likely to be the 
mediators of OPN’s actions.  Therefore, a better understanding of the roles of these 
receptors may lead to discovering new potential neuroprotective strategies.   
Integrin and CD44 receptors are ubiquitous transmembrane receptors involved 
in regulating vital functions such as adhesion, migration and proliferation (Chapter 
1).  They are up-regulated in inflammatory reactions in the CNS where they mediate 
inflammatory cell adhesion and proliferation as discussed in Section 5.4.2.  In the 
current studies, presence of these receptors in the SN suggests that they may play an 
important role in PD.  The up-regulation of these receptors following LPS insult to 
the SN supports this suggestion and may open the door for a new area of research in 
PD.  Expression of integrin receptors on some glial cells in LPS-lesioned SN 
suggests that OPN may act on glial cells to mediate its protective actions possibly by 
reducing release of pro-inflammatory cytokines.  These receptors are differentially 
activated by different ligands, some inducing pro-inflammatory and others anti-
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inflammatory actions (Milner et al., 2002) and targeting them via inhibitors seems to 
have anti-inflammatory effects in a number of disease models including arthritis 
(Homandberg et al., 1994) and encephalomyelitis (Brocke et al., 1999).  This further 
emphasises the potential of targeting these receptors as a means of treating PD.   
In addition, integrin receptors may be involved in neurotrophic factor 
signalling.  Integrin β1 is suggested to act as an alternative signalling receptor for 
GDNF (Cao et al., 2008).  In fact, GDNF enhances expression of integrin αv 
(Funahashi et al., 2003) and both GDNF and BDNF increase the expression of this 
integrin in primary dopaminergic neurons (Gao et al., 2002).  This suggests that 
neurotrophic factors may mediate their protective effects in dopaminergic neurons 
through integrin receptors.  In support of this concept, GDNF mediated survival of 
dopaminergic neurons was inhibited by integrin-blocking peptides (Chao et al., 
2003).  This area has not been extensively studied and future studies may reveal 
more important roles for integrin receptors in mediating neurotrophic factor effects.  
It is noteworthy here that OPN may also exert its protective effects through inducing 
neurotrophic factors particularly since unpublished studies in our laboratories 
showed that OPN induces the release of GDNF and BDNF in VM culture (Broom, 
2011, personal communication).   
Moreover, integrin receptors may have a role in neurogenesis.  Increased 
integrin expression following neuronal injury is correlated with successful 
regeneration of peripheral neurons (Previtali et al., 2001) and with limited 
regeneration of central neurons after neurotrophin treatment (Plantman et al., 2005).  
A number of integrin subunits, including Igα4, Igα5, Igα6, Igα7 and Igβ1, are 
upregulated in sensory and motor neurons during peripheral nerve regeneration 
(Lemons et al., 2008).  Further, dorsal root ganglia neurons that are subjected to a 
preconditioning injury, upregulate expression of Igα5 and Igα7 and subsequently 
show enhanced outgrowth when explanted in culture, suggesting a role of these 
integrins in neurogenesis (Ekström et al., 2003; Gardiner et al., 2007).  Although, the 
current study was not looking at neurogenesis, the role of integrin receptors in this 
process is very interesting and may be worth future studies.  The concept of 
pharmacologically inducing neurogenesis is receiving considerable interest but 
evidence for neurogenesis of dopaminergic neurons in basal ganglia is controversial 
and awaits clarification (Deierborg et al., 2008). 
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Nevertheless, integrins αv, β3 and β1 were expressed in all dopaminergic cell 
lines tested in this study, in neurons and glia of the VM culture and in neurons in the 
SN.  In fact, integrin receptors are ubiquitously expressed not only in the CNS but 
also in the periphery.  Targeting these receptors may thus be associated with 
unwanted, non-specific widespread effects.  Therefore, there may be a need for 
finding subunits or subunit dimers that aggregate specifically in the SN.  This may be 
difficult to achieve since it will require investigation of a large number of bodily 
tissues.  Ligands of these receptors including OPN may also be ubiquitous 
multifunctional proteins, making the situation more complicated.  Nonetheless, 
existing medicines such as aspirin are ubiquitous but also well tolerated.  This issue 
requires careful investigations.  
A limited number of these receptors were investigated in the current study 
(Igαv, Igβ3, Igβ1) due to time and resource constraints, but there remain many other 
integrin receptors which may have different expression patterns to the currently 
investigated ones and may also have important roles in PD.  For instance, integrins 
involved in neurogenesis include Igα4, Igα5, Igα6, Igα7 as discussed above.  Although 
receptors investigated here were shown to mediate pro-survival effects, OPN can 
bind to at least 7 different integrin receptors (Chapter 1) and not all of these have 
been tested.  Further investigations into the exact role of these receptors in PD may 
not only help in better understanding of the pathophysiology of the disease, but may 
also open possibilities for new neuroprotective strategies.    
6.5 Is OPN a future treatment for PD? 
One question arising from these studies is whether OPN would act differently 
in the human brain, particularly since effects of OPN varied in different models.  In 
cell lines, no effects of this protein were observed and while it exhibited protective 
effects in both VM culture and rats, the underlying effects on inflammatory cells 
were different.  OPN had a proliferating effect on microglia in VM culture, and a 
decrease in activated microglia in LPS treated rats.  It is interesting, however, that in 
both models OPN only affected microglia with no significant effects on astrocytes or 
macrophages and this is consistent.  In fact, in PD OPN was expressed in neurons 
and microglia (Iczkiewicz et al., 2006).  It is not clear why OPN did not have an 
effect on macrophages and astrocytes but it may be decreasing the release of NO 
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from these cells since it was previously shown to decrease NO release from 
macrophages (Crawford et al., 1998) and this needs further investigation.  The 
attenuated microgliosis in the rat LPS model is most probably protective, since 
activated microglia are discussed to have toxic effects on neurons (Chapter1) and 
LPS toxicity to neurons is a result of microglial activation and subsequent release of 
pro-inflammatory cytokines (Chapter 1).  However, the proliferative effect on 
microglia in untreated VM cultures is not very well understood.  This latter result 
should be treated with caution, as it is in line with the previously reported ability of 
OPN to recruit inflammatory cells to injury site (Giachelli et al., 1998; Kawashima et 
al., 1999; Murry et al., 1994b; O'Regan et al., 1999; Patarca et al., 1989b).  The 
difference in OPN effects may reflect the dissimilarity of models, as embryonic stage 
microglia cultured in an ‘aritificial’ environment may act differently to mature 
microglia in the intact SN.  It is noteworthy, however, that OPN only induced 
proliferation of microglia with no activation suggesting a possible protective effect.  
Treatment with OPN may have signalled a protective response of the VM culture by 
increasing the number of microglia in order to release more neurotrophic factors.  
Indeed OPN was shown to increase neurotrophic factor release in VM cultures 
(Broom, 2011, personal communication).  In support of this, growth factors have 
been shown to protect primary dopaminergic neurons against MPP
+
 toxicity through 
glial cell stimulation and proliferation (Dalia et al., 1993; Otto et al., 1993; Park et 
al., 1992).         
Consequently, further steps should be taken to investigate the underlying 
inflammatory regulation by OPN such as effects on inflammatory cytokines and this 
may explain better the results of the current studies.  This is particularly important 
since one recent study found that OPN deficient mice showed reduced striatal 
dopaminergic fibre loss after MPTP challenge (Maetzler et al., 2007).  In the same 
study, OPN levels were increased in serum and cerebrospinal fluid of PD patients 
compared to controls and higher OPN levels were associated with more severe motor 
symptoms (Maetzler et al., 2007).  Lower striatal dopaminergic fibre loss in MPTP-
treated OPN null mice suggests that lack of OPN is protective, but this has not been 
confirmed by other studies.  In contrast, the current study showed that OPN 
expressing or OPN lacking cell lines do not show differences in sensitivity to toxin.  
The increased OPN levels in body fluids from PD patients (Maetzler et al., 2007) 
 208 
does not necessarily suggest a harmful effect of the protein but may also indicate that 
it is a protective homeostatic reaction.  The pathophysiology in PD is considerably 
different to the models employed in the current study and much more complex as 
discussed in Chapter 1.  Therefore, although the overall expected effect in the human 
brain based on these studies would be a protective one, further studies are required 
before this conclusion can be made.   
  Another important issue to consider is the implication of OPN in cancer.  
OPN is up-regulated in a number of cancers and higher levels are associated with a 
metastatic phenotype (Chapter1).  Indeed, there is a close relationship between 
molecules that induce cell survival and tumorigenesis.  The involvement of OPN in 
inflammation and cell survival may be related to tumour pathology since it is 
consistent with the notion that tumours are ‘wounds that do not heal’(Balkwill et al., 
2001)  and ‘tissues that never cease to develop’ (Pollard, 2004).  In fact, some 
suggest that PD patients may be protected from some cancers but have higher 
incidence of other ones including melanoma and breast cancer (Inzelberg et al., 
2007), suggesting predisposition of parkinsonian patients to developing these cancers 
or a pathological link between PD and tumours.  Therefore, although in this study 
treatment of cultured or nigral dopaminergic cells with OPN did not induce neuronal 
proliferation, the consequences of administering OPN into SN in PD should be 
considered very carefully. 
Noteworthy, in the studies described here, OPN treatment was always 
introduced before toxic insult and this was because the toxins used induced very 
acute cell death.  Had OPN treatment been given after toxic insult, the cells may have 
already died or been severely damaged and this would be testing whether OPN has 
neurorestorative properties.  However, the aim of this study was to test whether OPN 
would protect the cells from dying.  This is because PD is progressive in nature and 
dopaminergic neurone loss is slow and on-going and the aim of neuroprotective 
agents is to be administered in early-diagnosed patients to prevent further loss of 
dopaminergic neurons from the SN and deterioration of symptoms.  Of course, there 
remains the possibility of future investigations of neuro-restorative properties.  PD is 
not diagnosed until considerable dopaminergic neurodegeneration had taken place 
(Agid, 1991; Fearnley et al., 1991), and a relevant question is whether an anti-
inflammatory effect at this stage would protect the remaining dopaminergic neurons 
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from undergoing degeneration.  Importantly, the use of NSAIDS is associated with 
lower risk of PD according to epidemiological studies (Chapter 1), suggesting that 
early prevention of an inflammatory reaction in the SN may protect against 
degeneration of dopaminergic neurons.  In addition, pre-clinical studies in animals 
showed protective effects of anti-inflammatory agents in toxin induced nigral cell 
death (Chapter 1).  However, there is no clinical evidence that anti-inflammatory 
agents given after the diagnosis of PD are neuroprotective.  Perhaps an anti-
inflammatory effect of OPN coupled with other pro-survival effects such as its 
ability to inhibit apoptosis would be more effective in preventing further loss of 
dopaminergic neurons if administered at early stages of the disease.  Overall, OPN 
showed promising results as a potential neuroprotective agent but further studies are 
required to clarify the underlying mechanism and to test safety.   
6.6 Further development of OPN as a treatment for PD 
The above discussion highlights few areas that require further investigations in 
order to establish the role of OPN as a potential protective agent.  First, testing 
whether OPN would be protective in MPTP treated primates as this may mimic more 
closely the human disease.  Second, further investigating the mechanisms that may 
be involved in the protective effects of OPN such as anti-apoptotic, anti-oxidant and 
anti-inflammatory effects.  Third, studying the role of CD44 and specific integrin 
receptors in the protective effects of OPN and elucidating the receptors and 
functional fragments of the protein important for this effect.  Further, other parts of 
the protein, not studied here, may have intrinsic protective actions and are worth 
future investigations.  For instance, OPN has a calcium binding site and is reported to 
bind this cation (Chapter 1) suggesting that it may also be able to bind other divalent 
metals implicated in PD pathology such as iron.  Calcium itself is suggested to play a 
role in neuronal death after accumulation in the neuron (Landfield et al., 1992).  Its 
role in dopaminergic cell death is supported by evidence of protective effects of the 
calcium buffering protein calbindin in the dopaminergic cell line PC12 (McMahon et 
al., 1998).  Further, the use of dihydropyridine calcium channel blockers as anti-
hypertensives was associated with lower risk of PD (Rodnitzky, 1999).  Recently, 
new cell binding sequences have been identified in OPN which may play a role in 
cell survival but receptors for these segments are still unknown (Rittling, 2011).  
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In addition to the above, administration of OPN also requires further 
development.  One of the major obstacles which could negatively impact the 
potential of using OPN as an effective neuroprotective and clinically viable candidate 
is its proteinaceous nature which renders it susceptible to first pass metabolism in 
addition to limiting its transport across the blood brain barrier.  OPN would require 
invasive surgery to be delivered to the SN which can be achieved via direct 
administration of the protein or delivery of the gene by means of a viral vector.  
However, this would be a major limitation to the use of OPN as a treatment in PD.  
Several strategies have been proposed to overcome these shortcomings.  Aerosolising 
the protein for nasal drug delivery could be a better alternative considering the 
advantageous absorption rates and improved bioavailability.  However, OPN might 
also exhibit limited blood-brain barrier penetrability considering its molecular size 
and charged polar surface. 
The use of permeation enhancers such as protease inhibitors as additives to 
attain consistently high bioavailability levels has gained increasing interest in recent 
reports (Morishita et al., 2006).  However, the applicability is questioned due to the 
potential toxic effects of protease blockers and the implications of polypharmacy.  
Another important aspect which can be exploited, is formulating OPN using 
advanced drug delivery systems into a dosage form which is administered orally or 
parenterally in order to improve stability and targetability. These systems include 
biodegradable polymeric conjugates and nano- and microparticulate carriers 
(microreservoir systems such as liposomes and micellar structures) which offer the 
advantage of controlling the rate of release in addition to localising the delivery of 
active pharmaceutical which can be site-specific (Gombotz et al., 1995). 
Importantly, A 15-mer fragment of OPN has also been shown here to be 
protective in MPP
+
 treated VM culture and in a previous study to be protective in rats 
against LPS and 6-OHDA (Iczkiewicz et al., 2010).  This fragment has advantages 
for systemic administration over the full length protein.  It is less likely to be 
metabolised and its smaller size means improved penetrability to the BBB.  The 
intranasal administration of a 13-mer fragment in mice has already been reported to 
provide neuroprotection in a stroke model (Doyle et al., 2008).  However, the effect 
of the 15-mer fragment was partial in this study and there is a possibility that other 
parts of the protein are protective or essential for full function of the protein.  
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Therefore, further investigations are required to identify segments of the protein 
which can offer the full spectrum of protective effects. 
One distinct approach which merits further investigation is designing 
peptidomimetics which offer comparable pharmacological potency but better 
bioavailability.  The design of pseudopeptide/non-peptide analogues requires the 
modification of physicochemical characteristics of the protein or fragment in order to 
overcome the physical and biochemical barrier properties of endogenous membranes 
(Pauletti et al., 1997).  The design of an effective peptidomimetic or a non-peptide 
analogue requires the application of various design strategies to understand the 
topographical and stereoelectronic properties of the pharmacophore and side chain 
moieties (Pauletti et al., 1997). 
6.7 Conclusion 
As hypothesized, OPN seems to be a promising potential neuroprotective 
agent, worth further investigation.  The potential of small peptide fragments carrying 
the same effect as the parent protein and the possibility of synthesizing 
peptidomimetics gives OPN an advantage over the currently investigated endogenous 
proteins.  The ability of OPN to protect neurons from inflammation mediated 
neurodegeneration makes it also a potential treatment candidate for other 
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